Conditions: Chronic Cough
Keywords: Cough Respiration disorders Respiratory tract diseases Signs and symptoms, respiratory Signs and symptoms
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 419
Healthy volunteers: no

Brief summary:
The purpose of this study is to evaluate the efficacy and safety of gefapixant in participants with recent onset chronic cough (duration \>8 weeks after onset of cough symptoms) for \<12 months and a diagnosis of refractory or unexplained chronic cough. The primary hypothesis is that gefapixant is superior to placebo in improving cough-related quality of life measured as change from baseline in the Leicester Cough Questionnaire (LCQ) total score at Week 12.

Detailed description:

Arms:
arm 1: Participants will receive gefapixant at a dose of 45 mg administered as an oral tablet twice daily for 12 weeks. arm 2: Participants will receive placebo matching gefapixant, administered as an oral tablet twice daily for 12 weeks.

Interventions: intervention 1: Gefapixant intervention 2: Placebo
Intervention descriptions: intervention 1: Administered twice daily as an oral tablet of 45 mg intervention 2: Administered twice daily as a placebo oral tablet matching gefapixant

Protocol document:
Prot_SAP_000.pdf: 
Official Protocol Title: 
NCT number: 
NCT04193202 
Document Date: 
25-Nov-2020
A Phase 3b Randomized, Double-blind, Placebo Controlled, 
Multicenter Study to Evaluate the Efficacy and Safety of Gefapixant 
in Adult Participants with Recent Onset Chronic Cough


PRODUCT: MK-7264  
1
PROTOCOL/AMENDMENT NO.: 043-03 
MK-7264-043-03 FINAL PROTOCOL
25-NOV-2020
Title Page
THIS PROTOCOL AMENDMENT AND ALL OF THE INFORMATION RELATING 
TO IT ARE CONFIDENTIAL AND PROPRIETARY PROPERTY OF MERCK 
SHARP & DOHME CORP., A SUBSIDIARY OF MERCK & CO., INC., NJ, U.S.A. 
(MSD).
Protocol Title: A Phase 3b Randomized, Double-blind, Placebo Controlled, Multicenter 
Study to Evaluate the Efficacy and Safety of Gefapixant in Adult Participants with Recent 
Onset Chronic Cough
Protocol Number: 043-03
Compound Number: MK-7264
Sponsor Name:
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
(hereafter referred to as the Sponsor or MSD)
Legal Registered Address:
One Merck Drive
P.O. Box 100
Whitehouse Station, New Jersey, 08889-0100, U.S.A.
Regulatory Agency Identifying Number(s):
IND
123007
EudraCT
2019-002308-42
Approval Date: 25 November 2020
 
 
05ND48
07YNSG


PRODUCT: MK-7264  
2
PROTOCOL/AMENDMENT NO.: 043-03 
MK-7264-043-03 FINAL PROTOCOL
25-NOV-2020
Sponsor Signatory
Typed Name:
Title:
Date
Protocol-specific Sponsor contact information can be found in the Investigator Study
File Binder (or equivalent).
Investigator Signatory
I agree to conduct this clinical study in accordance with the design outlined in this protocol 
and to abide by all provisions of this protocol.
Typed Name:
Title:
Date
 
 
05ND48
07YNSG


PRODUCT: MK-7264  
3
PROTOCOL/AMENDMENT NO.: 043-03 
MK-7264-043-03 FINAL PROTOCOL
25-NOV-2020
DOCUMENT HISTORY
Document
Date of Issue
Overall Rationale
Protocol Amendment 03
25-NOV-2020
Removal of procedures/assessments for specialized urine 
crystal analysis added in Protocol Amendment 02 and 
other clarifications.
Protocol Amendment 02
20-FEB-2020
Addition of procedures/assessments required for 
specialized urine crystal analysis.
Protocol Amendment 01
04-OCT-2019
Correction to entry criteria and other clarifications
Original Protocol
10-SEP-2019
Not applicable
 
 
05ND48
07YNSG


PRODUCT: MK-7264  
4
PROTOCOL/AMENDMENT NO.: 043-03 
MK-7264-043-03 FINAL PROTOCOL
25-NOV-2020
PROTOCOL AMENDMENT SUMMARY OF CHANGES
Amendment: 03
Overall Rationale for the Amendments:
Removal of procedures/assessments for specialized urine crystal analysis.
Summary of Changes Table:
Section # and Name
Description of Change 
Brief Rationale 
Section 1.3 – Schedule of 
Activities (SoA)
Added note to Urine Pregnancy Test:
Performed locally at study site.
To clarify that the urine pregnancy test is performed 
locally at the study site.
Section 1.3 – Schedule of 
Activities (SoA)
Deleted text:
Urine Collection and Preparation for 
Specialized Urine Crystal Analysis
Urine sample collected (at 
Visit 4/Discontinuation) is immediately 
prepared per central laboratory manual 
and stored at site; if central laboratory 
urinalysis positive for crystals and/or 
unexplained hematuria, sample shipped to 
Sponsor or designee for Specialized Urine 
Crystal Analysis.
See Section 8.3.7.
Urine collection for specialized urine crystal analysis is
removed from the list of assessments performed during 
the study.
 
 
05ND48
07YNSG


PRODUCT: MK-7264  
5
PROTOCOL/AMENDMENT NO.: 043-03 
MK-7264-043-03 FINAL PROTOCOL
25-NOV-2020
Section # and Name
Description of Change 
Brief Rationale 
Section 1.3 – Schedule of 
Activities (SoA)
Added footnote “d” for Pharmacokinetic 
Blood Collection:
A pharmacokinetic blood sample should be 
collected within approximately 96 hours of 
the final dose of study medication. If the 
discontinuation or final visit is scheduled 
to occur greater than 96 hours following 
the final dose of study medication, please 
contact the Sponsor for guidance.
To clarify the timing for pharmacokinetic samples.
Section 5.2 – Exclusion 
Criteria
Added note to number 18:
Note: Participants with a known history or 
current evidence of SARS-CoV-2 (COVID-
19) infection are ineligible to enroll in the 
study.
To clarify that participants with a known history or 
current evidence of SARS-CoV-2 (COVID-19) infection 
are ineligible to enroll in the study.
 
 
05ND48
07YNSG


PRODUCT: MK-7264  
6
PROTOCOL/AMENDMENT NO.: 043-03 
MK-7264-043-03 FINAL PROTOCOL
25-NOV-2020
Section # and Name
Description of Change 
Brief Rationale 
Section 7.1 –
Discontinuation of Study 
Intervention
Updated text (deleted strikethrough text):

The participant has a medical 
condition or personal circumstance 
which, in the opinion of the
investigator and/or Sponsor, placed 
the participant at unnecessary risk 
from continued administration of study 
intervention (including 
recommendation to discontinue 
participant from study intervention as 
part of monitoring for 
crystalluria/urolithiasis, see Section 
8.3.7).
To remove the recommendation for participants to be 
discontinued from the study intervention if gefapixant
crystalluria is detected.
Section 8.1.10 – Participant 
Blinding/Unblinding
Deleted text:
In the instance of identifying gefapixant 
crystals in the urine (see Section 8.3.7 for 
further details), the participant will be 
discontinued from the study intervention 
(see Section 7.1 for further details). If a 
participant has confirmed gefapixant 
crystals, it will be known that the 
participant was receiving gefapixant. In 
this circumstance, formal non-emergency 
unblinding should not be performed.
To remove that participants should be discontinued from 
the study intervention if gefapixant crystalluria is 
detected.
 
 
05ND48
07YNSG


PRODUCT: MK-7264  
7
PROTOCOL/AMENDMENT NO.: 043-03 
MK-7264-043-03 FINAL PROTOCOL
25-NOV-2020
Section # and Name
Description of Change 
Brief Rationale 
Section 8.2.1 Patient-
reported Outcomes
Updated text (new text in bold font, 
deleted text with strikethrough):
the e-Diary will allow the participant, 
based on recall, to complete these missed 
measures at any time in the next 24 hours
day (also see vendor’s site manual for 
further details)
To clarify when missed measures can be completed.
Section 8.2.1 Patient-
reported Outcomes
Updated text (new text in bold font, 
deleted text with strikethrough):
At the clinic visits, participants will be 
asked to complete ePRO measures (in the 
following order: LCQ, Cough Severity 
VAS, LCQ, PGIC, and WPAI), as outlined 
in the SoA (also see vendor’s site manual 
for further details).
To correct order of ePRO outcome measures.
8.3.7 – Renal and Urological 
Safety Assessments
Updated text (new text in bold font, 
deleted text with strikethrough): 
8.3.7.2 Visit 4/Discontinuation
At Visit 4 or Discontinuation Visit, a urine 
sample will be collected from all
participants, as outlined in the SoA. All 
urine samples will be collected and 
prepared as detailed in the central 
laboratory manual:
To remove procedures/assessments for specialized urine 
crystal analysis.
 
 
05ND48
07YNSG


PRODUCT: MK-7264  
8
PROTOCOL/AMENDMENT NO.: 043-03 
MK-7264-043-03 FINAL PROTOCOL
25-NOV-2020
Section # and Name
Description of Change 
Brief Rationale 

Part of the collected sample will be 
shipped to the central laboratory for 
urinalysis (that includes, but is not 
limited to, testing for blood and urinary 
crystals). 

The second part of the collected 
sample will be immediately prepared 
using a specialized filter for gefapixant 
urinary crystal analysis. The filtered 
sample will be stored at the study site 
until the urinalysis results from the 
central laboratory are received.
On receipt of the urinalysis results from 
the central laboratory, If results indicate a 
participant has unexplained hematuria 
and/or urinary crystals are identified and 
deemed to be clinically significant by the 
investigator, the participant should be 
considered for further evaluation. the 
filtered sample stored at the site will be 
immediately shipped to the Sponsor or 
designee and assessed for the presence of 
gefapixant urinary crystals via Raman 
spectroscopy. Raman spectroscopy is 
sensitive to the chemical structure of the 
 
 
05ND48
07YNSG


PRODUCT: MK-7264  
9
PROTOCOL/AMENDMENT NO.: 043-03 
MK-7264-043-03 FINAL PROTOCOL
25-NOV-2020
Section # and Name
Description of Change 
Brief Rationale 
molecule and gefapixant has a unique 
chemical structure compared with common 
urinary crystals. If there is an explanation 
for hematuria (for example, recent menses, 
urinary tract infection, or a recent 
procedure/instrumentation that would 
explain the hematuria) the sample will not 
be sent to the Sponsor or designee. See 
central laboratory manual for further 
procedural details.
If a participant has confirmed gefapixant 
urinary crystals, the Sponsor will inform 
the investigator and recommend follow-up 
with the participant at approximately 
2-week intervals; additional specialized 
urine crystal analyses should be performed 
until resolution of the gefapixant urinary
crystals. Once a participant has confirmed 
gefapixant crystals, it will be known that
the participant was receiving gefapixant 
(formal unblinding should not be 
performed [see Section 8.1.10]).
If an investigator deems it necessary to 
perform an unscheduled urinalysis at any
time during the study (after 
randomization), the same procedures for 
collection/preparation of the urine sample 
and evaluation of hematuria (as explained 
 
 
05ND48
07YNSG


PRODUCT: MK-7264  
10
PROTOCOL/AMENDMENT NO.: 043-03 
MK-7264-043-03 FINAL PROTOCOL
25-NOV-2020
Section # and Name
Description of Change 
Brief Rationale 
or unexplained) described for Visit 4 or 
Discontinuation Visit should be performed.
The sample will be analyzed for the 
presence of gefapixant urinary crystals as 
appropriate.
8.6.1 Blood Collection for 
Plasma Gefapixant
Added text:
A pharmacokinetic blood sample should be 
collected within approximately 96 hours of 
the final dose of study medication. If the 
discontinuation or final visit is scheduled 
to occur greater than 96 hours following 
the final dose of study medication, please 
contact the Sponsor for guidance.
To clarify the timing for pharmacokinetic samples.
 
 
05ND48
07YNSG


PRODUCT: MK-7264  
11
PROTOCOL/AMENDMENT NO.: 043-03 
MK-7264-043-03 FINAL PROTOCOL
25-NOV-2020
Section # and Name
Description of Change 
Brief Rationale 
8.10 3 Discontinued 
Participants Continuing to be 
Monitored in the Study
Updated text (new text in bold font):
If a participant is discontinued from the 
study intervention early:

the Discontinuation Visit should be 
performed as soon as possible; 
Procedures, including e-Diary 
assessments, should be performed 
as outlined for the 
Discontinuation Visit in the SoA 
(Section 1.3).
Note: If a participant discontinues at a 
regularly scheduled study visit, the 
procedures outlined for the 
Discontinuation Visit in the SoA should 
be followed in place of the procedures for 
the regularly scheduled study visit. 
To clarify the procedures that should be performed if a 
participant discontinues.
 
 
05ND48
07YNSG


PRODUCT: MK-7264  
12
PROTOCOL/AMENDMENT NO.: 043-03 
MK-7264-043-03 FINAL PROTOCOL
25-NOV-2020
Section # and Name
Description of Change 
Brief Rationale 
8.10.3 Discontinued 
Participants Continuing to be 
Monitored in the Study
Updated text (new text in bold font):

Study site visits should continue to 
be performed at timepoints that 
correspond to each remaining 
study visit. These visits will allow 
collection of follow-up information, 
limited to:
o
AEs;
o
Concomitant medication 
use; and 
o
e-Diary assessments, as 
outlined in the SoA (Section 
1.3).
Note: If the participant discontinues 
study intervention at a regularly 
scheduled study visit but remains in the 
study, the Discontinuation Visit should be 
performed, and the regularly scheduled 
study visits should resume thereafter. For 
example: If a participant discontinues 
study intervention at the time of Visit 3, 
procedures for the Discontinuation Visit 
should be performed at that time. The 
next expected study visit would be Visit 4.
To clarify the procedures that should be performed if a 
participant discontinues study intervention but remains in 
the study.
 
 
05ND48
07YNSG


PRODUCT: MK-7264  
13
PROTOCOL/AMENDMENT NO.: 043-03 
MK-7264-043-03 FINAL PROTOCOL
25-NOV-2020
Section # and Name
Description of Change 
Brief Rationale 
Section 9.1 Statistical 
Analysis Plan Summary
Updated text (new text in bold font, 
deleted text with strikethrough):
Interim Analyses
Timing: To be performed when 
approximately 40% of participants 
(approximately the first 166 enrolled
randomized participants) have either 
completed the study or discontinued the 
study intervention early.
Revised enrolled participants to randomized participants.
Section 9.7.1 Interim 
Efficacy Analysis
Updated text (new text in bold font, 
deleted text with strikethrough):
One planned efficacy IA will be conducted 
when approximately 40% of target 
participants (approximately the first 166 
enrolled randomized participants) have 
either completed the study (approximately 
141 enrolled randomized participants) or 
discontinued study intervention early.
Revised enrolled participants to randomized participants.
 
 
05ND48
07YNSG


PRODUCT: MK-7264  
14
PROTOCOL/AMENDMENT NO.: 043-03 
MK-7264-043-03 FINAL PROTOCOL
25-NOV-2020
Section # and Name
Description of Change 
Brief Rationale 
Section 9.7.2 Interim Safety 
Analysis
Updated text (new text in bold font, 
deleted text with strikethrough):
Interim safety will also be assessed at the 
time of prespecified IA for futility, ie, when 
approximately 40% of target participants 
(approximately the first 166 enrolled 
randomized participants) have either 
completed the study or discontinued the 
study intervention early.
Revised enrolled participants to randomized participants.
Throughout the document
Editorial and formatting changes.
Consistency.
 
 
05ND48
07YNSG


PRODUCT: MK-7264  
15
PROTOCOL/AMENDMENT NO.: 043-03 
MK-7264-043-03 FINAL PROTOCOL
25-NOV-2020
Table of Contents
DOCUMENT HISTORY ........................................................................................................3
PROTOCOL AMENDMENT SUMMARY OF CHANGES...............................................4
1
PROTOCOL SUMMARY ............................................................................................22
1.1
Synopsis.................................................................................................................22
1.2
Schema ..................................................................................................................25
1.3
Schedule of Activities (SoA)................................................................................26
2
INTRODUCTION..........................................................................................................29
2.1
Study Rationale....................................................................................................30
2.2
Background ..........................................................................................................31
Pharmaceutical and Therapeutic Background .............................................31
Preclinical and Clinical Studies ...................................................................31
Ongoing Clinical Studies.............................................................................31
2.3
Benefit/Risk Assessment......................................................................................31
3
HYPOTHESES, OBJECTIVES, AND ENDPOINTS................................................32
4
STUDY DESIGN............................................................................................................34
4.1
Overall Design......................................................................................................34
4.2
Scientific Rationale for Study Design.................................................................34
Rationale for Endpoints ...............................................................................35
4.2.1.1
Efficacy Endpoints.............................................................................35
4.2.1.2
Safety Endpoints................................................................................36
4.2.1.3
Pharmacokinetic Endpoints ...............................................................36
4.2.1.4
Pharmacodynamic Endpoints.............................................................37
4.2.1.5
Planned Exploratory Biomarker Research.........................................37
4.2.1.5.1
Planned Genetic Analysis ........................................................37
4.2.1.6
Future Biomedical Research..............................................................37
Rationale for the Use of Comparator/Placebo .............................................37
4.3
Justification for Dose...........................................................................................38
4.4
Beginning and End of Study Definition .............................................................38
Clinical Criteria for Early Study Termination .............................................38
5
STUDY POPULATION ................................................................................................38
5.1
Inclusion Criteria.................................................................................................39
5.2
Exclusion Criteria................................................................................................40
5.3
Lifestyle Considerations......................................................................................42
Meals and Dietary Restrictions....................................................................42
Caffeine, Alcohol, and Tobacco Restrictions ..............................................42
 
 
05ND48
07YNSG


PRODUCT: MK-7264  
16
PROTOCOL/AMENDMENT NO.: 043-03 
MK-7264-043-03 FINAL PROTOCOL
25-NOV-2020
Activity Restrictions ....................................................................................42
5.4
Screen Failures.....................................................................................................42
5.5
Participant Replacement Strategy......................................................................43
6
STUDY INTERVENTION............................................................................................43
6.1
Study Intervention(s) Administered...................................................................43
6.2
Preparation/Handling/Storage/Accountability .................................................45
Dose Preparation..........................................................................................45
Handling, Storage, and Accountability........................................................45
6.3
Measures to Minimize Bias: Randomization and Blinding..............................46
Intervention Assignment..............................................................................46
Stratification.................................................................................................46
Blinding........................................................................................................46
6.4
Study Intervention Compliance..........................................................................46
6.5
Concomitant Therapy..........................................................................................46
Rescue Medications and Supportive Care ...................................................48
6.6
Dose Modification (Escalation/Titration/Other)...............................................48
6.7
Intervention After the End of the Study............................................................48
6.8
Clinical Supplies Disclosure................................................................................48
7
DISCONTINUATION OF STUDY INTERVENTION AND PARTICIPANT 
WITHDRAWAL............................................................................................................49
7.1
Discontinuation of Study Intervention...............................................................49
7.2
Participant Withdrawal From the Study...........................................................50
7.3
Lost to Follow-up .................................................................................................50
8
STUDY ASSESSMENTS AND PROCEDURES........................................................50
8.1
Administrative and General Procedures ...........................................................51
Informed Consent.........................................................................................51
8.1.1.1
General Informed Consent.................................................................51
8.1.1.2
Consent and Collection of Specimens for Future Biomedical 
Research.............................................................................................52
Inclusion/Exclusion Criteria ........................................................................52
Participant Identification Card.....................................................................52
Medical History ...........................................................................................53
Prior and Concomitant Medications Review...............................................53
8.1.5.1
Prior Medications...............................................................................53
8.1.5.2
Concomitant Medications..................................................................53
Assignment of Screening Number...............................................................53
Assignment of Treatment/Randomization Number.....................................53
Study Intervention Administration ..............................................................53
 
 
05ND48
07YNSG


PRODUCT: MK-7264  
17
PROTOCOL/AMENDMENT NO.: 043-03 
MK-7264-043-03 FINAL PROTOCOL
25-NOV-2020
8.1.8.1
Timing of Dose Administration.........................................................54
Discontinuation and Withdrawal .................................................................54
8.1.9.1
Withdrawal From Future Biomedical Research ................................54
Participant Blinding/Unblinding..................................................................55
Calibration of Equipment.............................................................................55
8.2
Efficacy/Immunogenicity Assessments ..............................................................56
Patient-Reported Outcomes .........................................................................56
8.2.1.1
Leicester Cough Questionnaire..........................................................57
8.2.1.2
Cough Severity Diary ........................................................................57
8.2.1.3
Cough Severity Visual Analog Scale.................................................57
8.2.1.4
Patient Global Impression of Change Questionnaire.........................57
8.2.1.5
Work Productivity and Activity Impairment Questionnaire..............58
8.3
Safety Assessments...............................................................................................58
Chest Radiography/Computed Tomography Thorax Scan..........................58
Physical Examinations.................................................................................58
Vital Signs....................................................................................................59
Electrocardiograms ......................................................................................59
Spirometry....................................................................................................59
Clinical Safety Laboratory Assessments .....................................................59
Renal and Urological Safety Assessments...................................................60
8.3.7.1
Screening............................................................................................60
8.3.7.2
Visit 4/Discontinuation......................................................................60
8.4
Adverse Events (AEs), Serious Adverse Events (SAEs), and Other 
Reportable Safety Events ....................................................................................61
Time Period and Frequency for Collecting AE, SAE, and Other 
Reportable Safety Event Information ..........................................................61
Method of Detecting AEs, SAEs, and Other Reportable Safety Events......64
Follow-up of AE, SAE, and Other Reportable Safety Event Information...64
Regulatory Reporting Requirements for SAE .............................................64
Pregnancy and Exposure During Breastfeeding ..........................................64
Disease-related Events and/or Disease-related Outcomes Not Qualifying 
as AEs or SAEs............................................................................................65
Events of Clinical Interest (ECIs)................................................................65
8.5
Treatment of Overdose........................................................................................65
8.6
Pharmacokinetics.................................................................................................66
Blood Collection for Plasma Gefapixant .....................................................66
8.7
Pharmacodynamics..............................................................................................66
8.8
Biomarkers ...........................................................................................................66
 
 
05ND48
07YNSG


PRODUCT: MK-7264  
18
PROTOCOL/AMENDMENT NO.: 043-03 
MK-7264-043-03 FINAL PROTOCOL
25-NOV-2020
Planned Genetic Analysis Sample Collection..............................................66
8.9
Future Biomedical Research Sample Collection...............................................67
8.10
Visit Requirements...............................................................................................67
Screening......................................................................................................67
Treatment Period..........................................................................................67
Discontinued Participants Continuing to be Monitored in the Study ..........68
Poststudy......................................................................................................69
9
STATISTICAL ANALYSIS PLAN .............................................................................69
9.1
Statistical Analysis Plan Summary.....................................................................70
9.2
Responsibility for Analyses/In-house Blinding .................................................71
9.3
Hypotheses/Estimation ........................................................................................72
9.4
Analysis Endpoints...............................................................................................72
Efficacy Endpoints.......................................................................................72
9.4.1.1
Primary Efficacy Endpoint ................................................................72
9.4.1.2
Secondary Efficacy Endpoints...........................................................72
9.4.1.3
Exploratory Efficacy Endpoints.........................................................72
Safety Endpoints..........................................................................................72
9.5
Analysis Populations............................................................................................72
Efficacy Analysis Populations.....................................................................72
Safety Analysis Populations ........................................................................72
9.6
Statistical Methods...............................................................................................73
Statistical Methods for Efficacy Analyses...................................................73
Statistical Methods for Safety Analyses ......................................................74
Summaries of Baseline Characteristics, Demographics, and Other 
Analyses.......................................................................................................76
9.6.3.1
Demographic and Baseline Characteristics .......................................76
9.7
Interim Analyses ..................................................................................................77
Interim Efficacy Analysis ............................................................................77
Interim Safety Analysis................................................................................78
9.8
Multiplicity ...........................................................................................................78
9.9
Sample Size and Power Calculations .................................................................78
9.10
Subgroup Analyses...............................................................................................79
9.11
Compliance (Medication Adherence).................................................................80
9.12
Extent of Exposure...............................................................................................80
10
SUPPORTING DOCUMENTATION AND OPERATIONAL 
CONSIDERATIONS.....................................................................................................81
10.1
Appendix 1: Regulatory, Ethical, and Study Oversight Considerations........81
Code of Conduct for Clinical Trials.............................................................81
 
 
05ND48
07YNSG


PRODUCT: MK-7264  
19
PROTOCOL/AMENDMENT NO.: 043-03 
MK-7264-043-03 FINAL PROTOCOL
25-NOV-2020
Financial Disclosure.....................................................................................83
Data Protection.............................................................................................83
10.1.3.1
Confidentiality of Data ......................................................................84
10.1.3.2
Confidentiality of Participant Records...............................................84
10.1.3.3
Confidentiality of IRB/IEC Information............................................84
Committees Structure...................................................................................84
10.1.4.1
Executive Oversight Committee........................................................84
10.1.4.2
Scientific Advisory Committee (SAC)..............................................85
10.1.4.3
External Data Monitoring Committee ...............................................85
Publication Policy........................................................................................85
Compliance with Study Registration and Results Posting Requirements ...85
Compliance with Law, Audit, and Debarment ............................................86
Data Quality Assurance ...............................................................................86
Source Documents .......................................................................................87
Study and Site Closure.................................................................................88
10.2
Appendix 2: Clinical Laboratory Tests..............................................................89
10.3
Appendix 3: Adverse Events: Definitions and Procedures for Recording, 
Evaluating, Follow-up, and Reporting...............................................................91
Definition of AE ..........................................................................................91
Definition of SAE ........................................................................................92
Additional Events Reported.........................................................................93
Recording AE and SAE ...............................................................................93
Reporting of AEs, SAEs, and Other Reportable Safety Events to the 
Sponsor ........................................................................................................97
10.4
Appendix 4: Device Events, Adverse Device Events, and Medical Device 
Incidents: Definitions, Collection, and Documentation....................................98
10.5
Appendix 5: Contraceptive Guidance................................................................99
Definitions....................................................................................................99
Contraception Requirements........................................................................99
Pregnancy Testing......................................................................................100
10.6
Appendix 6: Collection and Management of Specimens for Future 
Biomedical Research..........................................................................................102
10.7
Appendix 7: Country-specific Requirements..................................................107
10.8
Appendix 8: Abbreviations ...............................................................................108
11
REFERENCES.............................................................................................................110
 
 
05ND48
07YNSG


PRODUCT: MK-7264  
20
PROTOCOL/AMENDMENT NO.: 043-03 
MK-7264-043-03 FINAL PROTOCOL
25-NOV-2020
LIST OF TABLES
Table 1
Study Interventions....................................................................................44
Table 2
Examples of Concomitant Treatment Permitted in the Study ...................48
Table 3
Reporting Time Periods and Time Frames for Adverse Events and 
Other Reportable Safety Events.................................................................63
Table 4
Analysis Strategy for Primary and Secondary Efficacy Endpoints ...........74
Table 5
Analysis Strategy for Safety Parameters....................................................76
Table 6
Protocol-required Safety Laboratory Assessments....................................90
Table 7
Contraceptive Methods ............................................................................100
 
 
05ND48
07YNSG


PRODUCT: MK-7264  
21
PROTOCOL/AMENDMENT NO.: 043-03 
MK-7264-043-03 FINAL PROTOCOL
25-NOV-2020
LIST OF FIGURES
Figure 1
Study Schema.............................................................................................25
 
 
05ND48
07YNSG


PRODUCT: MK-7264  
22
PROTOCOL/AMENDMENT NO.: 043-03 
MK-7264-043-03 FINAL PROTOCOL
25-NOV-2020
1
PROTOCOL SUMMARY
1.1
Synopsis
Protocol Title: A Phase 3b Randomized, Double-blind, Placebo Controlled, Multicenter 
Study to Evaluate the Efficacy and Safety of Gefapixant in Adult Participants with Recent 
Onset Chronic Cough
Short Title: Gefapixant Phase 3b Study in Adult Participants with Recent Onset Chronic 
Cough
Acronym: None
Hypotheses, Objectives, and Endpoints:
Hypotheses are aligned with objectives in the Objectives and Endpoints table.
In this study, the objectives/hypotheses and endpoints below will be evaluated in adult 
participants with unexplained or refractory chronic cough as follows:
Primary Objectives
Primary Endpoints
- Objective: To evaluate the efficacy of 
gefapixant in improving cough specific 
quality of life, measured as change from 
baseline in the Leicester Cough 
Questionnaire total score at Week 12
Hypothesis: Gefapixant is superior to 
placebo in increasing Leicester Cough 
Questionnaire total score change from 
baseline at Week 12
- Leicester Cough Questionnaire total score 
Secondary Objectives
Secondary Endpoints
- Objective: To evaluate the efficacy of 
gefapixant in improving self-rated cough 
severity, measured as change from baseline 
in the Cough Severity Visual Analog Scale 
score at Week 12
- Cough Severity Visual Analog Scale score
- Objective: To evaluate the safety and 
tolerability of gefapixant compared to 
placebo in percent of participants with 
adverse events
- Adverse events 
- Study intervention discontinuations due to 
an adverse event
 
 
05ND48
07YNSG


PRODUCT: MK-7264  
23
PROTOCOL/AMENDMENT NO.: 043-03 
MK-7264-043-03 FINAL PROTOCOL
25-NOV-2020
Overall Design:
Study Phase
Phase 3
Primary Purpose
Treatment
Indication
Treatment of Chronic Cough 
Population
Participants who are at least 18 years of age with recent
onset refractory or unexplained chronic cough
Study Type
Interventional
Intervention Model
Parallel
This is a multi-site study.
Type of Control
Placebo
Study Blinding
Double-blind with in-house blinding
Masking
Participant or Subject
Investigator
Estimated Duration of Study
The Sponsor estimates that the study will require 
approximately 18 months from the time the first participant 
(or their legally acceptable representative) provides 
documented informed consent until the last participant’s 
last study-related contact.
Number of Participants:
Approximately 414 participants will be randomized, with approximately 207 participants in 
each intervention group.
 
 
05ND48
07YNSG


PRODUCT: MK-7264  
24
PROTOCOL/AMENDMENT NO.: 043-03 
MK-7264-043-03 FINAL PROTOCOL
25-NOV-2020
Intervention Groups and Duration:
Intervention 
Groups
Intervention 
Group Name
Drug
Dose 
Strength
Dose 
Frequency
Route of 
Admin-
istration
Regimen/ 
Treatment 
Period
Use
Gefapixant
Gefapixant
45 mg
1 tablet 
BID
Oral
12 weeks
Experi-
mental
Placebo
Placebo
0 mg
matched to 
gefapixant
45 mg
1 tablet 
BID
Oral
12 weeks
Placebo
Abbreviations: BID = twice daily
Total 
Number
2 intervention groups
Duration of 
Participation
Each participant will participate in the study for approximately 16 weeks 
from the time the participant provides documented informed consent through 
the final contact. After a screening phase of approximately 2 weeks, each 
participant will receive assigned intervention for approximately 12 weeks. 
Each participant will have a safety follow-up telephone call 14 days (with an 
allowed variance of up to +7 days) after completion, discontinuation, or 
withdrawal of the study intervention.
Study Governance Committees:
Steering Committee
No
Executive Oversight Committee
Yes
Data Monitoring Committee
Yes
Clinical Adjudication Committee
No
Scientific Advisory Committee
Yes
Study governance considerations are outlined in Appendix 1.
Study Accepts Healthy Volunteers: No
A list of abbreviations used in this document can be found in Appendix 10.8.
 
 
05ND48
07YNSG


PRODUCT: MK-7264  
25
PROTOCOL/AMENDMENT NO.: 043-03 
MK-7264-043-03 FINAL PROTOCOL
25-NOV-2020
1.2
Schema
The study design is depicted in Figure 1.
Figure 1
Study Schema
BID = twice daily, e-Diary = electronic diary.
At study entry, participants will be randomized in a 1:1 ratio to 1 of 2 intervention groups: gefapixant 45 mg 
BID or placebo. Participants will remain on their assigned intervention at Randomization throughout the study.
Telephone contact will be made on Day 7 (+3 days) and Day 21 (±3 days) to review any adverse events, 
concomitant medications, study drug administration compliance, and e-Diary completion.
A safety follow-up telephone call will be conducted a minimum of 14 days (with an allowed variance of up to 
+7 days) after Visit 4 or after the last dose of study intervention (for participants who discontinue from 
intervention).
 
 
05ND48
07YNSG


PRODUCT: MK-7264  
26
PROTOCOL/AMENDMENT NO.: 043-03 
MK-7264-043-03 FINAL PROTOCOL
25-NOV-2020
1.3
Schedule of Activities (SoA)
Study Period
Screening
Baseline / 
Randomization
Intervention
Follow-up 
TCa
Discc
Notes
Visit 
1
2
TC
TC
3
4
-
NA
Scheduled Day
-14 to -1
1
7
21
42
84
98
NA
Scheduling Window (recommended)
NA
NA
+3 
days
±3 
days
±4
days
±4
days
+7 days
NA
Scheduled Week
-2 to -1
-
1
3
6
12
14
NA
Administrative Procedures
Informed Consent
X
Informed Consent for FBR
X
FBR is optional for the participant.
Participant Identification Card 
X
X
Update with allocation number once 
randomized.
Inclusion/Exclusion Criteria
X
X
Demographics, Medical History 
X
Prior/Concomitant Medication Review
X
X
X
X
X
X
X
X
Randomization 
X
Gefapixant/Placebo 
Administration/Dispensing
X
X
Study Intervention Accountability
X
X
X
Contact IRT System
X
X
X
X
X
Efficacy Procedures
Activate ePROs
X
X
X
X
X
See ePRO vendor manual.
Issue/instruct on use of e-Diary
X
Review e-Diary compliance and 
instructions for use
X
X
X
X
X
X
Disc: Only when participant 
discontinues from study intervention 
(not discontinues from study).
Deactivate/collect e-Diary
X
X
Disc: Only when participant 
discontinues from study (not just 
discontinues study intervention).
 
 
05ND48
07YNSG


PRODUCT: MK-7264  
27
PROTOCOL/AMENDMENT NO.: 043-03 
MK-7264-043-03 FINAL PROTOCOL
25-NOV-2020
Study Period
Screening
Baseline / 
Randomization
Intervention
Follow-up 
TCa
Discc
Notes
Visit 
1
2
TC
TC
3
4
-
NA
Scheduled Day
-14 to -1
1
7
21
42
84
98
NA
Scheduling Window (recommended)
NA
NA
+3 
days
±3 
days
±4
days
±4
days
+7 days
NA
Scheduled Week
-2 to -1
-
1
3
6
12
14
NA
LCQ
X
X
X
X
Complete at clinic visit:
- Visit 2: After confirming eligibility 
for randomization and before first 
dose of study intervention.
- Visits 3 & 4/Disc: Before all other 
procedures. 
CSD
Complete daily (in evening) 
Remind participant of need to complete 
daily.
Cough Severity VAS
Complete at Visit 1 clinic visit and daily (in evening) 
Visits 2 & 3: Remind participant of 
need to complete daily.
PGIC
X
X
Complete at clinic visit. 
WPAI
X
X
X
Visit 2: Complete at clinic visit before 
first dose of study intervention. 
Safety Procedures
Chest Radiograph or CT Thorax
X
Not required if done in the past 1 year 
and after onset of chronic cough.
Physical examination 
X
X
X
Visit 1 (Screening): full examination.
Visit 4 and Disc: directed examination.
Height
X
Weight
X
X
X
Vital Signs 
X
X
X
X
X
12-lead ECG
X
Spirometry
X
Urine Pregnancy Test 
X
Performed locally at study site.
Serum Pregnancy Test
X
Only if urine pregnancy test is positive.
Hematology & Chemistry
X
X
X
Urinalysis (with microscopy)
X
X
X
Adverse Event Monitoring
X
X
X
X
X
X
X
X
 
 
05ND48
07YNSG


PRODUCT: MK-7264  
28
PROTOCOL/AMENDMENT NO.: 043-03 
MK-7264-043-03 FINAL PROTOCOL
25-NOV-2020
Study Period
Screening
Baseline / 
Randomization
Intervention
Follow-up 
TCa
Discc
Notes
Visit 
1
2
TC
TC
3
4
-
NA
Scheduled Day
-14 to -1
1
7
21
42
84
98
NA
Scheduling Window (recommended)
NA
NA
+3 
days
±3 
days
±4
days
±4
days
+7 days
NA
Scheduled Week
-2 to -1
-
1
3
6
12
14
NA
Pharmacokinetics / Biomarkers
Pharmacokinetic blood collectiond
X
X
Only 1 sample will be collected, either 
at Visit 4 or Disc Visit, whichever is 
the first visit following the last dose of 
study intervention.
Blood for Genetic Analysisb
X
CSD = Cough Severity Diary; CT = computed tomography; Disc = Discontinuation; ECG = electrocardiogram; e-Diary = electronic diary; ePRO = electronic patient-reported 
outcomes; FBR = Future Biomedical Research; IRT = interactive response technology; LCQ = Leicester Cough Questionnaire; NA = not applicable; PGIC = Patient Global 
Impression of Change; TC = telephone call; VAS = Visual Analog Scale; WPAI = Work Productivity and Activity Impairment.
a. A safety follow-up telephone call will be conducted a minimum of 14 days (with an allowed variance of up to +7 days) after the last dose of study intervention (for participants 
who complete the study, discontinue from intervention, or discontinue from the study).
b. This sample should be drawn for planned analysis of the association between genetic variants in deoxyribonucleic acid and drug response. This sample will not be collected at a
site if there is either a local law or regulation prohibiting collection, or if the Institutional Review Board / Independent Ethics Committee does not approve the collection of the 
sample for these purposes. If the sample is collected, leftover extracted DNA will be stored for future biomedical research if the participant (or their legally acceptable 
representative) provides documented informed consent for future biomedical research. If the planned genetic analyses are not approved, but future biomedical research is 
approved and consent is given, this sample will be collected for the purpose of future biomedical research.
c. For participants who discontinue from study intervention early, study visits/assessments should continue to be performed at timepoints that correspond to each remaining study 
visit, but procedures will be limited to collection of adverse events, concomitant medications, and e-Diary assessments.
d. A pharmacokinetic blood sample should be collected within approximately 96 hours of the final dose of study medication. If the discontinuation or final visit is scheduled to 
occur greater than 96 hours following the final dose of study medication, please contact the Sponsor for guidance.
 
 
05ND48
07YNSG


PRODUCT: MK-7264  
29
PROTOCOL/AMENDMENT NO.: 043-03 
MK-7264-043-03 FINAL PROTOCOL
25-NOV-2020
2
INTRODUCTION
Cough is one of the most common presenting symptoms for patients seeking care from 
primary care specialists, allergists, pulmonologists, or otolaryngologists worldwide. 
Although cough is an important mechanism to protect the airway from potentially harmful
stimuli, excessive or inappropriate cough can be associated with significant morbidity 
including physical, psychological and social consequences [French, C. L., et al 1998] 
[Young, E. C. 2010] [Chamberlain, S. A., et al 2015] [Dicpinigaitis, P. V., et al 2006] 
[Kuzniar, T. J., et al 2007] [French, C. L., et al 2017] [Everett, C. F., et al 2007]. The 
importance of cough as a clinical problem globally has led to multiple societies publishing 
guidelines on the diagnosis and management of cough [Morice, A. H., et al 2004] [Chung, K. 
F., et al 2006] [Morice, A. H., et al 2006] [The committee for The Japanese Respiratory 
Society guidelines 2006] [Kardos, P., et al 2010] [Irwin, R. S. 2006] [Chung, K. F., et al 
2006] [Raj, A. A., et al 2009] [Irwin, R. S., et al 2014]. In these clinical guidelines, cough is 
categorized based upon the duration of the cough. Acute cough is present for less than 3 
weeks and most often due to acute viral upper respiratory tract infection. A cough that has 
been present longer than 3 weeks is either subacute (3 to 8 weeks) or chronic (>8 weeks)
[The committee for The Japanese Respiratory Society guidelines 2006]. There are multiple 
diagnostic possibilities for each category, acute, subacute, and chronic, that are presented in 
clinical guidelines [Gibson, P., et al 2016].
The overall prevalence of chronic cough is approximately 10% [Song, W. J., et al 2015]. For 
approximately two-thirds of these patients, a potential co-morbid condition can be identified,
and the cough effectively managed by optimizing therapy for the condition. Patients who 
have been diagnosed with conditions that are suspected to cause chronic cough (ie, asthma, 
GERD, UACS, or non-eosinophilic bronchitis [Irwin, R. S., et al 2018]) but whose cough 
does not resolve with the appropriate treatment of those conditions are considered to have 
refractory chronic cough [McCrory, D. C., et al 2013]. Patients with chronic cough in whom 
an underlying etiology cannot be identified despite a thorough diagnostic work-up are 
considered to have unexplained chronic cough [McCrory, D. C., et al 2013]. 
Professional guidelines describe systematic approaches to the evaluation and management of 
chronic cough. These guidelines are based largely on consensus opinion and observational 
data from the medical literature. There are currently no treatments approved by the United 
States FDA or EMA for the treatment of chronic cough [Smith, J. A. 2016]. Given the 
prolonged nature, significant morbidity, and lack of effective treatment, unexplained or 
refractory chronic cough is a major unmet medical need.
Mechanism of Cough
Each cough occurs through the stimulation of a complex reflex arc. Cough is initiated 
following activation of airway sensory nerves in the upper and lower respiratory tract. 
Airway sensory nerves are tailored to detect changes in the physical and chemical 
environment, and if required, elicit protective reflex events such as cough. These reflexes are 
normally protective; however, in disease, airway reflexes can become hyperresponsive, 
leading to an increase in symptoms and a pathologic cough. 
 
 
05ND48
07YNSG


PRODUCT: MK-7264  
30
PROTOCOL/AMENDMENT NO.: 043-03 
MK-7264-043-03 FINAL PROTOCOL
25-NOV-2020
P2X3 receptors are ligand-gated ion channels that respond to ATP and are almost exclusively 
localized on C-fiber sensory neurons, which innervate the upper and lower airways and are 
the main nerve fibers responsible for cough. Adenosine triphosphate is released by damaged, 
stressed, and inflamed tissues. The action of ATP at sensory neurons in the periphery and 
spinal cord contributes to neural excitability and may cause hyperresponsiveness through 
binding to P2X3 containing receptors and stimulation of C-fiber neurons [North, R. A. 2004]
[Khakh, B. S. 2006]. Antagonism of P2X3-containing receptors is predicted to normalize 
sensory neuron sensitivity, based on data from P2X3 knock-out mice and the effects of small 
interfering RNA knock-down and pharmacological antagonists [Barclay, J., et al 2002]
[Cockayne, D. A., et al 2000] [Souslova, V., et al 2000]. Adenosine triphosphate and P2X3-
containing receptors have been shown to be involved in airways sensitization and their 
involvement provides a rationale for P2X3 antagonism in the treatment of cough [Cockayne, 
D. A., et al 2000].
Recently, the term cough hypersensitivity syndrome has been proposed to describe a group of 
patients with chronic cough and similar clinical characteristics. These similar clinical 
characteristics include irritation in the throat or upper chest, cough triggered by stimuli that 
do not normally cause cough, increased cough sensitivity to inhaled stimuli, and cough 
paroxysms. A potential biologic explanation for cough hypersensitivity syndrome suggests 
an underlying sensory neuropathy characterized by sensory nerve hypersensitization. Prior 
Phase 2 data support the role of P2X3 antagonism in the treatment of patients with refractory 
or unexplained chronic cough.
2.1
Study Rationale
Current therapies for acute and subacute cough (narcotic, non-narcotic, and over-the-counter 
medications) have limited and/or unproven efficacy and an undesirable side effect profile. 
There are currently no approved therapies for chronic cough. 
Previous Phase 2 studies have demonstrated dose-related efficacy and an acceptable safety 
and tolerability profile for gefapixant in participants with refractory or unexplained chronic 
cough. Gefapixant, at a dose of 50 mg BID for 12 weeks, demonstrated a significant 
reduction in the objective measure of awake cough frequency compared to placebo (see 
gefapixant IB). 
The ongoing Phase 3 program is enrolling participants with chronic cough ≥12 months and a 
diagnosis of refractory chronic cough or unexplained chronic cough according to the current
ACCP guidelines. However, there may be value in treating unexplained or refractory chronic 
cough earlier in its course, in order to improve quality of life.
The purpose of this Phase 3b study is to evaluate the efficacy of gefapixant in participants 
with chronic cough (duration > 8 weeks after onset of cough symptoms) for <12 months and 
a diagnosis of refractory or unexplained chronic cough. The data from this study will 
supplement the ongoing pivotal Phase 3 program by directly informing the potential benefit 
of treating refractory or unexplained chronic cough within 14 months of the onset of cough 
symptoms (per participant report and/or medical history).
 
 
05ND48
07YNSG


PRODUCT: MK-7264  
31
PROTOCOL/AMENDMENT NO.: 043-03 
MK-7264-043-03 FINAL PROTOCOL
25-NOV-2020
2.2
Background
Refer to the IB for detailed background information on gefapixant.
Pharmaceutical and Therapeutic Background
Gefapixant is an oral P2X3 antagonist. Gefapixant has been evaluated in clinical studies for 
the treatment of chronic cough, interstitial cystitis/bladder pain syndrome, osteoarthritis pain, 
and asthma, and is currently being evaluated in endometriosis-related pain. Based on data 
generated from clinical studies to date, the gefapixant development program is focused on 
cough. Gefapixant has also been evaluated in an extensive nonclinical program.
Gefapixant is provided as a film-coated tablet. The gefapixant tablets provided for this study 
contain gefapixant 45 mg. The placebo tablets provided in this study are indistinguishable 
from the gefapixant tablets in appearance. The placebo tablets contain no gefapixant but 
contain the same inactive excipients as those included in the active tablets.
Preclinical and Clinical Studies
Refer to the IB for detailed information on preclinical and clinical studies.
Ongoing Clinical Studies
Gefapixant Development Program
The current gefapixant cough development plan consists of three 12-month Phase 3 studies, 
still ongoing, in participants with refractory or unexplained chronic cough (protocols 027, 
030, and 038). Protocols 027 and 030 are being conducted in approximately 720 and 
1290 participants, respectively, in the US, Europe, and other regions. In both studies, 
participants are randomized in a 1:1:1 ratio to either gefapixant 45 mg BID, gefapixant 15 mg 
BID, or placebo. Protocol 038 is being conducted in approximately 160 participants in Japan; 
participants are randomized in a 1:1 ratio to either gefapixant 45 mg BID or gefapixant 
15 mg BID.
2.3
Benefit/Risk Assessment
It cannot be guaranteed that participants in clinical studies will directly benefit from 
treatment during participation, as clinical studies are designed to provide information about 
the safety and effectiveness of an investigational medicine.
Gefapixant has been evaluated in an extensive nonclinical program. To date, there is little 
evidence from nonclinical studies that gefapixant has any direct cellular or direct target organ 
toxicity.
The efficacy and safety of gefapixant has been evaluated in multiple completed clinical 
studies for cough. In those studies, participants with chronic cough who took gefapixant
showed a reduction in cough frequency while awake and improvement in PROs (see IB for 
further details).
 
 
05ND48
07YNSG


PRODUCT: MK-7264  
32
PROTOCOL/AMENDMENT NO.: 043-03 
MK-7264-043-03 FINAL PROTOCOL
25-NOV-2020
In the completed and ongoing clinical studies, no major safety concerns have been noted. 
Taste-related adverse experiences (eg, dysgeusia [change in taste], hypogeusia [diminished 
taste], ageusia [loss of taste]) were the most frequently reported AEs in clinical studies with 
doses up to 1800 mg BID for 14 days. The percentage of participants receiving doses ≤50 mg 
BID reported less taste-related AEs than those receiving doses >50 mg BID. Some 
participants also described oral paresthesias (tingling sensation in the mouth and/or throat). 
In many instances, participants reported oral paresthesia or hypoesthesia (numbness) 
concurrent with taste disturbances. 
There is a rationale for taste disturbance with P2X2/3 antagonism because of the putative 
participation of ATP, acting via this receptor, in transducing taste signals from taste bud cells 
to sensory neurons. Attenuation of taste acuity, considered a tolerability concern as opposed 
to a safety concern, is fully reversible after discontinuation of study intervention and 
amenable to monitoring in clinical studies.
Overall, based on growing clinical evidence supporting the efficacy of gefapixant in 
participants with refractory or unexplained chronic cough and the lack of significant safety 
findings in completed and ongoing nonclinical and clinical studies, the benefit-risk balance 
of gefapixant is assessed as positive.
Additional details regarding specific benefits and risks for participants participating in this 
clinical study may be found in the accompanying IB and informed consent documents.
3
HYPOTHESES, OBJECTIVES, AND ENDPOINTS
In this study, the objectives/hypotheses and endpoints below will be evaluated in adult 
participants with refractory or unexplained chronic cough as follows:
Objectives
Endpoints
Primary

Objective: To evaluate the efficacy of 
gefapixant in improving cough-
specific quality of life, measured as 
change from baseline in the Leicester 
Cough Questionnaire total score at 
Week 12
Hypothesis: Gefapixant is superior to 
placebo in increasing Leicester Cough 
Questionnaire total score change from 
baseline at Week 12

Leicester Cough Questionnaire total 
score 
 
 
05ND48
07YNSG


PRODUCT: MK-7264  
33
PROTOCOL/AMENDMENT NO.: 043-03 
MK-7264-043-03 FINAL PROTOCOL
25-NOV-2020
Objectives
Endpoints
Secondary

Objective: To evaluate the efficacy of 
gefapixant in improving self-rated 
cough severity, measured as change 
from baseline in the Cough Severity 
Visual Analog Scale score at Week 12

Cough Severity Visual Analog Scale 
score

Objective: To evaluate the safety and 
tolerability of gefapixant compared to 
placebo in percent of participants with 
adverse events

Adverse events 

Study intervention discontinuations 
due to an adverse event
Tertiary/Exploratory

Objective: To evaluate the efficacy of 
gefapixant in improving self-rated 
cough frequency, intensity, and 
disruption, measured as change from 
baseline in the Cough Severity Diary 
total score at Week 12

Cough Severity Diary total score 

Objective: To evaluate the impact of 
gefapixant on work productivity 
(measured as change from baseline in 
the Work Productivity and Activity 
Impairment score) and global rating 
of change (measured by the Patient 
Global Impression of Change score)
at Week 12
•
Work Productivity and Activity 
Impairment score

Patient Global Impression of Change 
score

Objective: To explore the relationship 
between genetic variation and 
response to the treatment 
administered, and mechanisms of 
disease. Variation across the human 
genome may be analyzed for 
association with clinical data 
collected in this study.

Germline genetic variation
 
 
05ND48
07YNSG


PRODUCT: MK-7264  
34
PROTOCOL/AMENDMENT NO.: 043-03 
MK-7264-043-03 FINAL PROTOCOL
25-NOV-2020
4
STUDY DESIGN
4.1
Overall Design
This is a randomized, double-blind, placebo-controlled, parallel-group, multi-site study of 
gefapixant in participants with unexplained or refractory chronic cough. Approximately 
414 participants will be randomized in a 1:1 ratio to 1 of 2 intervention groups: gefapixant
45 mg BID or placebo. Participants will remain on their assigned intervention at
Randomization throughout the study. The duration of intervention for each participant is as 
follows:

Screening Period: approximately 14 days (see Section 8.10.1)

Study intervention period, including Randomization (12-week intervention period): 
approximately 84 days (see Section 8.10.2)

Follow-up period: approximately 14 days (see Section 8.10.4)
Individual participation is expected to be approximately 16 weeks from Screening through 
the Follow-up period.
The study will comprise of 4 study visits and 3 scheduled telephone calls: Visit 1 (Screening, 
from -2 weeks to -1 week), Visit 2 (Baseline/Randomization, Day 1), Telephone Call 
(Day 7), Telephone Call (Day 21), Visit 3 (Week 6), Visit 4 (Week 12), and a Telephone 
Safety Follow-up, Week 14.
Specific procedures to be performed during the study, as well as their prescribed times and 
associated visit windows, are outlined in the SoA in Section 1.3. Details of each procedure 
are provided in Section 8.
This study will use an external DMC to monitor efficacy and safety. There will be one 
planned IA when approximately 40% of the total randomized participants have either 
completed the study or discontinued study intervention early (all available follow-up data 
will be included in the analysis).
Results of the IA will be reviewed by the DMC, which will make recommendations to the 
EOC of the Sponsor to continue or stop the study according to the statistical analysis plan 
described in Section 9. The study may be stopped for futility or strong benefit (efficacy) 
according to the results of the IA. 
Final database lock will occur after all participants have completed the study, or discontinued 
study intervention early, and a full analysis will be conducted. Details of the blinding are in 
Section 9.2.
4.2
Scientific Rationale for Study Design
The ongoing Phase 3 studies (Protocols 27 and 30) are evaluating the efficacy of gefapixant 
in reducing objective cough frequency and improving quality of life in participants with 
 
 
05ND48
07YNSG


PRODUCT: MK-7264  
35
PROTOCOL/AMENDMENT NO.: 043-03 
MK-7264-043-03 FINAL PROTOCOL
25-NOV-2020
≥12 months of chronic cough and a diagnosis of refractory or unexplained chronic cough. 
This study, which will enroll participants with more recent onset chronic cough 
(< 12 months), will focus on an assessment of cough from the participant’s perspective, 
which is important for evaluating the response to therapy. 
Rationale for Endpoints
4.2.1.1
Efficacy Endpoints
Primary endpoint:

Leicester Cough Questionnaire (LCQ) total score 
The primary goal of the study is to demonstrate that gefapixant is superior to placebo in 
improving cough-related quality of life, evidenced by a change from baseline in the LCQ 
total score with gefapixant relative to placebo assessed at Week 12 (2-week recall period). 
The LCQ is a validated, 19-item, cough-specific HRQoL questionnaire which contains three 
domains (physical, psychological, and social). Each domain score is calculated as the mean 
score of the items within the domain, with a range from 1 to 7. The LCQ total score is the 
sum of the 3 domains, with a range from 3 to 21. Each item on the LCQ assesses symptoms 
or the impact of symptoms on HRQoL over the past 2 weeks using a 7-point Likert scale 
ranging from 1 to 7. Higher scores indicate better HRQoL. Data obtained from the LCQ will 
provide information on the impact of chronic cough on participants’ daily lives.
Secondary endpoint:

Cough Severity VAS score.
The secondary objective of the study is to evaluate the efficacy of gefapixant in improving 
self-rated cough severity as assessed by the Cough Severity VAS change from baseline at 
Week 12. 
The Cough Severity VAS is a single-item question asking the participant to rate the severity 
of their cough “today” using a 100 mm VAS anchored with “No Cough” at 0 and “Extremely 
Severe Cough” at 100. Similar to the well-established use of VAS scores in chronic pain, the 
Cough Severity VAS measure provides a quick and easily-interpreted subjective assessment 
useful for clinicians to monitor improvement of their chronic cough patients following 
treatment.
Exploratory endpoints:
This study will evaluate the impact of gefapixant on cough severity as assessed by the CSD. 
It will also evaluate the impact of gefapixant on global rating of change using the PGIC 
questionnaire and impact on work productivity using the WPAI.
 
 
05ND48
07YNSG


PRODUCT: MK-7264  
36
PROTOCOL/AMENDMENT NO.: 043-03 
MK-7264-043-03 FINAL PROTOCOL
25-NOV-2020

Cough Severity Diary (CSD): The CSD is a validated, 7-item, disease-specific PRO 
measure with a recall period of “today.” The measure evaluates frequency of cough 
(3 items), intensity of cough (2 items), and disruption due to cough (2 items); each 
item is rated on an 11-point scale ranging from 0 to 10, with higher scores indicating 
greater severity. A CSD total score and 3 domain scores (frequency, intensity, 
disruption) can be calculated. Domain scores are calculated as the average of the 
items within the domain and range from 1 to 7. The total score is the sum of the 
domain scores with a range of 3 to 21.

Patient Global Impression of Change (PGIC) questionnaire: The PGIC is a 2-part 
measure asking the participant to rate the change in their cough symptoms compared 
to the start of the study, with response options ranging from “very much improved” to 
“very much worse” (7-point scale). Based on the response to the initial question, the 
participant is asked a follow-up question to evaluate the meaningfulness of the 
improvement or worsening, with response options of ‘yes’ or ‘no’ indicating whether 
the improvement or worsening was important or not.

Work Productivity and Activity Impairment (WPAI) questionnaire: The WPAI 
questionnaire yields 4 types of scores as follows: (1) absenteeism (work time missed); 
(2) presenteeism (impairment at work/reduced on-the-job effectiveness); (3) work 
productivity loss (overall work impairment/absenteeism plus presenteeism); and 
(4) activity impairment. The WPAI outcomes are expressed as impairment 
percentages, with higher numbers indicating greater impairment and less productivity, 
ie, worse outcomes [Reilly, M. C., et al 1993]. 
Participants will be asked to indicate if they are currently employed and to respond to 
the following questions referring to “the past 7 days”: work hours missed due to 
health problems, work hours missed for other reasons, hours actually worked, the 
degree to which their health has affected productivity while working, and the degree 
to which their health affected productivity in regular unpaid activities
4.2.1.2
Safety Endpoints
The safety data for gefapixant to date has been described in detail in the gefapixant IB. 
In support of the safety objective to evaluate the safety and tolerability profile of gefapixant, 
the safety and tolerability endpoints will be assessed by clinical evaluation of AEs and 
discontinuation due to AEs. Inspection of other study parameters including vital signs, 
physical examination, and standard laboratory safety tests will be assessed at timepoints
specified in the SoA (Section 1.3). Adverse events are graded and recorded according to 
Section 8.4 and Appendix 3.
4.2.1.3
Pharmacokinetic Endpoints
To determine exposure to gefapixant, a blood sample will be collected as specified in the 
SoA (Section 1.3) to estimate the Ctrough.
 
 
05ND48
07YNSG


PRODUCT: MK-7264  
37
PROTOCOL/AMENDMENT NO.: 043-03 
MK-7264-043-03 FINAL PROTOCOL
25-NOV-2020
4.2.1.4
Pharmacodynamic Endpoints
No pharmacodynamic biomarkers that will require modeling are planned for this study.
4.2.1.5
Planned Exploratory Biomarker Research
4.2.1.5.1
Planned Genetic Analysis
Genetic variation may impact a participant’s response to therapy, susceptibility to, severity, 
and progression of disease. Variable response to therapy may be due to genetic determinants 
that impact drug absorption, distribution, metabolism, and excretion; mechanism of action of 
the drug; disease etiology; and/or molecular subtype of the disease being treated. Therefore, 
where local regulations and Institutional Review Board/Independent Ethics Committee 
(IRB/IEC) allow, a sample will be collected for deoxyribonucleic acid (DNA) analysis from 
consenting participants.
DNA samples may be used for research related to the study intervention(s), the disease under 
study, or related diseases. They may also be used to develop tests/assays including diagnostic 
tests related to the disease under study, related diseases, and study intervention(s). Genetic 
research may consist of the analysis of 1 or more candidate genes, the analysis of genetic 
markers throughout the genome, or analysis of the entire genome. Analysis may be 
conducted if it is hypothesized that this may help further understand the clinical data.
The samples may be analyzed as part of a multi-study assessment of genetic factors involved 
in the response to understand study disease or related conditions.
4.2.1.6
Future Biomedical Research
The Sponsor will conduct future biomedical research on DNA specimens for which consent 
was provided during this clinical study.
Such research is for biomarker testing to address emergent questions not described elsewhere 
in the protocol (as part of the main study) and will only be conducted on specimens from 
appropriately consented participants. The objective of collecting/retaining specimens for 
future biomedical research is to explore and identify biomarkers that inform the scientific 
understanding of diseases and/or their therapeutic treatments. The overarching goal is to use 
such information to develop safer, more effective drugs/vaccines, and/or to ensure that 
participants receive the correct dose of the correct drug/vaccine at the correct time. The 
details of future biomedical research are presented in Appendix 6.
Rationale for the Use of Comparator/Placebo
A placebo is included in this study to maintain the study blinding, allowing for an unbiased 
assessment of efficacy and safety. Participants may discontinue the study intervention at any 
time. Given that there is no approved treatment for chronic cough, use of a placebo is 
justified.
 
 
05ND48
07YNSG


PRODUCT: MK-7264  
38
PROTOCOL/AMENDMENT NO.: 043-03 
MK-7264-043-03 FINAL PROTOCOL
25-NOV-2020
4.3
Justification for Dose
In this study, gefapixant will be orally administered as gefapixant 45 mg BID based on the 
safety and efficacy results observed to date. Although the Phase 2 studies demonstrated 
efficacy of gefapixant at a dose of 50 mg BID, based on modeling and simulation work, a 
dosing regimen of 45 mg BID is proposed to provide maximum efficacy with a more 
acceptable tolerability profile than the 50 mg BID dose.
The known mechanism of action of gefapixant and related clinical study results support that 
the efficacy of gefapixant in decreasing cough, and the prevalence of the most common AE, 
dysgeusia, are both dose-related. Gefapixant 15 mg and 45 mg BID are being evaluated in 
the main Phase 3 program for chronic cough. The 45 mg BID dose is anticipated to provide 
meaningful efficacy in the reduction of cough symptoms with a manageable incidence of 
dysgeusia.
Based on PK studies, gefapixant is rapidly absorbed with a median time to reach maximum 
plasma concentration of 1.0 to 2.0 hours. In addition, the half-life of gefapixant is 
approximately 7 to 10 hours and consistent with a BID dosing schedule.
For this study, 12 weeks of intervention was selected for consistency with prior studies of 
gefapixant in chronic cough which have shown meaningful efficacy in cough reduction. 
4.4
Beginning and End of Study Definition
The overall study begins when the first participant (or their legally acceptable representative) 
provides documented informed consent. The overall study ends when the last participant 
completes the last study-related contact, withdraws consent, or is lost to follow-up (ie, the 
participant is unable to be contacted by the investigator).
Clinical Criteria for Early Study Termination
Early study termination will be the result of the following specified criterion:

During the IA, based on the interim data:
a.
If the futility criteria are met, then the study may be stopped for futility and all 
participants would be discontinued from the study.
b.
If the efficacy criteria are met, then the study may be stopped for efficacy and 
all participants would be discontinued from the study.
5
STUDY POPULATION
Male and female participants of at least 18 years of age, with chronic cough for <12 months 
and a diagnosis of refractory chronic cough or unexplained chronic cough according to the 
current ACCP guidelines.
 
 
05ND48
07YNSG


PRODUCT: MK-7264  
39
PROTOCOL/AMENDMENT NO.: 043-03 
MK-7264-043-03 FINAL PROTOCOL
25-NOV-2020
Prospective approval of protocol deviations to recruitment and enrollment criteria, also 
known as protocol waivers or exemptions, is not permitted.
5.1
Inclusion Criteria
A participant will be eligible for inclusion in the study if the participant:
Type of Participant and Disease Characteristics
1. Has a chest radiograph or CT thorax (within 1 year of Screening/Visit 1 and after the 
onset of chronic cough) not demonstrating any abnormality considered to be significantly 
contributing to the chronic cough or any other clinically significant lung disease, in the 
opinion of the principal investigator or the subinvestigator (subinvestigator must be a 
physician). Note: If not available, can be performed at Screening/Visit 1. Chest 
radiograph or CT scan of the thorax performed after the onset of cough symptoms but 
before the diagnosis of chronic cough require consultation with the Sponsor to determine 
if acceptable for inclusion in the study.
2. Has chronic cough (defined as duration of >8 weeks after onset of cough symptoms) for 
<12 months prior to the screening visit (ie, <14 months after onset of cough symptoms), 
per participant report and/or medical history.
3. Has a diagnosis of refractory chronic cough or unexplained chronic cough. Note: For the 
purposes of this study
a) A participant is defined as having refractory chronic cough when:
1. the participant has had a clinical evaluation that suggests a co-morbid condition 
that may be associated with chronic cough (eg, GERD, asthma, or UACS), AND
2. the participant has received appropriate diagnostic work-up and at least 2 months 
of therapy for the co-morbid condition, prior to Screening, according to the 
current ACCP guidelines, AND
3. the participant continues to cough despite being on therapy for the co-morbid 
condition.
b) A participant is defined as having unexplained chronic cough when:
1. the participant has had a clinical evaluation of their chronic cough per current 
ACCP guidelines, AND
2. the evaluation does not suggest a co-morbid condition that may be associated with 
chronic cough.
4. Has a score of ≥40 mm on the Cough Severity VAS at Screening/Visit 1 and 
Randomization/Visit 2. 
 
 
05ND48
07YNSG


PRODUCT: MK-7264  
40
PROTOCOL/AMENDMENT NO.: 043-03 
MK-7264-043-03 FINAL PROTOCOL
25-NOV-2020
Demographics
5. Is male or female, at least 18 years of age, at the time of signing the informed consent.
Female Participants
Contraceptive use by women should be consistent with local regulations regarding the 
methods of contraception for those participating in clinical studies.
6. A female participant is eligible to participate if she is not pregnant or breastfeeding, and 
at least one of the following conditions applies:
-
Is not a woman of childbearing potential (WOCBP)
OR
-
Is a WOCBP and using an acceptable contraceptive method, or be abstinent from 
heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long 
term and persistent basis), as described in Appendix 5 during the intervention 
period and for at least 2 weeks (14 days) after the last dose of study intervention. 
The investigator should evaluate the potential for contraceptive method failure (ie, 
noncompliance, recently initiated) in relationship to the first dose of study 
intervention.
Informed Consent
7. Provides documented informed consent/assent for the study (or legally acceptable 
representative). The participant may also provide consent for future biomedical research. 
However, the participant may participate in the main study without participating in future 
biomedical research.
Study Participation
8. Is willing and able to comply with all aspects of the protocol, including agreeing not to 
smoke during the study and demonstrating an ability to follow study procedures 
(including completion of the LCQ, CSD, and Cough Severity VAS) to the satisfaction of 
the investigator/qualified designee prior to randomization.
5.2
Exclusion Criteria
The participant must be excluded from the study if the participant:
Medical Conditions
1. Is a current smoker.
2. Has given up smoking within 12 months of Screening/Visit 1.
 
 
05ND48
07YNSG


PRODUCT: MK-7264  
41
PROTOCOL/AMENDMENT NO.: 043-03 
MK-7264-043-03 FINAL PROTOCOL
25-NOV-2020
3. Is a former smoker with a smoking history greater than 20 pack-years (eg, 1 pack 
[20 cigarettes] per day for 20 years).
4. Has a FEV1/ FVC ratio <60%.
5. Has a history of upper or lower respiratory tract infection or recent clinically significant 
change in pulmonary status within 4 weeks of Screening/Visit 1.
6. Has a history of chronic bronchitis, defined as a cough that produces a clinically 
significant amount of sputum (greater than approximately 1 tablespoon of phlegm) that 
occurs every day for at least 3 months in a row.
7. Has an estimated eGFR <30 mL/min/1.73 m2 at Screening/Visit 1 OR eGFR 
≥30 mL/min/1.73 m2 and <50 mL/min/1.73 m2 at Screening/Visit 1 with unstable renal 
function (defined as a ≥50% increase of serum creatinine compared to a value obtained at 
least 6 months prior to Screening/Visit 1).
8. Has a history of malignancy ≤5 years prior to signing informed consent except for
adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer.
9. Is, at the time of Screening/Visit 1, a user of recreational or illicit drugs or has a recent 
history (within the last year) of drug or alcohol abuse or dependence.
10. Has a history of anaphylaxis or cutaneous adverse drug reaction (with or without 
systemic symptoms) to sulfonamide antibiotics or other sulfonamide-containing drugs.
11. Has a known allergy/sensitivity or contraindication to gefapixant or its excipients (Note: 
Refer to the IB for details regarding excipients for gefapixant).
12. Has donated or lost ≥1 unit of blood (approximately 300 mL) within 8 weeks prior to the 
first dose of gefapixant.
13. Is a WOCBP who has a positive urine pregnancy test at Visit 1. If the urine test is 
positive or cannot be confirmed as negative, a serum pregnancy test will be required.
Prior/Concomitant Therapy
14. Requires treatment with a therapy that does not adhere to the guidance parameters 
specified in Section 6.5.
Prior/Concurrent Clinical Study Experience
15. Has previously received gefapixant or other P2X3 antagonists.
16. Is currently participating in or has participated in an interventional clinical study with an 
investigational compound or device within 30 days of participating in this current study.
 
 
05ND48
07YNSG


PRODUCT: MK-7264  
42
PROTOCOL/AMENDMENT NO.: 043-03 
MK-7264-043-03 FINAL PROTOCOL
25-NOV-2020
Diagnostic Assessments
17. Has significantly abnormal laboratory tests at Screening/Visit 1, including: 
a.
alkaline phosphatase, ALT, AST >200% of the upper limit of normal, or bilirubin 
>150% of the upper limit of normal. 
b. hemoglobin <10 g/dL, WBC count <2500 mm3 (<2.5 × 103/µL), neutrophil count 
<1500 mm3 (<1.5 × 103/µL), platelet count <100 × 103/mm3 (<100 × 103/uL).
For any of the above listed laboratory assessments, 1 repeat measurement will be allowed 
at the investigator’s discretion, before being considered a screen failure.
Other Exclusions
18. Has a history or current evidence of any condition, therapy, lab abnormality, or other 
circumstance that may increase the risk associated with study participation or study 
intervention administration or may interfere with the interpretation of study results, and 
in the judgment of the investigator or Sponsor, would make the participant inappropriate 
for entry into this study.
Note: Participants with a known history or current evidence of SARS-CoV-2 
(COVID-19) infection are ineligible to enroll in the study.
19. Is or has an immediate family member (eg, spouse, parent/legal guardian, sibling, or 
child) who is investigational site or Sponsor staff directly involved with this study.
5.3
Lifestyle Considerations
Meals and Dietary Restrictions
There are no meal or dietary restrictions.
Caffeine, Alcohol, and Tobacco Restrictions
Participants will be advised that smoking (including cigarettes, cigars, vapes/e-cigarettes, etc) 
is not permitted during the course of the study, and alcohol consumption should not increase
during the study.
Activity Restrictions
There are no exercise restrictions.
5.4
Screen Failures
Screen failures are defined as participants who consent to participate in the clinical study, but 
are not subsequently randomized in the study. A minimal set of screen failure information is 
required to ensure transparent reporting of screen failure participants to meet the 
 
 
05ND48
07YNSG


PRODUCT: MK-7264  
43
PROTOCOL/AMENDMENT NO.: 043-03 
MK-7264-043-03 FINAL PROTOCOL
25-NOV-2020
Consolidated Standards of Reporting Trials (CONSORT) publishing requirements and to 
respond to queries from regulatory authorities. Minimal information includes demography, 
screen failure details, eligibility criteria, and any AEs or SAEs meeting reporting 
requirements as outlined in the data entry guidelines.
Participants identified as screen failures can be rescreened once. If the Cough Severity VAS 
inclusion criterion is not met at Screening/Visit 1, the participant will not be allowed to be 
rescreened. If the Cough Severity VAS inclusion criterion is not met at
Randomization/Visit 2, the participant may be rescreened only with Sponsor consultation.
Any participant who is re-screened will retain the original screening number assigned at the 
initial screening visit. 
5.5
Participant Replacement Strategy
A participant who discontinues from study intervention OR withdraws from the study will 
not be replaced.
6
STUDY INTERVENTION
Study intervention is defined as any investigational intervention(s), marketed product(s), 
placebo, or medical device(s) intended to be administered to a study participant according to 
the study protocol.
Clinical supplies of gefapixant will be packaged to support enrollment where possible (eg, 
not applicable in the case where multiple lots or batches may be required due to the length of 
the study, etc.). Clinical supplies will be affixed with a clinical label in accordance with 
regulatory requirements.
6.1
Study Intervention(s) Administered
The study interventions to be used in this study are outlined in Table 1.
 
 
05ND48
07YNSG


PRODUCT: MK-7264  
44
PROTOCOL/AMENDMENT NO.: 043-03 
MK-7264-043-03 FINAL PROTOCOL
25-NOV-2020
Table 1
Study Interventions
Arm 
Name
Arm Type
Intervention 
Name
Type
Dose 
Formulation
Unit Dose 
Strength(s)
Dosage 
Level(s)
Route of 
Admin-
istration
Regimen/
Treatment 
Period
Use
IMP/
NIMP
Sourcing
Gefapixant
Experimental
Gefapixant
Drug
Tablet
45 mg 
1 tablet 
BID
Oral
12 weeks
Experimental
IMP
Central
Placebo
Placebo 
Comparator
Placebo to 
match 
Gefapixant 
45mg
Other
Tablet
0 mg 
1 tablet 
BID
Oral
12 weeks
Placebo
IMP
Central
BID = twice daily, IMP = Investigational Medicinal Product, NIMP = Non-Investigational Medicinal Product.
Note: Definition of IMP and NIMP is based on guidance issued by the European Commission. Regional and/or Country differences of the definition of 
IMP/NIMP may exist. In these circumstances, local legislation is followed.
 
 
05ND48
07YNSG


PRODUCT:  MK-7264  
45
PROTOCOL/AMENDMENT NO.:  043-03  
MK-7264-043-03 FINAL PROTOCOL
25-NOV-2020
All supplies indicated in Table 1 will be provided per the "Sourcing" column depending upon 
local country operational requirements.
Refer to Section 8.1.8 for details regarding administration of the study intervention.
All placebos were created by the Sponsor to match the active product.
6.2
Preparation/Handling/Storage/Accountability
Dose Preparation
There are no specific calculations or evaluations required to be performed in order to 
administer the proper dose to each participant. The rationale for selection of doses to be used 
in this study is provided in Section 4.3.
Handling, Storage, and Accountability
The investigator or designee must confirm appropriate temperature conditions have been 
maintained during transit for all study intervention received, and any discrepancies are 
reported and resolved before use of the study intervention.
Only participants enrolled in the study may receive study intervention, and only authorized 
site staff may supply or administer study intervention. All study interventions must be stored 
in a secure, environmentally controlled, and monitored (manual or automated) area in 
accordance with the labeled storage conditions with access limited to the investigator and 
authorized site staff.
The investigator, institution, or the head of the medical institution (where applicable) is 
responsible for study intervention accountability, reconciliation, and record maintenance (ie, 
receipt, reconciliation, and final disposition records).
For all study sites, the local country Sponsor personnel or designee will provide appropriate 
documentation that must be completed for drug accountability and return, or local discard 
and destruction if appropriate. Where local discard and destruction is appropriate, the 
investigator is responsible for ensuring that a local discard/destruction procedure is 
documented.
The study site is responsible for recording the lot number, manufacturer, and expiry date for 
any locally purchased product (if applicable) as per local guidelines unless otherwise 
instructed by the Sponsor.
The investigator shall take responsibility for and shall take all steps to maintain appropriate 
records and ensure appropriate supply, storage, handling, distribution, and usage of study 
interventions in accordance with the protocol and any applicable laws and regulations.
 
 
05ND48
07YNSG


PRODUCT:  MK-7264  
46
PROTOCOL/AMENDMENT NO.:  043-03  
MK-7264-043-03 FINAL PROTOCOL
25-NOV-2020
6.3
Measures to Minimize Bias: Randomization and Blinding
Intervention Assignment
Intervention randomization will occur centrally using an interactive response technology 
(IRT) system. There are 2 study intervention arms. Participants will be assigned randomly in 
a 1:1 ratio to gefapixant and placebo, respectively.
Stratification
Intervention allocation/randomization will be stratified according to the following factors:
1.
Gender (Male, Female)
2.
Geographical region (North America, Europe, Asia-Pacific, Other). Details of the 
regions will be provided in the separate supplemental document for randomization.
Blinding
A double-blinding technique with in-house blinding will be used. Gefapixant will be 
packaged identically relative to its matching placebo so that the blind is maintained
throughout the duration of the study. The participant, the investigator, and Sponsor personnel 
or delegate(s) who are involved in the study intervention administration or clinical evaluation 
of the participants are unaware of the intervention assignments.
Details on the analysis and in-house blinding are provided in Section 9.2.
See Section 8.1.10 for a description of the method of unblinding a participant during the 
study, should such action be warranted.
6.4
Study Intervention Compliance
Interruptions from the protocol-specified intervention plan (compliance <80% between study 
visits, based on review with the participant) require consultation between the investigator and 
the Sponsor and written documentation of the collaborative decision on participant 
management.
Records of intervention compliance for each participant will be kept during the study. The 
clinical research associates will review intervention compliance during investigational site 
visits and at the completion of the study. Compliance should be based on participant 
reporting (and supplemented by tablet count, where possible). Issues with compliance should 
be discussed with the participant and addressed as deemed appropriate by the investigator.
6.5
Concomitant Therapy
Medications specifically prohibited in the exclusion criteria are not allowed during the 
ongoing study unless otherwise stated in this section. If there is a clinical indication for any 
medication or vaccination specifically prohibited, discontinuation from study intervention 
 
 
05ND48
07YNSG


PRODUCT:  MK-7264  
47
PROTOCOL/AMENDMENT NO.:  043-03  
MK-7264-043-03 FINAL PROTOCOL
25-NOV-2020
may be required. The investigator should discuss any questions regarding this with the 
Sponsor Clinical Director. The final decision on any supportive therapy rests with the 
investigator and/or the participant’s primary physician. However, the decision to continue the 
participant on study intervention requires the mutual agreement of the investigator, the 
Sponsor, and the participant.
For participants who receive study intervention, any medication (including over-the-counter 
medications) or therapy administered to the participant during the course of the study will be 
recorded on the Prior and Concomitant Therapy CRF. Treatments for chronic cough received 
by the participant will also be recorded. The investigator(s) will record any AE on the AEs 
CRF for which a concomitant medication/therapy was administered.
Listed below are specific restrictions for concomitant therapy:
1. Opioids (including codeine) for the treatment of cough are not allowed from 1 week prior 
to Visit 2 through completion of the study. Opioids (including codeine) for indications 
other than chronic cough are permitted provided the participant is receiving a stable 
treatment regimen for at least 1 week prior to Visit 2 and, in the opinion of the 
investigator, is likely to remain on the stable treatment regimen through completion of the 
study.  
2. Pregabalin, gabapentin, amitriptyline, or nortriptyline for the treatment of cough is not 
allowed from 2 weeks prior to Visit 2 through completion of the study. Pregabalin, 
gabapentin, amitriptyline, or nortriptyline for indications other than chronic cough are 
permitted provided the participant is receiving a stable treatment regimen for at least 2 
weeks prior to Visit 2 and, in the opinion of the investigator, is likely to remain on the 
stable treatment regimen through completion of the study.
3. Dextromethorphan, guaifenesin, benzonatate and any other over the counter or 
prescription medication for the treatment of cough are not allowed from 2 weeks prior to 
Visit 2 through completion in the study. 
4. Lozenges/drops, teas/drinks, natural/herbal remedies, and other similar treatments which 
do not contain an active antitussive or expectorant are allowed, provided they have been 
used on a regular basis for at least 2 weeks prior to Visit 2. Lozenges/drops, teas/drinks, 
and natural/herbal remedies should not be initiated during the study. The Sponsor needs 
to be consulted for further information.
5. Treatments for conditions associated with chronic cough, such as GERD, asthma, UACS 
(formerly called postnasal drip), or non-asthmatic eosinophilic bronchitis, are permitted 
provided that participants have been treated for at least 2 months for these co-morbid 
conditions associated with chronic cough and are receiving a stable treatment regimen for 
at least 2 weeks prior to Visit 2 and, in the opinion of the investigator, are likely to 
remain on the stable treatment regimen through completion of the study. Possible 
treatments are provided in Table 2. Note, this list is not meant to be comprehensive. 
Sponsor to be consulted for further information.
 
 
05ND48
07YNSG


PRODUCT:  MK-7264  
48
PROTOCOL/AMENDMENT NO.:  043-03  
MK-7264-043-03 FINAL PROTOCOL
25-NOV-2020
Table 2
Examples of Concomitant Treatment Permitted in the Study
Condition
Treatment
GERD
Anti-reflux therapy (proton pump or H2-blockers) and/or 
pro-kinetic agents
Asthma
Bronchodilators, inhaled corticosteroids, and/or other 
anti-inflammatory agents
UACS (formerly 
postnasal drip)
Antihistamine/decongestant therapy with a first-generation 
antihistamine
Non-asthmatic 
eosinophilic 
bronchitis
Inhaled/oral corticosteroids
GERD = gastroesophageal reflux disease; UACS = upper airway cough syndrome.
Note: the treatments included in this table are not exhaustive, but examples of treatment class. The guidelines in bullet #5
above the table should be referred to when determining appropriate concomitant treatment use during the study.
6. Non-pharmacologic treatments (eg, physiotherapy, speech and language therapy) for 
cough are not allowed from 3 months prior to Screening/Visit 1 through study 
completion.
7. Angiotensin converting enzyme inhibitors are not allowed from 3 months prior to 
Screening/Visit 1 through completion of the study.
Rescue Medications and Supportive Care
No rescue or supportive medications are specified for use in this study.
6.6
Dose Modification (Escalation/Titration/Other)
No dose modification is allowed in this study.
6.7
Intervention After the End of the Study
There is no study-specified intervention following the end of the study.
6.8
Clinical Supplies Disclosure
The emergency unblinding call center will use the intervention/randomization schedule for 
the study to unblind participants and to unmask study intervention identity . The emergency 
unblinding call center should only be used in cases of emergency (see Section 8.1.10). In the 
event that the emergency unblinding call center is not available for a given site in this study, 
the central electronic intervention allocation/randomization system (IRT) should be used to 
unblind participants and to unmask study intervention identity. The Sponsor will not provide 
random code/disclosure envelopes or lists with the clinical supplies.
 
 
05ND48
07YNSG


PRODUCT:  MK-7264  
49
PROTOCOL/AMENDMENT NO.:  043-03  
MK-7264-043-03 FINAL PROTOCOL
25-NOV-2020
See Section 8.1.10 for a description of the method of unblinding a participant during the 
study, should such action be warranted. 
7
DISCONTINUATION OF STUDY INTERVENTION AND PARTICIPANT 
WITHDRAWAL
7.1
Discontinuation of Study Intervention
Discontinuation of study intervention does not represent withdrawal from the study.
As certain data on clinical events beyond study intervention discontinuation may be 
important to the study, they must be collected through the participant’s last scheduled follow-
up, even if the participant has discontinued study intervention. Therefore, all participants 
who discontinue study intervention prior to completion of the protocol-specified treatment 
period will still continue to participate in the study as specified in Section 1.3.
Participants may discontinue study intervention at any time for any reason or be discontinued 
from the study intervention at the discretion of the investigator should any untoward effect 
occur. In addition, a participant may be discontinued from study intervention by the 
investigator or the Sponsor if study intervention is inappropriate, the study plan is violated, or 
for administrative and/or other safety reasons. Specific details regarding procedures to be 
performed at study intervention discontinuation are provided in Section 8.1.9.
A participant must be discontinued from study intervention but continue to be monitored in 
the study for any of the following reasons:

The participant or participant’s legally acceptable representative requests to 
discontinue study intervention.

The participant’s treatment assignment has been unblinded by the investigator, MSD 
subsidiary, or through the emergency unblinding call center.

The participant has a medical condition or personal circumstance which, in the 
opinion of the investigator and/or Sponsor, placed the participant at unnecessary risk 
from continued administration of study intervention.

The participant has a confirmed positive serum pregnancy test.

In case of clinically significant and potentially drug-related rash or signs and/or 
symptoms consistent with allergic drug reaction or anaphylaxis to study intervention.

Chronic failure to comply with the dosing, evaluations, or other requirements of the 
study, despite documentation at the site of repeated efforts to reinforce compliance.
For participants who discontinue study intervention early, refer to Section 8.10.3.
 
 
05ND48
07YNSG


PRODUCT:  MK-7264  
50
PROTOCOL/AMENDMENT NO.:  043-03  
MK-7264-043-03 FINAL PROTOCOL
25-NOV-2020
Discontinuation from study intervention is “permanent.” Once a participant is discontinued, 
he/she shall not be allowed to restart study intervention.
7.2
Participant Withdrawal From the Study
A participant must be withdrawn from the study if the participant or participant’s legally 
acceptable representative withdraws consent from the study.
If a participant withdraws from the study, they will no longer receive study intervention or be 
followed at scheduled protocol visits.
Specific details regarding procedures to be performed at the time of withdrawal from the 
study, as well as specific details regarding withdrawal from future biomedical research, are 
outlined in Section 8.1.9. The procedures to be performed should a participant repeatedly fail 
to return for scheduled visits and/or if the study site is unable to contact the participant are 
outlined in Section 7.3.
7.3
Lost to Follow-up
If a participant fails to return to the clinic for a required study visit and/or if the site is unable 
to contact the participant, the following procedures are to be performed:

The site must attempt to contact the participant and reschedule the missed visit. If the 
participant is contacted, the participant should be counseled on the importance of 
maintaining the protocol-specified visit schedule.

The investigator or designee must make every effort to regain contact with the 
participant at each missed visit (eg, telephone calls and/or a certified letter to the 
participant’s last known mailing address or locally equivalent methods). These 
contact attempts should be documented in the participant’s medical record.

Note: A participant is not considered lost to follow-up until the last scheduled visit for 
the individual participant. The missing data for the participant will be managed via 
the prespecified statistical data handling and analysis guidelines.
8
STUDY ASSESSMENTS AND PROCEDURES

Study procedures and their timing are summarized in the SoA.

Adherence to the study design requirements, including those specified in the SoA, is 
essential and required for study conduct.

The investigator is responsible for ensuring that procedures are conducted by 
appropriately qualified (by education, training, and experience) staff. Delegation of 
study site personnel responsibilities will be documented in the Investigator Trial File 
Binder (or equivalent).
 
 
05ND48
07YNSG


PRODUCT:  MK-7264  
51
PROTOCOL/AMENDMENT NO.:  043-03  
MK-7264-043-03 FINAL PROTOCOL
25-NOV-2020

All study-related medical decisions must be made by an investigator who is a 
qualified physician.

All screening evaluations must be completed and reviewed to confirm that potential 
participants meet all eligibility criteria. The investigator will maintain a screening log 
to record details of all participants screened and to confirm eligibility or record 
reasons for screening failure, as applicable.

Procedures conducted as part of the participant’s routine clinical management (eg, 
chest x-ray) and obtained before signing of ICF may be utilized for screening or 
baseline purposes provided the procedure met the protocol-specified criteria and were 
performed within the time frame defined in the SoA. The Sponsor may provide 
protocol-specific guidance and/or guidance for special circumstances.

Additional evaluations/testing may be deemed necessary by the investigator and or 
the Sponsor for reasons related to participant safety. In some cases, such 
evaluation/testing may be potentially sensitive in nature (eg, HIV, Hepatitis C), and 
thus local regulations may require that additional informed consent be obtained from 
the participant. In these cases, such evaluations/testing will be performed in 
accordance with those regulations.
The maximum amount of blood collected from each participant over the duration of the study
will not exceed 40 mL (Appendix 2).
Repeat or unscheduled samples may be taken for safety reasons or for technical issues with 
the samples; blood volumes for these repeat or unscheduled samples are not included in the 
above calculation of maximum amount of blood collected. Some local regulations require 
blood samples to be drawn for additional serology testing; blood volumes for these samples 
are also not included in the maximum amount of blood collected.
8.1
Administrative and General Procedures
Informed Consent
The investigator or medically qualified designee (consistent with local requirements) must 
obtain documented informed consent from each potential participant or their legally 
acceptable representative prior to participating in this clinical study or future biomedical 
research. If there are changes to the participant’s status during the study (eg, health or age of 
majority requirements), the investigator or medically qualified designee must ensure the 
appropriate documented informed consent is in place.
8.1.1.1
General Informed Consent
Informed consent given by the participant or their legally acceptable representative must be 
documented on a consent form. The form must include the trial protocol number, trial 
protocol title, dated signature, and /agreement of the participant (or his/her legally acceptable 
representative) and of the person conducting the consent discussion.
 
 
05ND48
07YNSG


PRODUCT:  MK-7264  
52
PROTOCOL/AMENDMENT NO.:  043-03  
MK-7264-043-03 FINAL PROTOCOL
25-NOV-2020
A copy of the signed and dated informed consent form should be given to the participant (or 
their legally acceptable representative) before participation in the study.
The initial ICF, any subsequent revised ICF, and any written information provided to the 
participant must receive the IRB/IEC’s approval/favorable opinion in advance of use. The 
participant or his/her legally acceptable representative should be informed in a timely manner 
if new information becomes available that may be relevant to the participant’s willingness to 
continue participation in the study. The communication of this information will be provided 
and documented via a revised consent form or addendum to the original consent form that 
captures the participant’s or the participant’s legally acceptable representative’s dated 
signature.
Specifics about the study and the study population are to be included in the study informed 
consent form.
Informed consent will adhere to IRB/IEC requirements, applicable laws and regulations, and 
Sponsor requirements.
8.1.1.2
Consent and Collection of Specimens for Future Biomedical Research
The investigator or medically qualified designee will explain the future biomedical research 
consent to the participant, or the participant’s legally acceptable representative, answer all of 
his/her questions, and obtain documented informed consent before performing any procedure 
related to future biomedical research. A copy of the informed consent will be given to the 
participant before performing any procedure related to future biomedical research.
Inclusion/Exclusion Criteria
All inclusion and exclusion criteria will be reviewed by the investigator, who is a qualified 
physician, to ensure that the participant qualifies for the study.
For Inclusion Criteria 2 and 3 (see Section 5.1 for details), a combination of medical records 
and/or verbal history from the participant can be used to fulfill these criteria if documented in 
the participant study file by the investigator.
Source documentation for all eligibility criteria needs to be maintained at the site. 
For participants with eGFR ≥30 mL/min/1.73 m2 and <50 mL/min/1.73 m2 at Screening with 
stable renal function (unstable renal function is defined as a ≥50% increase of serum 
creatinine compared to a value obtained at least 6 months prior to the screening visit), 
documentation of stable serum creatinine must be retained as source documentation at the 
study site.
Participant Identification Card
All participants will be given a participant identification card identifying them as participants 
in a research study. The card will contain study site contact information (including direct 
telephone numbers) to be used in the event of an emergency. The investigator or qualified 
 
 
05ND48
07YNSG


PRODUCT:  MK-7264  
53
PROTOCOL/AMENDMENT NO.:  043-03  
MK-7264-043-03 FINAL PROTOCOL
25-NOV-2020
designee will provide the participant with a participant identification card immediately after 
the participant provides documented informed consent. At the time of intervention
(randomization), site personnel will add the treatment/randomization number to the 
participant identification card.
The participant identification card also contains contact information for the emergency 
unblinding call center so that a healthcare provider can obtain information about study 
intervention in emergency situations where the investigator is not available.
Medical History
A medical history will be obtained by the investigator or qualified designee (refer to eCRF 
entry guidelines).
Prior and Concomitant Medications Review
8.1.5.1
Prior Medications
The investigator or qualified designee will review prior medication use at Screening/Visit 1
(see Section 6.5 and refer to eCRF entry guidelines).
8.1.5.2
Concomitant Medications
The investigator or qualified designee will record medication, if any, taken by the participant 
during the study.
Assignment of Screening Number
All consented participants will be given a unique screening number that will be used to 
identify the participant for all procedures that occur prior to randomization. Each participant 
will be assigned only 1 screening number. Screening numbers must not be re-used for 
different participants.
Assignment of Treatment/Randomization Number
All eligible participants will be randomly allocated and will receive a 
treatment/randomization number. The treatment/randomization number identifies the 
participant for all procedures occurring after treatment allocation/randomization. Once a 
treatment/randomization number is assigned to a participant, it can never be re-assigned to 
another participant.
A single participant cannot be assigned more than 1 treatment/randomization number.
Study Intervention Administration
The distribution of study intervention will be performed by the investigator and/or study staff 
at the study site visits.
 
 
05ND48
07YNSG


PRODUCT:  MK-7264  
54
PROTOCOL/AMENDMENT NO.:  043-03  
MK-7264-043-03 FINAL PROTOCOL
25-NOV-2020
At Randomization/Visit 2, study intervention will be dispensed by the study site. 
Then, according to when the clinic visit is during the day, the participant will take the first 
dose of study intervention either in the morning or in the evening. Subsequent dosing should 
be performed by the participant BID approximately 12 hours apart and approximately at the 
same time each day for the duration of the study.
The last dose of study intervention will be on the evening prior to Visit 4. Study intervention 
supplies will be collected at Visit 3 and Visit 4.
8.1.8.1
Timing of Dose Administration
Study intervention will be administered orally, BID, approximately 12 hours apart for 
approximately 12 weeks (84 days) during the study.
A missed dose may be taken if it is <4 hours after the expected dosing time. If it is ≥4 hours 
after the expected dosing time, then the dose can be skipped, and the regular schedule 
resumed.
Discontinuation and Withdrawal
Participants who discontinue study intervention prior to completion of the intervention period
should be encouraged to continue to be followed for all remaining study visits as outlined in 
the SoA (Section 1.3 and Section 8.10.3).
When a participant withdraws from participation in the study, all applicable activities 
scheduled for the Discontinuation Visit should be performed (at the time of withdrawal). Any 
AEs that are present at the time of withdrawal should be followed in accordance with the 
safety requirements outlined in Section 8.3.
8.1.9.1
Withdrawal From Future Biomedical Research
Participants may withdraw their consent for future biomedical research. Participants may 
withdraw consent at any time by contacting the investigator for the main study. If medical 
records for the main study are still available, the investigator will contact the Sponsor using 
the designated mailbox (clinical.specimen.management@merck.com). Subsequently, the 
participant's consent for future biomedical research will be withdrawn. A letter will be sent 
from the Sponsor to the investigator confirming the withdrawal. It is the responsibility of the 
investigator to inform the participant of completion of withdrawal. Any analyses in progress 
at the time of request for withdrawal or already performed prior to the request being received 
by the Sponsor will continue to be used as part of the overall research study data and results. 
No new analyses would be generated after the request is received.
In the event that the medical records for the main study are no longer available (eg, if the 
investigator is no longer required by regulatory authorities to retain the main study records) 
or the specimens have been completely anonymized, there will no longer be a link between 
 
 
05ND48
07YNSG


PRODUCT:  MK-7264  
55
PROTOCOL/AMENDMENT NO.:  043-03  
MK-7264-043-03 FINAL PROTOCOL
25-NOV-2020
the participant’s personal information and their specimens. In this situation, the request for 
specimen withdrawal cannot be processed.
Participant Blinding/Unblinding
STUDY INTERVENTION IDENTIFICATION INFORMATION IS TO BE UNMASKED 
ONLY IF NECESSARY FOR THE WELFARE OF THE PARTICIPANT. EVERY 
EFFORT SHOULD BE MADE NOT TO UNBLIND.
For emergency situations where the investigator or medically qualified designee (consistent 
with local requirements) needs to identify the intervention used by a participant and/or the 
dosage administered, he/she will contact the emergency unblinding call center by telephone 
and make a request for emergency unblinding. As requested by the investigator or medically 
qualified designee, the emergency unblinding call center will provide the information to 
him/her promptly and report unblinding to the Sponsor. Prior to contacting the emergency 
unblinding call center to request unblinding of a participant’s intervention assignment, the 
investigator who is a qualified physician should make reasonable attempts to enter the
intensity of the AEs observed, the relation to study intervention, the reason thereof, etc, in the 
medical chart. If it is not possible to record this assessment in the chart prior to the 
unblinding, the unblinding should not be delayed.
In the event that unblinding has occurred, the circumstances around the unblinding (eg, date, 
reason, and person performing the unblinding) must be documented promptly, and the 
Sponsor Clinical Director notified as soon as possible.
Once an emergency unblinding has taken place, the investigator, site personnel, and Sponsor 
personnel may be unblinded so that the appropriate follow-up medical care can be provided 
to the participant.
Participants whose treatment assignment has been unblinded by the investigator or medically 
qualified designee and/or nonstudy treating physician must be discontinued from study 
intervention, but should continue to be monitored in the study.
Additionally, the investigator or medically qualified designee must go into the IRT system 
and perform the unblind in the IRT system to update drug disposition. In the event that the 
emergency unblinding call center is not available for a given site in this study, the IRT 
system should be used for emergency unblinding in the event that this is required for 
participant safety.
Calibration of Equipment
The investigator or qualified designee has the responsibility to ensure that any device or 
instrument used for a clinical evaluation/test during a clinical study that provides information 
about inclusion/exclusion criteria and/or safety or efficacy parameters shall be suitably 
calibrated and/or maintained to ensure that the data obtained are reliable and/or reproducible. 
Documentation of equipment calibration must be retained as source documentation at the 
study site.
 
 
05ND48
07YNSG


PRODUCT:  MK-7264  
56
PROTOCOL/AMENDMENT NO.:  043-03  
MK-7264-043-03 FINAL PROTOCOL
25-NOV-2020
8.2
Efficacy/Immunogenicity Assessments
Compliance with the efficacy and safety assessments (along with study intervention use and 
visit schedule) is essential, and any noncompliance noted by the investigator or designee 
should result in consultation with the participant on corrective measures needed to ensure 
compliance.
Patient-Reported Outcomes
At Screening/Visit 1, each participant will be properly trained and instructed on the use of an 
e-Diary for completing the ePRO measures. At Screening/Visit 1, participants will be 
dispensed the e-Diary for completion between visits. Participants should bring their e-Diary
device for all study visits and should be contacted and reminded to do so (eg, by telephone or 
text) before each study site visit.
Between clinic visits, participants will be instructed to complete the ePRO measures (in the 
following order: CSD and Cough Severity VAS) at approximately the same time each 
evening, as outlined in the SoA (Section 1.3). If a participant fails to complete the evening 
CSD and/or Cough Severity VAS ePRO measure(s), the e-Diary will allow the participant, 
based on recall, to complete these missed measures in the next day (also see vendor’s site 
manual for further details). Participants will be prompted within the e-Diary to complete the 
missed measures first, prior to the measures for the current day.
At the clinic visits, participants will be asked to complete ePRO measures (in the following 
order: Cough Severity VAS, LCQ, PGIC, and WPAI), as outlined in the SoA (also see 
vendor’s site manual for further details). All Visit 2 ePRO measures MUST be activated and 
completed prior to the first dose of study intervention/randomization (see vendor’s site 
manual for further details). For subsequent clinic visits, the e-Diary must be activated by the 
site to enable the collection of the ePROs at the clinic visit.
Electronic PRO measures must be activated, as outlined in the SoA (Section 1.3). More 
details on PRO measures are given in Section 4.2.1.1.
Participants who discontinue study intervention early will continue to be monitored in the 
study and should be encouraged to continue to complete the ePRO measures for the 
remaining visits (as outlined in the SoA, Section 1.3) through the end of the study.
Compliance with daily completion of the eDiaries must be monitored by the investigator or 
designee. Each investigator site will contact individual participants who are non-compliant in 
order to retrain and/or remind them to complete their assessments as per the SoA 
(Section 1.3). Discussion with the participant and retraining will be performed if any 
question on any e-Diary is missing and/or if any e-Diary scheduled for completion per the 
SoA is missing, in error.
Once a participant has completed the study (or discontinued from the study), the participant 
should return the e-Diary to the study site, and all ePRO measures should be deactivated.
 
 
05ND48
07YNSG


PRODUCT:  MK-7264  
57
PROTOCOL/AMENDMENT NO.:  043-03  
MK-7264-043-03 FINAL PROTOCOL
25-NOV-2020
Data collection for all ePRO measures will be dependent on ePRO device and software 
availability.
8.2.1.1
Leicester Cough Questionnaire
Participants will be asked to complete the 19-item LCQ to assess the impact of their cough 
severity on physical, social and psychological functioning, as detailed in SoA (Section 1.3).
Leicester Cough Questionnaire will be completed at Randomization/Visit 2, after eligibility 
for randomization has been confirmed, and at Visits 3 and 4 before all other assessments.
8.2.1.2
Cough Severity Diary 
Participants will complete the CSD at approximately the same time each evening before 
going to bed beginning at Visit 1 and continuing through Visit 4, as outlined in the SoA 
(Section 1.3). 
8.2.1.3
Cough Severity Visual Analog Scale 
Participants will be asked to rate the severity of their cough over the past 24 hours using a 
100-mm Cough Severity VAS single-item questionnaire, with the response ranging from 0 
(“No Cough”) to 100 (“Extremely Severe Cough”).
At Screening/Visit 1, participants will complete a single Cough Severity VAS questionnaire 
at the study visit in order to assess the eligibility criterion. For the remainder of the study, 
beginning with the evening of Screening/Visit 1, participants will complete the Cough 
Severity VAS at approximately the same time each evening before going to bed, as outlined 
in the SoA (Section 1.3). The Cough Severity VAS assessment completed the evening before 
Randomization/Visit 2 will be used as the baseline value and to assess the 
Randomization/Visit 2 Cough Severity VAS eligibility criterion. If the assessment was not 
completed the evening before randomization, then a measurement done on the day of 
randomization, prior to any non-PRO Randomization/Visit 2 procedures, can be used as the 
baseline value and to assess the Randomization/Visit 2 Cough Severity VAS eligibility 
criterion.
In order to confirm participant eligibility, study site staff will be required to review/confirm
the participant met the Cough Severity VAS eligibility criteria from the measurement done at 
Screening/Visit 1 at the clinic and the measurement done the evening before 
Randomization/Visit 2 (or from the morning of Randomization/Visit 2, prior to conducting 
any Visit 2 procedures, if the evening measurement was missed). A score of ≥40 mm on the 
Cough Severity VAS, for both Screening/Visit 1 and Randomization/Visit 2 is required for 
randomization into the study.
8.2.1.4
Patient Global Impression of Change Questionnaire
Participants are required to complete the PGIC at the last clinic visit, as outlined in the SoA
(Section 1.3).
 
 
05ND48
07YNSG


PRODUCT:  MK-7264  
58
PROTOCOL/AMENDMENT NO.:  043-03  
MK-7264-043-03 FINAL PROTOCOL
25-NOV-2020
8.2.1.5
Work Productivity and Activity Impairment Questionnaire
The WPAI questionnaire will be used to assess impairment and productivity at work. 
Participants will be asked to indicate if they are currently employed and to respond to a series 
of work-related questions referring to “the past 7 days” (Section 4.2.1.1).
Participants are required to complete the WPAI at Visits 2 and 4, as outlined in the SoA
(Section 1.3).
8.3
Safety Assessments
Details regarding specific safety procedures/assessments to be performed in this study are 
provided. 
The total amount of blood/tissue to be drawn/collected over the course of the study (from 
prestudy to poststudy visits), including approximate blood/tissue volumes drawn/collected by 
visit and by sample type per participant, can be found at the beginning of Section 8.
Planned time points for all safety assessments are provided in the SoA.
Chest Radiography/Computed Tomography Thorax Scan
A chest radiograph or CT scan of the thorax should be performed locally for participants, at 
Screening/Visit 1, if this has not been done within the last 1 year and after the onset of 
chronic cough. The chest radiograph or CT scan of the thorax should not demonstrate any 
abnormality considered to be significantly contributing to the chronic cough or any other 
clinically significant lung disease, in the opinion of the principal investigator (or 
subinvestigator; Inclusion Criterion 1, Section 5.1). Chest radiograph or CT scan of the 
thorax performed after the onset of cough symptoms but before the diagnosis of chronic 
cough requires consultation with the Sponsor to determine if acceptable for inclusion in the 
study.
Physical Examinations
A complete physical examination will be conducted as described in the SoA (Section 1.3)
and will include assessments of the following: general appearance; skin and lymphatic; eyes, 
ears, nose, throat; cardiovascular system; respiratory system; abdomen/gastrointestinal 
system; urological system; musculoskeletal and neurological systems. Other body systems 
may be examined at the discretion of the investigator. 
Any clinically significant abnormalities in physical examinations noted after Visit 1 will be 
recorded as AEs in the eCRF.
A brief directed physical examination should be performed at Visit 4 or the Discontinuation 
Visit. 
A brief directed physical examination may be performed at any study visit that does not 
already include a physical examination if deemed necessary by the investigator due to 
 
 
05ND48
07YNSG


PRODUCT:  MK-7264  
59
PROTOCOL/AMENDMENT NO.:  043-03  
MK-7264-043-03 FINAL PROTOCOL
25-NOV-2020
signs/symptoms. A physical examination (complete or directed) can be performed at any 
unscheduled visit if deemed necessary by the investigator.
Investigators should pay special attention to clinical signs related to previous serious 
illnesses.
Vital Signs
Vital sign measurements, including systolic blood pressure (mm Hg), diastolic blood 
pressure (mm Hg), heart rate (beats per minute), respiratory rate (breaths per minute), and 
body temperature will be collected, as outlined in the SoA (Section 1.3). All blood pressure 
measurements should be performed on the same arm, preferably by the same person. Height 
and weight will also be collected as per the SoA (Section 1.3). 
Any clinically significant abnormalities in vital signs noted after Visit 1 will be recorded as 
AEs in the eCRF.
Electrocardiograms
A 12-lead ECG will be performed at Screening/Visit 1 using local standard procedures. 
Clinically significant abnormal findings should be recorded in the AE eCRF.
Spirometry
A spirometry assessment will be performed locally at Screening/Visit 1 using a calibrated 
spirometer. Assessments will include FEV1, FVC, and FEV1/FVC ratio.
Spirometry should be performed in accordance with guidelines established by the American 
Thoracic Society / European Respiratory Society (Available from: 
http://www.thoracic.org/statements/). For safety reasons, spirometry should be performed 
with the participant sitting, using a chair with arms and without wheels; however, if 
necessary to undertake the testing with the participant standing or in another position, this 
should be noted in the participant’s study file.
Clinical Safety Laboratory Assessments
Refer to Appendix 2 for the list of clinical laboratory tests to be performed and to the SoA for 
the timing and frequency.

The investigator or medically qualified designee (consistent with local requirements) 
must review the laboratory report, document this review, and record any clinically 
relevant changes occurring during the study in the AE section of the case report form 
(CRF). The laboratory reports must be filed with the source documents. Clinically 
significant abnormal laboratory findings are those which are not associated with the 
underlying disease, unless judged by the investigator to be more severe than expected for 
the participant's condition.
 
 
05ND48
07YNSG


PRODUCT:  MK-7264  
60
PROTOCOL/AMENDMENT NO.:  043-03  
MK-7264-043-03 FINAL PROTOCOL
25-NOV-2020

All protocol-required laboratory assessments, as defined in Appendix 2, must be 
conducted in accordance with the laboratory manual and the SoA.

If laboratory values from nonprotocol-specified laboratory assessments performed at the 
institution’s local laboratory require a change in study participant management or are 
considered clinically significant by the investigator (eg, SAE or AE or dose 
modification), then the results must be recorded in the appropriate CRF (eg, SLAB).

For any laboratory tests with values considered clinically significantly abnormal during 
participation in the study or within 7 days after the last dose of study intervention, every 
attempt should be made to perform repeat assessments until the values return to normal or 
baseline or if a new baseline is established as determined by the investigator.
Renal and Urological Safety Assessments
Safety assessments will be performed in all participants in order to monitor renal and 
urological safety during the course of the study. Participants will be monitored for hematuria 
and urinary crystals through urinalysis (performed at the central laboratory). Urinalyses 
(including microscopy) will be collected as outlined in the SoA (Section 1.3).
8.3.7.1
Screening
If, during Screening/Visit 1, a participant has crystalluria and/or unexplained hematuria 
(defined as, for example, participants without a history of recent menses, urinary tract 
infection, or recent procedure/instrumentation that would explain the hematuria), the 
investigator should perform the below steps. (Note: Any other explanation for hematuria 
finding must be reviewed with the Sponsor).

Review and confirm if the finding is a new finding or a previously documented finding. 

Evaluate the participant’s medical history to identify conditions (ie, prior renal 
disease, prior history of kidney stones, medications, gastrointestinal conditions) and 
make a clinical determination if the participant is at high or low risk of potential 
complications/worsening due to an associated renal/urinary condition or its treatment, 
or requires a change in therapy for that condition that may interfere with 
interpretation of safety data collected during the study.

If high risk, the participant should not be enrolled and should be considered for 
further evaluation.

If low risk, the participant may continue with screening.
8.3.7.2
Visit 4/Discontinuation 
At Visit 4 or Discontinuation Visit, a urine sample will be collected from all participants, as 
outlined in the SoA.  If, unexplained hematuria and/or urinary crystals are identified, and 
deemed to be clinically significant by the investigator, the participant should be considered 
 
 
05ND48
07YNSG


PRODUCT:  MK-7264  
61
PROTOCOL/AMENDMENT NO.:  043-03  
MK-7264-043-03 FINAL PROTOCOL
25-NOV-2020
for further evaluation. If an investigator deems it necessary to perform an unscheduled 
urinalysis at any time during the study (after randomization), the same procedures for 
collection/preparation of the urine sample and evaluation of hematuria (as explained or 
unexplained) described for Visit 4 or Discontinuation Visit should be performed.
8.4
Adverse Events (AEs), Serious Adverse Events (SAEs), and Other Reportable 
Safety Events
The definitions of an AE or SAE, as well as the method of recording, evaluating, and 
assessing causality of AE and SAE and the procedures for completing and transmitting AE, 
SAE, and other reportable safety event reports can be found in Appendix 3.
Adverse events, SAEs, and other reportable safety events will be reported by the participant 
(or, when appropriate, by a caregiver, surrogate, or the participant's legally authorized 
representative).
The investigator and any designees are responsible for detecting, documenting, and reporting 
events that meet the definition of an AE or SAE as well as other reportable safety events. 
Investigators remain responsible for following up AEs, SAEs, and other reportable safety 
events for outcome according to Section 8.4.3.
The investigator, who is a qualified physician, will assess events that meet the definition of 
an AE or SAE as well as other reportable safety events with respect to seriousness, 
intensity/toxicity and causality.
Time Period and Frequency for Collecting AE, SAE, and Other Reportable 
Safety Event Information
All AEs, SAEs, and other reportable safety events that occur after the participant provides 
documented informed consent but before intervention randomization must be reported by the 
investigator if the participant is receiving placebo run-in or other run-in treatment, if the 
event causes the participant to be excluded from the study, or is the result of a protocol-
specified intervention, including but not limited to washout or discontinuation of usual 
therapy, diet, or a procedure.
From the time of intervention randomization through 14 days following cessation of 
treatment, all AEs, SAEs, and other reportable safety events must be reported by the 
investigator. However, for those participants who discontinue from the study intervention but 
continue to be monitored, only the AEs and other reportable safety events that are shown in
Table 3 need to be reported. This specific approach for reporting starts from completion of 
the safety follow-up telephone call following cessation of intervention until the last study-
related off-intervention telephone call.
Additionally, any SAE brought to the attention of an investigator at any time outside of the 
time period specified in the previous paragraph must be reported immediately to the Sponsor 
if the event is considered related to study intervention.
 
 
05ND48
07YNSG


PRODUCT:  MK-7264  
62
PROTOCOL/AMENDMENT NO.:  043-03  
MK-7264-043-03 FINAL PROTOCOL
25-NOV-2020
Investigators are not obligated to actively seek AEs or SAEs or other reportable safety events 
in former study participants. However, if the investigator learns of any SAE, including a 
death, at any time after a participant has been discharged from the study, and he/she 
considers the event to be reasonably related to the study intervention or study participation, 
the investigator must promptly notify the Sponsor.
All initial and follow-up AEs, SAEs, and other reportable safety events will be recorded and 
reported to the Sponsor or designee within the time frames as indicated in Table 3.
 
 
05ND48
07YNSG


PRODUCT:  MK-7264  
63
PROTOCOL/AMENDMENT NO.:  043-03  
MK-7264-043-03 FINAL PROTOCOL
25-NOV-2020
Table 3
Reporting Time Periods and Time Frames for Adverse Events and Other 
Reportable Safety Events
Type of Event
Reporting Time 
Period:
Consent to 
Randomization/ 
Allocation
Reporting Time 
Period:
Randomization/ 
Allocation through 
Protocol-specified 
Follow-up Period
Reporting Time Period:
After the Protocol-
specified Follow-up 
Period
Time Frame to 
Report Event 
and Follow-up 
Information to 
Sponsor:
Nonserious Adverse 
Event (NSAE)
Report if:
- due to protocol-
specified intervention
- causes exclusion
- participant is 
receiving placebo run-
in or other run-in 
treatment
Report all
Not required
Per data entry 
guidelines
Serious Adverse Event 
(SAE)
Report if:
- due to protocol-
specified intervention
- causes exclusion
- participant is 
receiving placebo run-
in or other run-in 
treatment
Report all
Report if:
- drug/vaccine related.
(Follow ongoing to 
outcome)
Within 24 hours 
of learning of 
event
Pregnancy/Lactation 
Exposurea
Report if:
- due to intervention
- causes exclusion
Report alla
Previously reported –
Follow to 
completion/termination; 
report outcome
Within 24 hours 
of learning of 
event
Event of Clinical Interest 
(require regulatory 
reporting)
Report if:
- due to intervention
- causes exclusion
Reporta
- Potential drug-induced 
liver injury (DILI)
- Require regulatory 
reporting
Not required
Within 24 hours 
of learning of 
event
Event of Clinical Interest 
(do not require 
regulatory reporting)
Report if:
- due to intervention
- causes exclusion
Reporta
- non-DILI ECIs and 
those not requiring 
regulatory reporting
Not required
Within 5 
calendar days of 
learning of event
Cancer
Report if:
- due to intervention
- causes exclusion
Report all
Not required
Within 5 
calendar days of 
learning of event
Overdose
Report if:
- receiving placebo 
run-in or other run-in 
medication 
Report alla
Not required
Within 5 
calendar days of 
learning of event
DILI = drug-induced liver injury; ECI = event of clinical interest.
a
Participants who discontinue study intervention and are continuing to be monitored in the study do not 
require the reporting of ECIs, pregnancy/lactation exposure, and overdose. Previously reported 
pregnancies/lactations exposure need to be followed for completion/termination; report outcome.
 
 
05ND48
07YNSG


PRODUCT:  MK-7264  
64
PROTOCOL/AMENDMENT NO.:  043-03  
MK-7264-043-03 FINAL PROTOCOL
25-NOV-2020
Method of Detecting AEs, SAEs, and Other Reportable Safety Events
Care will be taken not to introduce bias when detecting AEs and/or SAEs and other 
reportable safety events. Open-ended and nonleading verbal questioning of the participant is 
the preferred method to inquire about AE occurrence.
Follow-up of AE, SAE, and Other Reportable Safety Event Information
After the initial AE/SAE report, the investigator is required to proactively follow each 
participant at subsequent visits/contacts. All AEs, SAEs, and other reportable safety events,
including pregnancy and exposure during breastfeeding, events of clinical interest (ECIs), 
cancer, and overdose will be followed until resolution, stabilization, until the event is 
otherwise explained, or the participant is lost to follow-up (as defined in Section 7.3). In 
addition, the investigator will make every attempt to follow all nonserious AEs that occur in
randomized participants for outcome. Further information on follow-up procedures is given 
in Appendix 3.
Regulatory Reporting Requirements for SAE
Prompt notification (within 24 hours) by the investigator to the Sponsor of SAE is essential 
so that legal obligations and ethical responsibilities towards the safety of participants and the 
safety of a study intervention under clinical investigation are met.
The Sponsor has a legal responsibility to notify both the local regulatory authority and other 
regulatory agencies about the safety of a study intervention under clinical investigation. The 
Sponsor will comply with country-specific regulatory requirements and global laws and 
regulations relating to safety reporting to regulatory authorities, IRB/IECs, and investigators.
Investigator safety reports must be prepared for suspected unexpected serious adverse 
reactions (SUSARs) according to local regulatory requirements and Sponsor policy and 
forwarded to investigators as necessary.
An investigator who receives an investigator safety report describing an SAE or other 
specific safety information (eg, summary or listing of SAE) from the Sponsor will file it 
along with the IB and will notify the IRB/IEC, if appropriate according to local requirements.
Pregnancy and Exposure During Breastfeeding
Although pregnancy and infant exposure during breastfeeding are not considered AEs, any 
pregnancy or infant exposure during breastfeeding in a participant (spontaneously reported to 
the investigator or their designee) that occurs during the study are reportable to the Sponsor.
All reported pregnancies must be followed to the completion/termination of the pregnancy. 
Pregnancy outcomes of spontaneous abortion, missed abortion, benign hydatidiform mole, 
blighted ovum, fetal death, intrauterine death, miscarriage, and stillbirth must be reported as 
serious events (Important Medical Events). If the pregnancy continues to term, the outcome 
(health of infant) must also be reported.
 
 
05ND48
07YNSG


PRODUCT:  MK-7264  
65
PROTOCOL/AMENDMENT NO.:  043-03  
MK-7264-043-03 FINAL PROTOCOL
25-NOV-2020
Reporting time periods and time frames are fully detailed in Table 3.
Disease-related Events and/or Disease-related Outcomes Not Qualifying as AEs 
or SAEs
There are no disease-related events and/or disease-related outcomes not qualifying as AEs or 
SAEs.
Events of Clinical Interest (ECIs)
Selected nonserious and SAEs are also known as ECIs and must be reported to the Sponsor.
Events of clinical interest for this study include:

An elevated AST or ALT lab value that is greater than or equal to 3X the upper 
limit of normal and an elevated total bilirubin lab value that is greater than or 
equal to 2X the upper limit of normal and, at the same time, an alkaline 
phosphatase lab value that is less than 2X the upper limit of normal, as 
determined by way of protocol-specified laboratory testing or unscheduled 
laboratory testing.*
*Note: These criteria are based upon available regulatory guidance documents. The 
purpose of the criteria is to specify a threshold of abnormal hepatic tests that may require 
an additional evaluation for an underlying etiology. The study site guidance for 
assessment and follow-up of these criteria can be found in the Investigator Study File 
Binder (or equivalent).
Reporting time periods and time frames are fully detailed in Table 3.
8.5
Treatment of Overdose
In this study, an overdose is any dose >1 tablet BID (Section 4.3). Study intervention should 
be taken once in the morning and once in the evening. If more than the protocol-specified 
intervention is taken within a 1-day period (ie, >2 tablets/day) this is regarded as an 
overdose.
No specific information is available on the treatment of overdose. Oral doses of up to 
1800 mg BID for 14 days were explored in earlier clinical studies without any untoward 
clinical effects (see gefapixant IB). Overdose should be treated according to the participant’s 
clinical signs and symptoms.
Decisions regarding dose interruptions or modifications will be made by the investigator in 
consultation with the Sponsor Clinical Director based on the clinical evaluation of the 
participant.
 
 
05ND48
07YNSG


PRODUCT:  MK-7264  
66
PROTOCOL/AMENDMENT NO.:  043-03  
MK-7264-043-03 FINAL PROTOCOL
25-NOV-2020
8.6
Pharmacokinetics
Blood Collection for Plasma Gefapixant
Blood samples will be collected, as outlined in the SoA in Section 1.3. A pharmacokinetic 
blood sample should be collected within approximately 96 hours of the final dose of study 
medication. If the discontinuation or final visit is scheduled to occur greater than 96 hours 
following the final dose of study medication, please contact the Sponsor for guidance.
The date and time for the last dose of study intervention taken prior to the study visit on 
which the PK sample was collected should be recorded in the eCRF. In addition, the date and 
time of the PK sample collection should also be recorded in the eCRF.
Gefapixant plasma concentrations will be determined using a validated LC-MS/MS assay. 
Sample collection, storage and shipment instructions for plasma samples will be provided in 
the operations/laboratory manual for the study.
8.7
Pharmacodynamics
Pharmacodynamic parameters will not be evaluated in this study.
8.8
Biomarkers
Collection of samples for other biomarker research is also part of this study. The following 
samples for biomarker research are required and will be collected from all participants as 
specified in the SoA (Section 1.3):

Blood for Genetic Analysis
Planned Genetic Analysis Sample Collection
The planned genetic analysis sample should be drawn for planned analysis of the association 
between genetic variants in DNA and drug response. This sample will not be collected at the 
site if there is either a local law or regulation prohibiting collection, or if the IRB/IEC does 
not approve the collection of the sample for these purposes. If the sample is collected, 
leftover extracted DNA will be stored for future biomedical research if the participant 
provides documented informed consent for future biomedical research. If the planned genetic
analysis is not approved, but future biomedical research is approved and consent is given, 
this sample will be collected for the purpose of future biomedical research.
Sample collection, storage, and shipment instructions for planned genetic analysis samples 
will be provided in the operations/laboratory manual.
 
 
05ND48
07YNSG


PRODUCT:  MK-7264  
67
PROTOCOL/AMENDMENT NO.:  043-03  
MK-7264-043-03 FINAL PROTOCOL
25-NOV-2020
8.9
Future Biomedical Research Sample Collection
If the participant provides documented informed consent for future biomedical research, the 
following specimens will be obtained as part of future biomedical research:

Leftover DNA for future research
8.10
Visit Requirements
Visit requirements are outlined in Section 1.3. Specific procedure-related details are provided 
in Section 8.
Screening
Approximately 2 weeks prior to intervention randomization, potential participants will be 
evaluated to determine that they fulfill the entry requirements as set forth in Section 5. 
Screening/Visit 1 procedures may be repeated after consultation with the Sponsor. However, 
participants will not be permitted to rescreen if the inclusion criterion for the Cough Severity 
VAS is not met at Screening/Visit 1.
Participants who are consented will complete the Cough Severity VAS on the day of 
Screening/Visit 1 in the clinic, prior to completing other screening procedures (in order to 
first determine if the participant meets the Screening/Visit 1 Cough Severity VAS entry 
criterion). 
Washout of concomitant medication (Section 6.5) is permitted after signing informed consent
and participants must remain off these medications throughout the study. The investigator 
should evaluate medical history and overall condition when making the decision as to 
whether individuals can withdraw from medications in order to participate in the study. The 
screening period would begin after the completion of washout. These individuals should 
return to the clinic after washout for Screening/Visit 1 procedures. Participants are to be 
reminded to bring their e-Diary device with them to the next visit.
Treatment Period
The Randomization/Visit 2 must be scheduled between 7 days and approximately 14 days 
after Screening/Visit 1.
The CSD and Cough Severity VAS will be collected daily in the evening between
Screening/Visit 1 and Randomization/Visit 2. Participants must meet the Cough Severity 
VAS inclusion criterion at both Screening/Visit 1 and Randomization/Visit 2 (Section 5.1) in 
order to be eligible for study participation. Study intervention will be dispensed at 
Randomization/Visit 2. Once randomized, participants will receive either gefapixant 45 mg 
or placebo BID for 12 weeks. Both the participants and study personnel will be blinded to the 
study intervention.
Participants will be contacted by telephone on Day 7 (+3 days; following 
Randomization/Visit 2) and Day 21 (±3 days; following Randomization/Visit 2) to review 
 
 
05ND48
07YNSG


PRODUCT:  MK-7264  
68
PROTOCOL/AMENDMENT NO.:  043-03  
MK-7264-043-03 FINAL PROTOCOL
25-NOV-2020
any AEs that may have occurred and concomitant medications taken, instructions 
on/compliance with study drug administration, and e-Diary completion (as necessary), and 
any questions the participant may have about the study.
For all study site visits, participants are to be reminded to bring their e-Diary device with 
them to the next visit. 
Randomization/Visit 2 will be assigned as Day 1, and subsequent visit scheduling will be 
calculated from Day 1 (and not from the previous study visit).
Discontinued Participants Continuing to be Monitored in the Study  
It is intended that all participants should be followed throughout the study, regardless of 
premature discontinuation of intervention, unless the participant withdraws consent. Thus, 
participants who discontinue from study intervention prior to completion of the study should 
continue to be monitored to obtain relevant information through the end of the study. 
If a participant is discontinued from the study intervention early:

the Discontinuation Visit should be performed as soon as possible; Procedures, 
including the e-Diary assessments, should be performed as outlined for the 
Discontinuation Visit in the SoA (Section 1.3). 
Note: If a participant discontinues at a regularly scheduled study visit, the procedures
outlined for the Discontinuation Visit in the SoA should be followed in place of the 
procedures for the regularly scheduled study visit.

a safety follow-up telephone call should be conducted a minimum of 14 days (with an 
allowed variance of up to +7 days) after the last dose of study intervention; and 

Study site visits should continue to be performed at timepoints that correspond to 
each remaining study visit. These visits will allow collection of follow-up 
information, limited to:
o
AEs;
o
Concomitant medication use; and 
o
e-Diary assessments, as outlined in the SoA (Section 1.3).
Note: If the participant discontinues study intervention at a regularly scheduled study 
visit but remains in the study, the Discontinuation Visit should be performed, and the 
regularly scheduled study visits should resume thereafter. For example: If a 
participant discontinues study intervention at the time of Visit 3, procedures for the 
Discontinuation Visit should be performed at that time. The next expected study visit 
would be Visit 4.
 
 
05ND48
07YNSG


PRODUCT:  MK-7264  
69
PROTOCOL/AMENDMENT NO.:  043-03  
MK-7264-043-03 FINAL PROTOCOL
25-NOV-2020
Concomitant therapies specifically prohibited (Section 6.5) while the participant was on 
study intervention are no longer prohibited after discontinuation of study intervention.

For these participants who have discontinued study intervention early, sites will be 
instructed to exert diligent efforts to continue to contact them. To enable sites to reach 
participants, the participants should provide primary and secondary contact 
information (eg, home telephone, work telephone, mobile telephone). Sites must 
document the outcome of the telephone contact(s), to demonstrate diligent efforts 
have been made.
Additionally, the ICF will explain the importance of continued data collection from 
participants, including the use of continued contact by telephone.
Poststudy
All participants that complete the treatment period will be required to complete the safety 
follow-up telephone call approximately 2 weeks (14 days, with an allowed variance of up to 
+7 days) after the last dose of study intervention to determine if any AEs have occurred since 
discontinuing study intervention.
Note: Participants that discontinue intervention and/or discontinue from the study should also 
complete the safety follow-up telephone call 14 days (+7 days) after the last dose of 
intervention.
If the safety follow-up telephone contact occurs less than 14 days after the last dose of study 
intervention, a subsequent follow-up telephone call should be made at approximately 
2 weeks (14 days, with an allowed variance of up to +7 days) post the last dose of study 
intervention.
9
STATISTICAL ANALYSIS PLAN
This section outlines the statistical analysis strategy and procedures for the study. If, after the 
study has begun, but prior to any unblinding, changes are made to primary and/or key 
secondary hypotheses, or the statistical methods related to those hypotheses, then the 
protocol will be amended (consistent with ICH Guidance E9). Changes to exploratory or 
other non-confirmatory analyses made after the protocol has been finalized, but prior to 
unblinding, will be documented in a sSAP and referenced in the CSR for the study. Post-hoc 
exploratory analyses will be clearly identified in the CSR.
 
 
05ND48
07YNSG


PRODUCT:  MK-7264  
70
PROTOCOL/AMENDMENT NO.:  043-03  
MK-7264-043-03 FINAL PROTOCOL
25-NOV-2020
9.1
Statistical Analysis Plan Summary
Key elements of the statistical analysis plan are summarized below. The comprehensive plan 
is provided in Sections 9.2 through 9.12.
Study Design Overview
A Phase 3b, Randomized, Double-blind, Placebo Controlled, 
Multicenter Study to Evaluate the Efficacy and Safety of 
Gefapixant in Adult Participants with Recent Onset Chronic 
Cough (P043)
Treatment Assignment
Participants will be randomized in a 1:1 ratio to 1 of 2 
treatment groups: Gefapixant 45 mg BID or Placebo.
Analysis Populations
Efficacy: FAS population, which consists of all randomized 
participants who have taken at least 1 dose of study 
intervention.
Safety: APaT population, which consists of all randomized 
participants who received at least 1 dose of study 
intervention.
Primary Endpoint
LCQ total score 
Statistical Methods for Key 
Efficacy Analyses
The primary analysis will be based on the FAS population. 
The primary analysis approach will be conducted utilizing the 
longitudinal ANCOVA model. In this model, the response 
vector consists of LCQ change from baseline in total score at 
each post-Baseline visit. The model will include factors for 
intervention group, visit, the interaction between intervention
group and visit, gender, and baseline LCQ total score. The 
model will use all available LCQ change from baseline in 
total score data at Weeks 6 and 12. Contrasts will be 
constructed to compare the Gefapixant group to the Placebo
group at each post-Baseline visit. The least squares mean 
change from baseline with the associated standard errors will 
be displayed for each intervention group. Estimated treatment 
differences (Gefapixant − Placebo) along with corresponding 
p-values and CIs will also be presented.
Statistical Methods for Key 
Safety Analyses
The analysis of safety endpoints will follow a tiered approach. 
The tiers differ with respect to the analyses that will be 
performed. Tier 1 and Tier 2 safety endpoints will be 
evaluated via point estimates and 95% CIs for between-group 
comparisons, with p-values provided for the Tier 1 safety 
endpoints. Tier 3 safety endpoints will be evaluated via point 
estimates only.
 
 
05ND48
07YNSG


PRODUCT:  MK-7264  
71
PROTOCOL/AMENDMENT NO.:  043-03  
MK-7264-043-03 FINAL PROTOCOL
25-NOV-2020
Interim Analyses
One planned IA will be performed in this study to examine 
the futility and efficacy. Results will be reviewed by the
DMC. The IA is summarized below. Details are provided in 
Section 9.7. 
•
Timing: To be performed when approximately 40% of 
participants (approximately the first 166 randomized
participants) have either completed the study or
discontinued the study intervention early.
•
Testing: Futility and Strong Benefit (Efficacy) analysis 
based on the primary endpoint of LCQ change from 
baseline in total score at Week 12 will be provided. 
Multiplicity
Since there is only one hypothesis (for the primary endpoint), 
no multiplicity adjustment is planned other than the IA alpha 
adjustment to the primary efficacy endpoint.
Sample Size and Power 
Calculations
The planned sample size is 414 participants (207 per 
treatment group) for comparing the primary endpoint of LCQ 
change from baseline in total score at Week 12, assuming a 
pooled SD of 3.5 points. This sample size will detect a 
treatment difference of 1.1 points or more with at least 80% 
power at an overall one-sided 0.025 alpha level, adjusted for 
the IA (α=0.001) for strong benefit and the final analysis
(α=0.024). This sample size accounts for a 15% dropout rate,
targeting for 352 evaluable participants at Week 12. The 
details are described in Section 9.9.
9.2
Responsibility for Analyses/In-house Blinding
The statistical analysis of the data obtained from this study will be the responsibility of the 
designee of the Sponsor. 
This study will be conducted as a double-blind study under in-house blinding procedures. 
The official, final database will not be unblinded until medical/scientific review has been 
performed, protocol deviations have been identified, and data have been declared final and 
complete. The investigator site personnel and the participants will be blinded to intervention 
assignment until the entire study completion.
The Clinical Biostatistics department will generate the randomized allocation schedule(s) for 
study intervention assignment. Treatment assignment will be implemented in an IRT system
by a study vendor according to the adaptive allocation scheme provided in Section 6.3.1.
Blinding issues related to the planned IA are described in Section 9.7.
 
 
05ND48
07YNSG


PRODUCT:  MK-7264  
72
PROTOCOL/AMENDMENT NO.:  043-03  
MK-7264-043-03 FINAL PROTOCOL
25-NOV-2020
9.3
Hypotheses/Estimation
The primary hypothesis for this study is stated in Section 3.
9.4
Analysis Endpoints
Efficacy and safety endpoints for evaluation are listed below.
Efficacy Endpoints 
9.4.1.1
Primary Efficacy Endpoint 

LCQ total score measured as change from baseline at Week 12
9.4.1.2
Secondary Efficacy Endpoints

Cough Severity VAS score measured as change from baseline at Week 12
9.4.1.3
Exploratory Efficacy Endpoints

CSD total score measured as change from baseline at Week 12

PGIC measured at Week 12

WPAI measured as change from baseline at Week 12
Safety Endpoints 

Adverse events

Study intervention discontinuations due to an AE
9.5
Analysis Populations
Efficacy Analysis Populations
The FAS population will serve as the primary population for the analysis of efficacy data in 
this study. The FAS population consists of all randomized participants who have taken at 
least 1 dose of study intervention. 
Participants will be included in the intervention group to which they are randomized for the 
analysis of efficacy data using the FAS population. Details on the approach to handling 
missing data are provided in Section 9.6.
Safety Analysis Populations
The APaT population will be used for the analysis of safety data in this study. The APaT 
population consists of all randomized participants who received at least 1 dose of study 
 
 
05ND48
07YNSG


PRODUCT:  MK-7264  
73
PROTOCOL/AMENDMENT NO.:  043-03  
MK-7264-043-03 FINAL PROTOCOL
25-NOV-2020
intervention. Participants will be included in the intervention group corresponding to the 
study intervention they actually received for the analysis of safety data using the APaT 
population. For most participants, this will be the intervention group to which they are 
randomized. Participants who take incorrect study intervention for the entire intervention
period will be included in the intervention group corresponding to the study intervention 
actually received. Participants who take incorrect study intervention during only a part of the 
treatment period and took at least 1 dose of active study intervention will be included in the 
active treatment group.
At least 1 laboratory or vital sign measurement obtained subsequent to at least 1 dose of 
study intervention is required for inclusion in the analysis of each specific parameter. To 
assess change from baseline, a baseline measurement is also required.
9.6
Statistical Methods
This section describes the statistical methods that address the primary objective. Methods 
related to exploratory objectives and supportive analyses will be described in the sSAP. 
Statistical testing and inference for efficacy and safety analyses are described in 
Sections 9.6.1 and 9.6.2, respectively. The statistical test of the primary efficacy endpoint
will be conducted at the overall significance level of 0.05 (2-sided).
Statistical Methods for Efficacy Analyses
The analysis of efficacy endpoints will be based on the FAS population. Unless otherwise 
specified, all efficacy data from participants who have taken at least 1 dose of study 
intervention will be included in efficacy analyses.
Primary Efficacy Analysis 
The LCQ is collected at baseline and after administration of the study intervention at
Weeks 6 and 12. The primary efficacy endpoint of this study is the LCQ change from 
baseline in total score. The primary analysis approach will be conducted utilizing the 
longitudinal ANCOVA model. In this model, the response vector consists of the LCQ change 
from baseline in total score at each post-Baseline visit. The model will include factors for 
intervention group, visit, interaction of treatment by visit, gender, and the baseline LCQ 
score. The model will use all available LCQ change from baseline in total score at Weeks 6
and 12. Contrasts will be constructed to compare the Gefapixant intervention group to the 
Placebo group at Week 6 and Week 12. The least squares mean change from baseline with 
the associated standard errors will be displayed for each intervention group. Overall
estimated treatment differences (Gefapixant −Placebo) along with corresponding p-values 
and 95% CIs will also be presented, with the exception of the primary efficacy endpoint, in 
which the CI width will be adjusted for an IA (Section 9.6). Further details of the model 
specification, assumptions, and SAS implementation codes will be provided in the sSAP. 
 
 
05ND48
07YNSG


PRODUCT:  MK-7264  
74
PROTOCOL/AMENDMENT NO.:  043-03  
MK-7264-043-03 FINAL PROTOCOL
25-NOV-2020
Secondary Efficacy Analysis 
The continuous secondary efficacy endpoints will be analyzed using a similar longitudinal 
ANCOVA model as used for the primary efficacy analysis. The model will include terms for 
intervention group, visit, interaction of treatment by visit, gender, and baseline score. 
Table 4 summarizes the analysis strategy of the primary and secondary efficacy endpoints. 
Table 4
Analysis Strategy for Primary and Secondary Efficacy Endpoints
Endpoint/Variable 
(at Week 12)
Statistical Method
Missing Data Approach
Primary
Change from baseline in LCQ 
total score
Longitudinal ANCOVA
Model-baseda
Secondary
Change from baseline in Cough 
Severity VAS score
Longitudinal ANCOVA
Model-baseda
ANCOVA=analysis of covariance; LCQ=Leicester Cough Questionnaire; VAS=Visual Analog Scale
a Includes data collected after early intervention discontinuation. 
The strategy for the IA is described in Section 9.7. 
Exploratory Efficacy Analyses
Details of the exploratory efficacy analysis methods will be provided in the sSAP.
Handling of Missing Data 
A participant will be considered for inclusion in the assessment of an efficacy endpoint if the
CSD and Cough Severity VAS are completed on at least 4 days during the 7-day period prior 
to a post-Baseline visit (other ePROs are completed at the clinic visit only). All efficacy 
analyses will be conducted based on the observed data only. No imputation is planned for the 
missing diaries or missing questionnaire items. The pattern of missing is assumed to be 
MAR. The missing pattern will be inspected to determine if the MAR assumption is met. 
Sensitivity analyses will be implemented to explore the impact of departures from the 
assumption made in missing diaries. Additional sensitivity analyses with respect to the 
handling of missing data will be specified in the sSAP.
Statistical Methods for Safety Analyses
Safety and tolerability will be assessed by clinical review of all relevant parameters including 
AEs, laboratory tests, and vital signs. 
 
 
05ND48
07YNSG


PRODUCT:  MK-7264  
75
PROTOCOL/AMENDMENT NO.:  043-03  
MK-7264-043-03 FINAL PROTOCOL
25-NOV-2020
The analysis of safety results will follow a tiered approach (Table 5). The tiers differ with 
respect to the analyses that will be performed. Adverse events (specific terms as well as 
system organ class terms) and events that meet predefined limits of change in laboratory and
vital signs are either prespecified as “Tier 1” endpoints, or will be classified as belonging to 
"Tier 2" or "Tier 3" based on the observed proportions of participants with an event. 
Tier 1 Events
Safety parameters or adverse events of interest that are identified a priori constitute “Tier 1” 
safety endpoints that will be subject to inferential testing for statistical significance with 
p-values and 95% CIs to be provided for between-treatment differences in the proportion of 
participants with events; these analyses will be performed using the Miettinen and Nurminen 
(M&N) method (1985) [Miettinen, O. and Nurminen, M. 1985], an unconditional, asymptotic 
method. For this protocol, taste-related AEs (including dysgeusia, ageusia, and hypogeusia, 
as well as other related terms) are considered Tier 1 events. The definition of taste-related 
AEs will be finalized and documented before the database lock of the study.
Tier 2 Events
Tier 2 parameters will be assessed via point estimates and 95% CIs provided for differences 
in the proportion of participants with events. 
Membership in Tier 2 requires that at least 4 participants in any treatment group exhibit the 
event. The threshold of at least 4 events was chosen because the 95% confidence interval for 
the between-group difference in percent incidence will always include zero when treatment 
groups of equal size each have less than 4 events and, thus, would add little to the 
interpretation of potentially meaningful differences. Because many 95% confidence intervals 
for Tier 2 events may be provided without adjustment for multiplicity, the confidence 
intervals should be regarded as a helpful descriptive measure to be used in review, not a 
formal method for assessing the statistical significance of the between-group differences in 
adverse events and safety parameters that meet predefined limits of change.
In addition to individual events that occur in 4 or more participants in any treatment group,
any oral paresthesia AE, any oral hypoesthesia AE, and the broad AE categories consisting of 
the proportion of participants with any AE, a drug-related AE, a serious AE, an AE which is 
both drug-related and serious, and discontinuation due to an AE will be considered Tier 2 
events.
Tier 3 Events
Safety endpoints that are not Tier 1 or 2 events are considered Tier 3 events. Only point 
estimates by treatment group are provided for Tier 3 safety parameters. 
 
 
05ND48
07YNSG


PRODUCT:  MK-7264  
76
PROTOCOL/AMENDMENT NO.:  043-03  
MK-7264-043-03 FINAL PROTOCOL
25-NOV-2020
Continuous Safety Measures
For continuous measures such as changes from baseline in laboratory and vital signs,
summary statistics for baseline, on-treatment, and change from baseline values will be 
provided by intervention group in table format.
Table 5
Analysis Strategy for Safety Parameters
Safety 
Tier
Safety Endpointa
p-value
95% CI for 
Treatment 
Comparison
Descriptive 
Statistics
Tier 1
Any taste-related AE (including dysgeusia,
ageusia, and hypogeusia, as well as other 
related terms)
X
X
X
Tier 2
Any oral paresthesia AE
X
X
Any oral hypoesthesia AE
X
X
Any AE
X
X
Any Serious AE
X
X
Any Drug-related AE
X
X
Any Serious and Drug-related AE
X
X
Discontinuation due to AE
X
X
Specific AEs, SOCs, or PDLCsb (incidence 
≥ 4 participants in 1 of the intervention
groups)
X
X
Tier 3
Specific AEs, SOCs, or PDLCsb (incidence 
< 4 participants in all the intervention
groups)
X
Change from baseline results (Labs, Vital 
Signs)
X
AE =adverse event; CI=confidence interval; PDLC=predefined limit of change; SOC=system organ class; X =results will be 
provided.
a
Adverse experience references refer to both clinical and laboratory AEs. 
b 
Includes only those endpoints not prespecified as Tier 1 or not already prespecified as Tier 2 endpoints. 
Summaries of Baseline Characteristics, Demographics, and Other Analyses
9.6.3.1
Demographic and Baseline Characteristics 
The comparability of the treatment groups for each relevant demographic and baseline 
characteristic will be assessed by the use of tables and/or graphs. No statistical hypothesis 
tests will be performed on these characteristics. The number and percentage of participants 
screened and randomized and the primary reasons for screening failure and discontinuation 
will be displayed. Demographic variables (eg, age, gender, race, weight, and height), baseline 
characteristics, primary and secondary diagnoses, and prior and concomitant therapies will be 
summarized by treatment either by descriptive statistics or categorical tables.
 
 
05ND48
07YNSG


PRODUCT:  MK-7264  
77
PROTOCOL/AMENDMENT NO.:  043-03  
MK-7264-043-03 FINAL PROTOCOL
25-NOV-2020
9.7
Interim Analyses
There is one planned IA for this study. Study enrollment is likely to be ongoing at the time of 
any IA. Blinding to treatment assignment will be maintained at all investigational sites. The 
results of IA will not be shared with the investigators prior to the completion of the study.
Participant-level unblinding will be restricted to an external unblinded statistician and 
scientific programmer performing the IA, who will have no other responsibilities associated 
with the study.
If the study is stopped early, the CSR will include all available data up to and including the 
close-out visits.
Unblinding for Interim Analyses 
After approximately 40% of the enrolled participants (approximately the first 166 enrolled 
participants) have completed the study or discontinued the study intervention early, a copy of 
the database will be locked for the IA, and an independent statistician and scientific 
programmer will be unblinded to perform the IA. 
An external DMC will serve as the primary reviewer of the results of the IA of the study and 
will make recommendations for discontinuation of the study or protocol modifications to the 
EOC of the Sponsor. If the DMC recommends modifications to the design of the protocol or 
discontinuation of the study, this executive committee may be unblinded to results at the 
treatment level in order to act on these recommendations. The extent to which individuals are 
unblinded with respect to results of interim analyses will be documented by the unblinded 
statistician. Additional logistical details will be provided in the DMC charter
(Section 10.1.4.3). Key aspects of the interim analyses are described in Sections 9.7.1 and 
9.7.2.
Treatment-level results from the interim analysis will be provided to the DMC by the 
unblinded statistician. Prior to final study unblinding, the unblinded statistician will not be 
involved in any discussions regarding modifications to the protocol, statistical methods, 
identification of protocol deviations, or data validation efforts after the interim analyses.
Interim Efficacy Analysis
One planned efficacy IA will be conducted when approximately 40% of target participants
(approximately the first 166 randomized participants) have either completed the study 
(approximately 141 randomized participants) or discontinued study intervention early. All 
available data will be included in the analysis, including follow-up data and partial data from 
participants enrolled after the participants triggering the IA.
The purpose of the IA is to allow early stop for strong benefit (efficacy) or for futility. The 
efficacy IA will be based on the primary endpoint of the LCQ change from baseline in total 
score at Week 12.
 
 
05ND48
07YNSG


352'8&70.

35272&2/$0(1'0(1712
0. ),1$/ 35272&2/
129
7KH GHFLVLRQFULWHULDDUHSUHVSHFLILHGDVIROORZV
,QWHULP6DIHW\ $QDO\VLV
,QWHULPVDIHW\ZLOODOVREHDVVHVVHGDWWKHWLPHRISUHVSHFLILHG,$ IRUIXWLOLW\LH ZKHQ
DSSUR[LPDWHO\RIWDUJHWSDUWLFLSDQWVDSSUR[LPDWHO\ WKHILUVW UDQGRPL]HG
SDUWLFLSDQWVKDYHHLWKHUFRPSOHWHG WKHVWXG\ RUGLVFRQWLQXHGWKHVWXG\ LQWHUYHQWLRQ HDUO\ $
JHQHUDOUHYLHZRIVDIHW\UHVXOWVZLOOEHSHUIRUPHGEDVHGRQUHYLHZRI$(VODERUDWRU\VDIHW\
SDUDPHWHUVDQGRWKHUVDIHW\HQGSRLQWV

0XOWLSOLFLW\
2WKHUWKDQDQ DGMXVWPHQWWRWKHDOSKDOHYHOIRUWKH,$ IRUHIILFDF\QRPXOWLSOLFLW\DGMXVWPHQW
LV SODQQHG

6DPSOH6L]HDQG3RZHU&DOFXODWLRQV
7KHVDPSOHVL]HFDOFXODWLRQVDUHSRZHUHGWRWHVW WKHSULPDU\HIILFDF\HQGSRLQWZLWKWKH
IROORZLQJDVVXPSWLRQVEDVHGRQWKHUHVXOWVIURPDSKDVHFKURQLFFRXJKVWXG\


1'
CCI
CCI
CCI
CCI
<16*


352'8&70.

35272&2/$0(1'0(1712
0. ),1$/ 35272&2/
129
%DVHGRQWKHDVVXPSWLRQVDERYH DWRWDORI SDUWLFLSDQWV SDUWLFLSDQWVSHULQWHUYHQWLRQ
JURXS ZLOOSURYLGHDWOHDVWSRZHU 7KHFDOFXODWLRQLV EDVHGRQ DQRYHUDOO RQHVLGHG
Į  VLJQLILFDQFH OHYHODGMXVWHGIRURQH ,$IRU HIILFDF\Į DQGRQH ILQDOHIILFDF\
DQDO\VLV Į  $ GURSRXWUDWHRI DW:HHN LV DFFRXQWHGIRUWKHVDPSOHVL]H
FDOFXODWLRQWRHQVXUHHYDOXDEOHSDUWLFLSDQWVFRPSOHWHWKH :HHN HYDOXDWLRQ
:LWKDVVXPSWLRQVRQWKH$(UDWHVLQWKHSODFHERJURXSEDVHGRQWKH3URWRFROUHVXOWVWKH
PLQLPXPGHWHFWDEOH$(UDWHGLIIHUHQFHVDUHDQGLQRYHUDOOWDVWHUHODWHG
$(VRUDOSDUHVWKHVLD$(VDQGRUDOK\SRHVWKHVLD$(V UHVSHFWLYHO\

6XEJURXS$QDO\VHV
$QDO\VLVIRUWKHSULPDU\HIILFDF\HQGSRLQWZLOOEHSURYLGHGIRUWKHIROORZLQJVXEJURXSVRI
EDVHOLQHIDFWRUV
•
*HQGHUPDOHIHPDOH
•
5HJLRQ1RUWK$PHULFD(XURSH$VLD3DFLILF2WKHU
•
$JHJURXS\HDUV\HDUVROG
•
%DVHOLQH&RXJK6HYHULW\9$6PPPP
•
3RWHQWLDOFRPRUELGFRQGLWLRQV DVVRFLDWHGZLWKFRXJKLH*(5'DVWKPD8$&6
1RWH'HWDLOVRIWKHFRQGLWLRQVZLOOEHSURYLGHGLQDVHSDUDWHV6$3
•
&RQFRPLWDQWPHGLFDWLRQVLHDQWLWXVVLYHVDQGWUHDWPHQWVIRUSRWHQWLDOFRPRUELG
FRQGLWLRQVSURWRQSXPSLQKLELWRUVLQKDOHGFRUWLFRVWHURLGVILUVWJHQHUDWLRQDQWL
KLVWDPLQHV1RWH'HWDLOVRIWKHFRQFRPLWDQWPHGLFDWLRQVZLOOEHSURYLGHGLQD
VHSDUDWHV6$3
$VLPLODUORQJLWXGLQDO$1&29$PRGHODVWKDWXVHGIRUWKHSULPDU\HIILFDF\HQGSRLQWZLOO
EHXWLOL]HG)RUHDFKVXEJURXSVXPPDU\VWDWLVWLFVLQFOXGLQJPHDQV DQGWKHLU&,VZLOOEH
SURYLGHGIRUHDFKLQWHUYHQWLRQ JURXS DW:HHN )RUWKHVXEJURXSVZLWK RUPRUH RI WKH
)$6SRSXODWLRQDFURVVERWKLQWHUYHQWLRQ JURXSVWKHPHDQWUHDWPHQWGLIIHUHQFHV
JHIDSL[DQW  SODFHERDQGWKHLU&,VZLOODOVREHSURYLGHGDW:HHN

1'
CCI
<16*


PRODUCT:  MK-7264  
80
PROTOCOL/AMENDMENT NO.:  043-03  
MK-7264-043-03 FINAL PROTOCOL
25-NOV-2020
9.11
Compliance (Medication Adherence)
For each participant, percent compliance will be calculated using the following formula:
A day within the study will be considered an “on-therapy” day if the participant takes all 
required intervention as instructed in Section 8. When a participant takes less than or more 
than the required intervention on a day, that day is not considered an on-therapy day. 
For participants who are followed for the entire study period, the “Number of Days Should 
be on Therapy” is the total number of days from the first scheduled intervention day to the 
last scheduled intervention day. For participants who discontinue from the study 
permanently, the “Number of Days Should Be on Therapy” is the total number of days from 
the first scheduled intervention day to the last dose day. 
Summary statistics will be provided on percent compliance by intervention group for the 
APaT population.
9.12
Extent of Exposure
The duration of intervention for each participant will be evaluated by calculating the number 
of days on therapy. Exposure to study intervention will be summarized using descriptive 
statistics (mean, SD, median, minimum, and maximum) for the APaT population.
 
 
05ND48
07YNSG


PRODUCT:  MK-7264  
81
PROTOCOL/AMENDMENT NO.:  043-03  
MK-7264-043-03 FINAL PROTOCOL
25-NOV-2020
10
SUPPORTING DOCUMENTATION AND OPERATIONAL 
CONSIDERATIONS
10.1
Appendix 1: Regulatory, Ethical, and Study Oversight Considerations
Code of Conduct for Clinical Trials
Merck Sharp and Dohme Corp., a subsidiary of Merck & Co., Inc. (MSD)
Code of Conduct for Interventional Clinical Trials
I. Introduction
A. Purpose
MSD, through its subsidiaries, conducts clinical trials worldwide to evaluate the safety and effectiveness of our 
products. As such, we are committed to designing, implementing, conducting, analyzing, and reporting these trials 
in compliance with the highest ethical and scientific standards. Protection of participants in clinical trials is the 
overriding concern in the design and conduct of clinical trials. In all cases, MSD clinical trials will be conducted 
in compliance with local and/or national regulations, and International Council for Harmonisation Good Clinical 
Practice (ICH-GCP), and also in accordance with the ethical principles that have their origin in the Declaration of 
Helsinki.
B. Scope
Highest ethical and scientific standards shall be endorsed for all clinical interventional investigations sponsored by 
MSD irrespective of the party (parties) employed for their execution (e.g., contract research organizations, 
collaborative research efforts). This Code is not intended to apply to trials that are observational in nature, or 
which are retrospective. Further, this Code does not apply to investigator-initiated trials, which are not under the 
full control of MSD.
II. Scientific Issues
A. Trial Conduct
1. Trial Design
Except for pilot or estimation trials, clinical trial protocols will be hypothesis-driven to assess safety, efficacy 
and/or pharmacokinetic or pharmacodynamic indices of MSD or comparator products. Alternatively, MSD
may conduct outcomes research trials, trials to assess or validate various endpoint measures, or trials to 
determine patient preferences, etc.
The design (i.e., participant population, duration, statistical power) must be adequate to address the specific
purpose of the trial. Participants must meet protocol entry criteria to be enrolled in the trial. 
2. Site Selection
MSD selects investigative sites based on medical expertise, access to appropriate participants, adequacy of 
facilities and staff, previous performance in clinical trials, as well as budgetary considerations. Prior to trial 
initiation, sites are evaluated by MSD personnel (or individuals acting on behalf of MSD) to assess the ability 
to successfully conduct the trial.
3. Site Monitoring/Scientific Integrity
Investigative trial sites are monitored to assess compliance with the trial protocol and Good Clinical Practice
(GCP). MSD reviews clinical data for accuracy, completeness, and consistency. Data are verified versus 
source documentation according to standard operating procedures. Per MSD policies and procedures, if fraud, 
 
 
05ND48
07YNSG


PRODUCT:  MK-7264  
82
PROTOCOL/AMENDMENT NO.:  043-03  
MK-7264-043-03 FINAL PROTOCOL
25-NOV-2020
scientific/research misconduct or serious GCP-non-compliance is suspected, the issues are investigated. 
When necessary, the clinical site will be closed, the responsible regulatory authorities and ethics review 
committees notified.
B. Publication and Authorship
Regardless of trial outcome, MSD commits to publish the primary and secondary results of its registered trials of 
marketed products in which treatment is assigned, according to the pre-specified plans for data analysis. To the 
extent scientifically appropriate, MSD seeks to publish the results of other analyses it conducts that are important 
to patients, physicians, and payers. Some early phase or pilot trials are intended to be hypothesis-generating rather 
than hypothesis testing; in such cases, publication of results may not be appropriate since the trial may be 
underpowered and the analyses complicated by statistical issues such as multiplicity.
MSD’s policy on authorship is consistent with the recommendations published by the International Committee of 
Medical Journal Editors (ICMJE). In summary, authorship should reflect significant contribution to the design and 
conduct of the trial, performance or interpretation of the analysis, and/or writing of the manuscript. All named 
authors must be able to defend the trial results and conclusions. MSD funding of a trial will be acknowledged in 
publications.
III. Participant Protection
A. Regulatory Authority and Ethics Committee Review (Institutional Review Board [IRB]/Independent Ethics 
Committee [IEC])
All protocols and protocol amendments will be submitted by MSD for regulatory authority 
acceptance/authorization prior to implementation of the trial or amendment, in compliance with local and/or 
national regulations.
The protocol, protocol amendment(s), informed consent form, investigator’s brochure, and other relevant trial 
documents must be reviewed and approved by an IRB/IEC before being implemented at each site, in compliance 
with local and/or national regulations. Changes to the protocol that are required urgently to eliminate an 
immediate hazard and to protect participant safety may be enacted in anticipation of ethics committee approval.  
MSD will inform regulatory authorities of such new measures to protect participant safety, in compliance with 
local and/or national regulations.
B. Safety
The guiding principle in decision-making in clinical trials is that participant welfare is of primary importance. 
Potential participants will be informed of the risks and benefits of, as well as alternatives to, trial participation. At 
a minimum, trial designs will take into account the local standard of care.
All participation in MSD clinical trials is voluntary. Participants enter the trial only after informed consent is 
obtained. Participants may withdraw from an MSD trial at any time, without any influence on their access to, or 
receipt of, medical care that may otherwise be available to them.
C. Confidentiality
MSD is committed to safeguarding participant confidentiality, to the greatest extent possible. Unless required by 
law, only the investigator, Sponsor (or individuals acting on behalf of MSD), ethics committee, and/or regulatory 
authorities will have access to confidential medical records that might identify the participant by name.
D. Genomic Research
Genomic research will only be conducted in accordance with a protocol and informed consent authorized by an 
ethics committee.
 
 
05ND48
07YNSG


PRODUCT:  MK-7264  
83
PROTOCOL/AMENDMENT NO.:  043-03  
MK-7264-043-03 FINAL PROTOCOL
25-NOV-2020
IV. Financial Considerations
A. Payments to Investigators
Clinical trials are time- and labor-intensive. It is MSD’s policy to compensate investigators (or the sponsoring 
institution) in a fair manner for the work performed in support of MSD trials. MSD does not pay incentives to 
enroll participants in its trials. However, when enrollment is particularly challenging, additional payments may be 
made to compensate for the time spent in extra recruiting efforts.
MSD does not pay for participant referrals. However, MSD may compensate referring physicians for time spent 
on chart review and medical evaluation to identify potentially eligible participants.
B. Clinical Research Funding
Informed consent forms will disclose that the trial is sponsored by MSD, and that the investigator or sponsoring 
institution is being paid or provided a grant for performing the trial. However, the local ethics committee may 
wish to alter the wording of the disclosure statement to be consistent with financial practices at that institution. As 
noted above, all publications resulting from MSD trials will indicate MSD as a source of funding.
C. Funding for Travel and Other Requests
Funding of travel by investigators and support staff (e.g., to scientific meetings, investigator meetings, etc.) will be 
consistent with local guidelines and practices.
V. Investigator Commitment
Investigators will be expected to review MSD’s Code of Conduct as an appendix to the trial protocol, and in signing the 
protocol, agree to support these ethical and scientific standards.
Financial Disclosure
Financial Disclosure requirements are outlined in the US Food and Drug Administration 
Regulations, Financial Disclosure by Clinical Investigators (21 CFR Part 54). It is the 
Sponsor's responsibility to determine, based on these regulations, whether a request for 
Financial Disclosure information is required. It is the investigator's/subinvestigator's 
responsibility to comply with any such request.
The investigator/subinvestigator(s) agree, if requested by the Sponsor in accordance with 21 
CFR Part 54, to provide his/her financial interests in and/or arrangements with the Sponsor to 
allow for the submission of complete and accurate certification and disclosure statements. 
The investigator/subinvestigator(s) further agree to provide this information on a 
Certification/Disclosure Form, commonly known as a financial disclosure form, provided by 
the Sponsor. The investigator/subinvestigator(s) also consent to the transmission of this 
information to the Sponsor in the United States for these purposes. This may involve the 
transmission of information to countries that do not have laws protecting personal data.
Data Protection
Participants will be assigned a unique identifier by the Sponsor. Any participant records or 
datasets that are transferred to the Sponsor will contain the identifier only; participant names 
or any information that would make the participant identifiable will not be transferred.
 
 
05ND48
07YNSG


PRODUCT:  MK-7264  
84
PROTOCOL/AMENDMENT NO.:  043-03  
MK-7264-043-03 FINAL PROTOCOL
25-NOV-2020
The participant must be informed that his/her personal study-related data will be used by the 
Sponsor in accordance with local data protection law. The level of disclosure must also be 
explained to the participant. 
The participant must be informed that his/her medical records may be examined by Clinical 
Quality Assurance auditors or other authorized personnel appointed by the Sponsor, by 
appropriate IRB/IEC members, and by inspectors from regulatory authorities.
10.1.3.1
Confidentiality of Data
By signing this protocol, the investigator affirms to the Sponsor that information furnished to 
the investigator by the Sponsor will be maintained in confidence, and such information will 
be divulged to the IRB, IEC, or similar or expert committee; affiliated institution and 
employees, only under an appropriate understanding of confidentiality with such board or 
committee, affiliated institution and employees. Data generated by this study will be 
considered confidential by the investigator, except to the extent that it is included in a 
publication as provided in the Publications section of this protocol.
10.1.3.2
Confidentiality of Participant Records
By signing this protocol, the investigator agrees that the Sponsor (or Sponsor representative), 
IRB/IEC, or regulatory authority representatives may consult and/or copy study documents to
verify worksheet/CRF data. By signing the consent form, the participant agrees to this 
process. If study documents will be photocopied during the process of verifying 
worksheet/CRF information, the participant will be identified by unique code only; full 
names/initials will be masked prior to transmission to the Sponsor.
By signing this protocol, the investigator agrees to treat all participant data used and 
disclosed in connection with this study in accordance with all applicable privacy laws, rules 
and regulations.
10.1.3.3
Confidentiality of IRB/IEC Information
The Sponsor is required to record the name and address of each IRB/IEC that reviews and 
approves this study. The Sponsor is also required to document that each IRB/IEC meets 
regulatory and ICH GCP requirements by requesting and maintaining records of the names 
and qualifications of the IRB/IEC members and to make these records available for 
regulatory agency review upon request by those agencies.
Committees Structure
10.1.4.1
Executive Oversight Committee
The EOC is comprised of members of Sponsor Senior Management. The EOC will receive 
and decide upon any recommendations made by the DMC regarding the study.
 
 
05ND48
07YNSG


PRODUCT:  MK-7264  
85
PROTOCOL/AMENDMENT NO.:  043-03  
MK-7264-043-03 FINAL PROTOCOL
25-NOV-2020
10.1.4.2
Scientific Advisory Committee (SAC)
This study was developed in collaboration with a SAC. The SAC is comprised of both 
Sponsor and non-Sponsor scientific experts who provide input with respect to study design, 
interpretation of study results, and subsequent peer-reviewed scientific publications.
10.1.4.3
External Data Monitoring Committee
To supplement the routine study monitoring outlined in this protocol, an external DMC will 
monitor the interim data from this study. The voting members of the committee are external 
to the Sponsor. The members of the DMC must not be involved with the study in any other 
way (eg, they cannot be study investigators) and must have no competing interests that could 
affect their roles with respect to the study.
The DMC will make recommendations to the EOC regarding steps to ensure both participant 
safety and the continued ethical integrity of the study. Also, the DMC will review interim 
study results, consider the overall risk and benefit to study participants (Section 9.7 [Interim 
Analysis]) and recommend to the EOC whether the study should continue in accordance with 
the protocol.
Specific details regarding composition, responsibilities, and governance, including the roles 
and responsibilities of the various members and the Sponsor protocol team; meeting 
facilitation; the study governance structure; and requirements for and proper documentation 
of DMC reports, minutes, and recommendations will be described in the DMC charter that is 
reviewed and approved by all the DMC members.
Publication Policy
The results of this study may be published or presented at scientific meetings. The Sponsor 
will comply with the requirements for publication of study results. In accordance with 
standard editorial and ethical practice, the Sponsor will generally support publication of 
multicenter studies only in their entirety and not as individual site data. In this case, a 
coordinating investigator will be designated by mutual agreement.
If publication activity is not directed by the Sponsor, the investigator agrees to submit all 
manuscripts or abstracts to the Sponsor before submission. This allows the Sponsor to protect 
proprietary information and to provide comments.
Authorship will be determined by mutual agreement and in line with International Committee 
of Medical Journal Editors authorship requirements.
Compliance with Study Registration and Results Posting Requirements
Under the terms of the Food and Drug Administration Amendments Act (FDAAA) of 2007 
and the European Medicines Agency (EMA) clinical trial Directive 2001/20/EC, the Sponsor 
of the study is solely responsible for determining whether the study and its results are subject
to the requirements for submission to http://www.clinicaltrials.gov, 
 
 
05ND48
07YNSG


PRODUCT:  MK-7264  
86
PROTOCOL/AMENDMENT NO.:  043-03  
MK-7264-043-03 FINAL PROTOCOL
25-NOV-2020
www.clinicaltrialsregister.eu or other local registries. MSD, as Sponsor of this study, will 
review this protocol and submit the information necessary to fulfill these requirements. MSD 
entries are not limited to FDAAA or the EMA clinical trial directive mandated trials. 
Information posted will allow participants to identify potentially appropriate studies for their 
disease conditions and pursue participation by calling a central contact number for further 
information on appropriate study locations and study site contact information.
By signing this protocol, the investigator acknowledges that the statutory obligations under 
FDAAA, the EMA clinical trials directive, or other locally mandated registries are that of the 
Sponsor and agrees not to submit any information about this study or its results to those 
registries.
Compliance with Law, Audit, and Debarment
By signing this protocol, the investigator agrees to conduct the study in an efficient and 
diligent manner and in conformance with this protocol; generally accepted standards of GCP
(eg, International Council on Harmonisation of Technical Requirements for Registration of 
Pharmaceuticals for Human Use GCP: Consolidated Guideline and other generally accepted 
standards of GCP); and all applicable federal, state and local laws, rules and regulations 
relating to the conduct of the clinical study.
The Code of Conduct, a collection of goals and considerations that govern the ethical and 
scientific conduct of clinical investigations sponsored by MSD, is provided in this appendix 
under the Code of Conduct for Clinical Studies.
The investigator agrees not to seek reimbursement from participants, their insurance 
providers, or from government programs for procedures included as part of the study 
reimbursed to the investigator by the Sponsor.
The investigator will promptly inform the Sponsor of any regulatory authority inspection 
conducted for this study.
The investigator agrees to provide the Sponsor with relevant information from inspection 
observations/findings to allow the Sponsor to assist in responding to any citations resulting 
from regulatory authority inspection and will provide the Sponsor with a copy of the 
proposed response for consultation before submission to the regulatory authority. 
Persons debarred from conducting or working on clinical studies by any court or regulatory 
authority will not be allowed to conduct or work on this Sponsor’s studies. The investigator 
will immediately disclose in writing to the Sponsor if any person who is involved in 
conducting the study is debarred or if any proceeding for debarment is pending or, to the best 
of the investigator’s knowledge, threatened.
Data Quality Assurance
All participant data relating to the study will be recorded on printed or electronic CRF unless 
transmitted to the Sponsor or designee electronically (eg, laboratory data). The investigator 
 
 
05ND48
07YNSG


PRODUCT:  MK-7264  
87
PROTOCOL/AMENDMENT NO.:  043-03  
MK-7264-043-03 FINAL PROTOCOL
25-NOV-2020
or qualified designee is responsible for verifying that data entries are accurate and correct by 
physically or electronically signing the CRF.
Detailed information regarding Data Management procedures for this protocol will be 
provided separately.
The investigator must maintain accurate documentation (source data) that supports the 
information entered in the CRF.
The investigator must permit study-related monitoring, audits, IRB/IEC review, and 
regulatory agency inspections and provide direct access to source data documents.
Study documentation will be promptly and fully disclosed to the Sponsor by the investigator 
upon request and also shall be made available at the study site upon request for inspection, 
copying, review, and audit at reasonable times by representatives of the Sponsor or any 
regulatory authorities. The investigator agrees to promptly take any reasonable steps that are 
requested by the Sponsor or any regulatory authorities as a result of an audit or inspection to 
cure deficiencies in the study documentation and worksheets/CRFs.
The Sponsor or designee is responsible for the data management of this study including 
quality checking of the data.
Study monitors will perform ongoing source data review and verification to confirm that data 
entered into the CRF by authorized site personnel are accurate, complete, and verifiable from 
source documents; that the safety and rights of participants are being protected; and that the 
study is being conducted in accordance with the currently approved protocol and any other 
study agreements, ICH GCP, and all applicable regulatory requirements.
Records and documents, including participants’ documented informed consent, pertaining to 
the conduct of this study must be retained by the investigator for 15 years after study 
completion unless local regulations or institutional policies require a longer retention period. 
No records may be destroyed during the retention period without the written approval of the 
Sponsor. No records may be transferred to another location or party without written 
notification to the Sponsor.
Source Documents
Source documents provide evidence for the existence of the participant and substantiate the 
integrity of the data collected. The investigator/institution should maintain adequate and 
accurate source documents and study records that include all pertinent observations on each 
of the site’s participants. Source documents and data should be attributable, legible, 
contemporaneous, original, accurate, and complete. Changes to source data should be 
traceable, should not obscure the original entry, and should be explained if necessary (eg, via 
an audit trail). Source documents are filed at the investigator’s site.
Data reported on the CRF or entered in the eCRF that are transcribed from source documents 
must be consistent with the source documents or the discrepancies must be explained. The 
 
 
05ND48
07YNSG


PRODUCT:  MK-7264  
88
PROTOCOL/AMENDMENT NO.:  043-03  
MK-7264-043-03 FINAL PROTOCOL
25-NOV-2020
investigator/institution may need to request previous medical records or transfer records, 
depending on the study. Also, current medical records must be available.
Study and Site Closure
The Sponsor or its designee may stop the study or study site participation in the study for 
medical, safety, regulatory, administrative, or other reasons consistent with applicable laws, 
regulations, and GCP.
In the event the Sponsor prematurely terminates a particular study site, the Sponsor or 
designee will promptly notify that study site’s IRB/IEC as specified by applicable regulatory 
requirement(s).
 
 
05ND48
07YNSG


PRODUCT:  MK-7264  
89
PROTOCOL/AMENDMENT NO.:  043-03  
MK-7264-043-03 FINAL PROTOCOL
25-NOV-2020
10.2
Appendix 2: Clinical Laboratory Tests
The tests detailed in Table 6 will be performed at the study site or by the central laboratory.
Protocol-specific requirements for inclusion or exclusion of participants are detailed in 
Section 5.1 and Section 5.2 of the protocol.
Additional tests may be performed at any time during the study as determined necessary by 
the investigator or required by local regulations.
Pregnancy testing:
-
Pregnancy testing requirements for study inclusion are described in Section 5.1.
-
Additional serum or urine pregnancy tests may be performed, as determined 
necessary by the investigator or required by local regulation, to establish the absence 
of pregnancy at any time during the subject's participation in the study.
 
 
05ND48
07YNSG


PRODUCT:  MK-7264  
90
PROTOCOL/AMENDMENT NO.:  043-03  
MK-7264-043-03 FINAL PROTOCOL
25-NOV-2020
Table 6
Protocol-required Safety Laboratory Assessments
Laboratory 
Assessments
Parameters
Hematology
Platelet Count 
WBC count with Differential:
Neutrophils
Lymphocytes
Monocytes
Eosinophils
Basophils
RBC Count
Hemoglobin
Hematocrit
Chemistry
Electrolytes
Sodium
Potassium
Chloride
Bicarbonate
Calcium
Phosphorous
Liver function tests
AST/ SGOT
ALT/ SGPT
Alkaline phosphatase
Total bilirubin (and direct bilirubin, if total bilirubin is elevated 
above the upper limit of normal)
Renal function tests
Blood Urea Nitrogen
Creatinine
eGFR calculation
eGFR will be calculated with each serum creatinine 
measurement (using the Chronic Kidney Disease Epidemiology 
Collaboration [CKD EPI] formula [http://mdrd.com/])
Other
Glucose (nonfasting)
Albumin
Total Protein
Routine 
Urinalysis

Routine urinalysis will be performed at a central laboratory for all participants and 
include: specific gravity, pH, glucose, protein, and blood. Microscopic 
examination will also be performed (crystals will be analyzed).
Other Screening 
Tests
Serum or urine β-hCG pregnancy test (as needed for women of childbearing potential)
1.
Urine pregnancy test will be performed at site in women of child bearing 
potential. Refer to Section 1.3.
ALT = alanine aminotransferase; AST = aspartate aminotransferase; β-hCG = β-human chorionic gonadotropin; eGFR = 
estimated glomerular filtration rate; RBC = red blood cell; SGOT = serum glutamic-oxaloacetic transaminase; SGPT = 
serum glutamic-pyruvic transaminase; WBC = white blood cell.
The investigator (or medically qualified designee) must document their review of each 
laboratory safety report.
 
 
05ND48
07YNSG


PRODUCT:  MK-7264  
91
PROTOCOL/AMENDMENT NO.:  043-03  
MK-7264-043-03 FINAL PROTOCOL
25-NOV-2020
10.3
Appendix 3: Adverse Events: Definitions and Procedures for Recording, 
Evaluating, Follow-up, and Reporting
Definition of AE
AE definition

An AE is any untoward medical occurrence in a clinical study participant, temporally 
associated with the use of study intervention, whether or not considered related to the 
study intervention.

NOTE: An AE can therefore be any unfavorable and unintended sign (including an 
abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally 
associated with the use of a study intervention.

NOTE: For purposes of AE definition, study intervention (also referred to as Sponsor’s 
product) includes any pharmaceutical product, biological product, vaccine, diagnostic 
agent, or protocol specified procedure whether investigational or marketed (including 
placebo, active comparator product, or run-in intervention), manufactured by, licensed 
by, provided by, or distributed by the Sponsor for human use in this study.
Events meeting the AE definition

Any abnormal laboratory test results (hematology, clinical chemistry, or urinalysis) or 
other safety assessments (eg, ECG, radiological scans, vital signs measurements), 
including those that worsen from baseline, considered clinically significant in the medical 
and scientific judgment of the investigator.

Exacerbation of a chronic or intermittent pre-existing condition including either an 
increase in frequency and/or intensity of the condition.

New conditions detected or diagnosed after study intervention administration even 
though it may have been present before the start of the study.

Signs, symptoms, or the clinical sequelae of a suspected drug-drug interaction.

Signs, symptoms, or the clinical sequelae of a suspected overdose of either study 
intervention or a concomitant medication.

For all reports of overdose (whether accidental or intentional) with an associated AE, the 
AE term should reflect the clinical symptoms or abnormal test result. An overdose 
without any associated clinical symptoms or abnormal laboratory results is reported using 
the terminology “accidental or intentional overdose without adverse effect.”

Any new cancer or progression of existing cancer.
 
 
05ND48
07YNSG


PRODUCT:  MK-7264  
92
PROTOCOL/AMENDMENT NO.:  043-03  
MK-7264-043-03 FINAL PROTOCOL
25-NOV-2020
Events NOT meeting the AE definition

Medical or surgical procedure (eg, endoscopy, appendectomy): the condition that leads to 
the procedure is the AE.

Situations in which an untoward medical occurrence did not occur (social and/or 
convenience admission to a hospital).

Anticipated day-to-day fluctuations of pre-existing disease(s) or condition(s) present or 
detected at the start of the study that do not worsen.

Surgery planned prior to informed consent to treat a pre-existing condition that has not 
worsened.

Refer to Section 8.4.6 for protocol-specific exceptions.
Definition of SAE
If an event is not an AE per definition above, then it cannot be an SAE even if serious 
conditions are met.
An SAE is defined as any untoward medical occurrence that, at any dose:
a.
Results in death
b.
Is life-threatening

The term “life-threatening” in the definition of “serious” refers to an event in which 
the participant was at risk of death at the time of the event. It does not refer to an 
event, which hypothetically might have caused death, if it were more severe.
c.
Requires inpatient hospitalization or prolongation of existing hospitalization

Hospitalization is defined as an inpatient admission, regardless of length of stay, 
even if the hospitalization is a precautionary measure for continued observation. 
(Note: Hospitalization for an elective procedure to treat a pre-existing condition that 
has not worsened is not an SAE. A pre-existing condition is a clinical condition that 
is diagnosed prior to the use of an MSD product and is documented in the 
participant’s medical history.)
d.
Results in persistent or significant disability/incapacity

The term disability means a substantial disruption of a person’s ability to conduct 
normal life functions.

This definition is not intended to include experiences of relatively minor medical 
significance such as uncomplicated headache, nausea, vomiting, diarrhea, influenza, 
 
 
05ND48
07YNSG


PRODUCT:  MK-7264  
93
PROTOCOL/AMENDMENT NO.:  043-03  
MK-7264-043-03 FINAL PROTOCOL
25-NOV-2020
and accidental trauma (eg, sprained ankle) that may interfere with or prevent 
everyday life functions but do not constitute a substantial disruption.
e.
Is a congenital anomaly/birth defect

In offspring of participant taking the product regardless of time to diagnosis.
f.
Other important medical events

Medical or scientific judgment should be exercised in deciding whether SAE 
reporting is appropriate in other situations such as important medical events that may 
not be immediately life-threatening or result in death or hospitalization but may 
jeopardize the participant or may require medical or surgical intervention to prevent 
1 of the other outcomes listed in the above definition. These events should usually be 
considered serious.
Examples of such events include invasive or malignant cancers, intensive treatment in an 
emergency room or at home for allergic bronchospasm, blood dyscrasias or convulsions 
that do not result in hospitalization, or development of drug dependency or drug abuse.
Additional Events Reported
Additional events that require reporting
In addition to the above criteria, AEs meeting either of the below criteria, although not 
serious per ICH definition, are reportable to the Sponsor.

Is a cancer

Is associated with an overdose
Recording AE and SAE
AE and SAE recording

When an AE/SAE occurs, it is the responsibility of the investigator to review all 
documentation (eg, hospital progress notes, laboratory, and diagnostics reports) related to 
the event.

The investigator will record all relevant AE/SAE information on the AE 
CRFs/worksheets at each examination.

It is not acceptable for the investigator to send photocopies of the participant’s medical 
records to the Sponsor in lieu of completion of the AE CRF page.

There may be instances when copies of medical records for certain cases are requested by 
the Sponsor. In this case, all participant identifiers, with the exception of the participant 
 
 
05ND48
07YNSG


PRODUCT:  MK-7264  
94
PROTOCOL/AMENDMENT NO.:  043-03  
MK-7264-043-03 FINAL PROTOCOL
25-NOV-2020
number, will be blinded on the copies of the medical records before submission to the 
Sponsor.

The investigator will attempt to establish a diagnosis of the event based on signs, 
symptoms, and/or other clinical information. In such cases, the diagnosis (not the 
individual signs/symptoms) will be documented as the AE/SAE.
Assessment of intensity

An event is defined as “serious” when it meets at least 1 of the predefined outcomes as 
described in the definition of an SAE, not when it is rated as severe.

The investigator will make an assessment of intensity for each AE and SAE (and other 
reportable safety event) reported during the study and assign it to 1 of the following 
categories:
-
Mild: An event that is easily tolerated by the participant, causing minimal discomfort, 
and not interfering with everyday activities (for pediatric studies, awareness of 
symptoms, but easily tolerated).
-
Moderate: An event that causes sufficient discomfort to interfere with normal 
everyday activities (for pediatric studies, definitely acting like something is wrong).
-
Severe: An event that prevents normal everyday activities. An AE that is assessed as 
severe should not be confused with an SAE. Severe is a category used for rating the 
intensity of an event; and both AE and SAE can be assessed as severe (for pediatric 
studies, extremely distressed or unable to do usual activities).
Assessment of causality

Did the Sponsor’s product cause the AE?

The determination of the likelihood that the Sponsor’s product caused the AE will be 
provided by an investigator who is a qualified physician. The investigator’s signed/dated 
initials on the source document or worksheet that supports the causality noted on the AE 
form, ensures that a medically qualified assessment of causality was done. This initialed 
document must be retained for the required regulatory time frame. The criteria below are 
intended as reference guidelines to assist the investigator in assessing the likelihood of a 
relationship between the test product and the AE based upon the available information.

The following components are to be used to assess the relationship between the 
Sponsor’s product and the AE; the greater the correlation with the components and 
their respective elements (in number and/or intensity), the more likely the Sponsor’s 
product caused the AE:
-
Exposure: Is there evidence that the participant was actually exposed to the Sponsor’s 
product such as: reliable history, acceptable compliance assessment (pill count, diary, 
 
 
05ND48
07YNSG


PRODUCT:  MK-7264  
95
PROTOCOL/AMENDMENT NO.:  043-03  
MK-7264-043-03 FINAL PROTOCOL
25-NOV-2020
etc.), expected pharmacologic effect, or measurement of drug/metabolite in bodily 
specimen?
-
Time Course: Did the AE follow in a reasonable temporal sequence from 
administration of the Sponsor’s product? Is the time of onset of the AE compatible 
with a drug-induced effect (applies to studies with investigational medicinal product)?
-
Likely Cause: Is the AE not reasonably explained by another etiology such as 
underlying disease, other drug(s)/vaccine(s), or other host or environmental factors.
-
Dechallenge: Was the Sponsor’s product discontinued or dose/exposure/frequency 
reduced?

If yes, did the AE resolve or improve?

If yes, this is a positive dechallenge.

If no, this is a negative dechallenge.
(Note: This criterion is not applicable if: (1) the AE resulted in death or permanent 
disability; (2) the AE resolved/improved despite continuation of the Sponsor’s 
product; (3) the study is a single-dose drug study; or (4) Sponsor’s product(s) is/are 
only used 1 time.)
-
Rechallenge: Was the participant re-exposed to the Sponsor’s product in this study?

If yes, did the AE recur or worsen?

If yes, this is a positive rechallenge.

If no, this is a negative rechallenge.
(Note: This criterion is not applicable if: (1) the initial AE resulted in death or 
permanent disability, or (2) the study is a single-dose drug study; or (3) Sponsor’s 
product(s) is/are used only 1 time.)
NOTE: IF A RECHALLENGE IS PLANNED FOR AN AE THAT WAS SERIOUS AND 
MAY HAVE BEEN CAUSED BY THE SPONSOR’S PRODUCT, OR IF RE-EXPOSURE 
TO THE SPONSOR’S PRODUCT POSES ADDITIONAL POTENTIAL SIGNIFICANT 
RISK TO THE PARTICIPANT THEN THE RECHALLENGE MUST BE APPROVED IN 
ADVANCE BY THE SPONSOR CLINICAL DIRECTOR, AND IF REQUIRED, THE 
IRB/IEC.

Consistency with study intervention profile: Is the clinical/pathological presentation of 
the AE consistent with previous knowledge regarding the Sponsor’s product or drug class 
pharmacology or toxicology?
 
 
05ND48
07YNSG


PRODUCT:  MK-7264  
96
PROTOCOL/AMENDMENT NO.:  043-03  
MK-7264-043-03 FINAL PROTOCOL
25-NOV-2020

The assessment of relationship will be reported on the case report forms/worksheets by an 
investigator who is a qualified physician according to his/her best clinical judgment, 
including consideration of the above elements.

Use the following scale of criteria as guidance (not all criteria must be present to be 
indicative of a Sponsor’s product relationship).
-
Yes, there is a reasonable possibility of Sponsor’s product relationship:

There is evidence of exposure to the Sponsor’s product. The temporal sequence of the 
AE onset relative to the administration of the Sponsor’s product is reasonable. 
The AE is more likely explained by the Sponsor’s product than by another cause.
-
No, there is not a reasonable possibility of Sponsor’s product relationship:

Participant did not receive the Sponsor’s product OR temporal sequence of the AE 
onset relative to administration of the Sponsor’s product is not reasonable OR the 
AE is more likely explained by another cause than the Sponsor’s product. (Also 
entered for a participant with overdose without an associated AE.)

For each AE/SAE, the investigator must document in the medical notes that he/she has 
reviewed the AE/SAE and has provided an assessment of causality.

There may be situations in which an SAE has occurred and the investigator has minimal 
information to include in the initial report to the Sponsor. However, it is very important 
that the investigator always make an assessment of causality for every event before the 
initial transmission of the SAE data to the Sponsor.

The investigator may change his/her opinion of causality in light of follow-up 
information and send an SAE follow-up report with the updated causality assessment.

The causality assessment is 1 of the criteria used when determining regulatory reporting 
requirements.
Follow-up of AE and SAE

The investigator is obligated to perform or arrange for the conduct of supplemental 
measurements and/or evaluations as medically indicated or as requested by Sponsor to 
elucidate the nature and/or causality of the AE or SAE as fully as possible. This may 
include additional laboratory tests or investigations, histopathological examinations, or 
consultation with other health care professionals.

New or updated information will be recorded in the CRF.

The investigator will submit any updated SAE data to the Sponsor within 24 hours of 
receipt of the information.
 
 
05ND48
07YNSG


PRODUCT:  MK-7264  
97
PROTOCOL/AMENDMENT NO.:  043-03  
MK-7264-043-03 FINAL PROTOCOL
25-NOV-2020
Reporting of AEs, SAEs, and Other Reportable Safety Events to the Sponsor
AE, SAE, and other reportable safety event reporting to Sponsor via electronic data 
collection tool

The primary mechanism for reporting to the Sponsor will be the electronic data collection 
(EDC) tool.
-
Electronic reporting procedures can be found in the EDC data entry guidelines (or 
equivalent).
-
If the electronic system is unavailable for more than 24 hours, then the site will use 
the paper AE Reporting form.

Reference Section 8.4.1 for reporting time requirements.

The site will enter the SAE data into the electronic system as soon as it becomes 
available.

After the study is completed at a given site, the EDC tool will be taken off-line to prevent 
the entry of new data or changes to existing data.

If a site receives a report of a new SAE from a study participant or receives updated data 
on a previously reported SAE after the EDC tool has been taken off-line, then the site can 
report this information on a paper SAE form or by telephone (see next section).

Contacts for SAE reporting can be found in the Investigator Study File Binder (or 
equivalent).
SAE reporting to the Sponsor via paper CRF

If the EDC tool is not operational, facsimile transmission or secure e-mail of the SAE 
paper CRF is the preferred method to transmit this information to the Sponsor.

In rare circumstances and in the absence of facsimile equipment, notification by 
telephone is acceptable with a copy of the SAE data collection tool sent by overnight 
mail or courier service.

Initial notification via telephone does not replace the need for the investigator to complete 
and sign the SAE CRF pages within the designated reporting time frames.

Contacts and instructions for SAE reporting and paper reporting procedures can be found 
in the Investigator Study File Binder (or equivalent).
 
 
05ND48
07YNSG


PRODUCT:  MK-7264  
98
PROTOCOL/AMENDMENT NO.:  043-03  
MK-7264-043-03 FINAL PROTOCOL
25-NOV-2020
10.4
Appendix 4: Device Events, Adverse Device Events, and Medical Device 
Incidents: Definitions, Collection, and Documentation
Not applicable.
 
 
05ND48
07YNSG


PRODUCT:  MK-7264  
99
PROTOCOL/AMENDMENT NO.:  043-03  
MK-7264-043-03 FINAL PROTOCOL
25-NOV-2020
10.5
Appendix 5: Contraceptive Guidance
Definitions
Women of Childbearing Potential (WOCBP)
A woman is considered fertile following menarche and until becoming postmenopausal 
unless permanently sterile.
Women in the following categories are not considered WOCBP:

Premenarchal

Premenopausal female with 1 of the following:
o
Documented hysterectomy
o
Documented bilateral salpingectomy
o
Documented bilateral oophorectomy
Note: Documentation can come from the site personnel’s review of the participant’s medical 
records, medical examination, or medical history interview.

Postmenopausal female
o
A postmenopausal state is defined as no menses for 12 months without an 
alternative medical cause.

A high FSH level in the postmenopausal range may be used to confirm a 
postmenopausal state in women not using hormonal contraception or HRT. However, 
in the absence of 12 months of amenorrhea, confirmation with 2 FSH measurements 
in the postmenopausal range is required.
o
Females on HRT and whose menopausal status is in doubt will be required to 
use 1 of the nonhormonal highly effective contraception methods if they wish 
to continue their HRT during the study. Otherwise, they must discontinue 
HRT to allow confirmation of postmenopausal status before study enrollment.
Contraception Requirements
Male Participants
Male participants are not required to use a form of contraception.
 
 
05ND48
07YNSG


PRODUCT:  MK-7264  
100
PROTOCOL/AMENDMENT NO.:  043-03  
MK-7264-043-03 FINAL PROTOCOL
25-NOV-2020
Female Participants
Female participants of childbearing potential are eligible to participate if they agree to use 
one of the contraception methods described in Table 7 consistently and correctly during the 
protocol-defined time frame in Section 5.1.
Table 7
Contraceptive Methods
Highly Effective Contraceptive Methods That Are User Dependenta
Failure rate of <1% per year when used consistently and correctly.
●Combined (estrogen- and progestogen- containing) hormonal contraceptionb
○
Oral
○
Intravaginal
○
Transdermal
○
Injectable
●Progestogen only hormonal contraceptionb
○
Oral
○
Injectable
Highly Effective Methods That Have Low User Dependency
Failure rate of <1% per year when used consistently and correctly.
●Progestogen- only contraceptive implantb
●Intrauterine hormone-releasing systemb
●Intrauterine device 
●Bilateral tubal occlusion
●Vasectomized partner
A vasectomized partner is a highly effective contraception method provided that the partner is the sole 
male sexual partner of the WOCBP and the absence of sperm has been confirmed. If not, an additional 
highly effective method of contraception should be used.
●Sexual abstinence
Sexual abstinence is considered a highly effective method only if defined as refraining from heterosexual 
intercourse during the entire period of risk associated with the study intervention. The reliability of sexual 
abstinence needs to be evaluated in relation to the duration of the study and the preferred and usual 
lifestyle of the participant.
Notes:
Use should be consistent with local regulations regarding the use of contraceptive methods for participants of clinical 
studies.

Typical use failure rates are higher than perfect-use failure rates (ie, when used consistently and correctly).

If locally required, in accordance with Clinical Trial Facilitation Group guidelines, acceptable hormonal 
contraceptives are limited to those which inhibit ovulation.
WOCBP = women of childbearing potential
Pregnancy Testing
WOCBP should only be included after a negative highly sensitive urine or serum pregnancy 
test.
 
 
05ND48
07YNSG


PRODUCT:  MK-7264  
101
PROTOCOL/AMENDMENT NO.:  043-03  
MK-7264-043-03 FINAL PROTOCOL
25-NOV-2020
Pregnancy testing will be performed at Screening/Visit 1 (in WOCBP) and after 
Screening/Visit 1 whenever an expected menstrual cycle is missed or when pregnancy is 
otherwise suspected. Testing can also be performed, as necessary, based on local 
requirements.
 
 
05ND48
07YNSG


PRODUCT:  MK-7264  
102
PROTOCOL/AMENDMENT NO.:  043-03  
MK-7264-043-03 FINAL PROTOCOL
25-NOV-2020
10.6
Appendix 6: Collection and Management of Specimens for Future Biomedical 
Research
1.  Definitions
a.
Biomarker: A biological molecule found in blood, other body fluids, or tissues that is a 
sign of a normal or abnormal process or of a condition or disease. A biomarker may be 
used to see how well the body responds to a treatment for a disease or condition.1
b. Pharmacogenomics: The investigation of variations of DNA and RNA characteristics as 
related to drug/vaccine response.2
c.
Pharmacogenetics: A subset of pharmacogenomics, pharmacogenetics is the influence of 
variations in DNA sequence on drug/vaccine response.2
d. DNA: Deoxyribonucleic acid.
e.
RNA: Ribonucleic acid.
2.  Scope of Future Biomedical Research
The specimens consented and/or collected in this study as outlined in Section 8.9 will be used 
in various experiments to understand:
•
The biology of how drugs/vaccines work
•
Biomarkers responsible for how a drug/vaccine enters and is removed by the body
•
Other pathways drugs/vaccines may interact with
•
The biology of disease
The specimen(s) may be used for future assay development and/or drug/vaccine 
development.
It is now well recognized that information obtained from studying and testing clinical 
specimens offers unique opportunities to enhance our understanding of how individuals 
respond to drugs/vaccines, enhance our understanding of human disease and ultimately 
improve public health through development of novel treatments targeted to populations with 
the greatest need. All specimens will be used by the Sponsor or those working for or with the 
Sponsor.
3.  Summary of Procedures for Future Biomedical Research.
a.
Participants for Enrollment
All participants enrolled in the clinical study will be considered for enrollment in future 
biomedical research.
 
 
05ND48
07YNSG


PRODUCT:  MK-7264  
103
PROTOCOL/AMENDMENT NO.:  043-03  
MK-7264-043-03 FINAL PROTOCOL
25-NOV-2020
b. Informed Consent
Informed consent for specimens (ie, DNA, RNA, protein, etc.) will be obtained during 
screening for protocol enrollment from all participants or legal guardians, at a study visit by 
the investigator or his or her designate. Informed consent for future biomedical research 
should be presented to the participants on the visit designated in the SoA. If delayed, present 
consent at next possible Participant Visit. Consent forms signed by the participant will be 
kept at the clinical study site under secure storage for regulatory reasons.
A template of each study site’s approved informed consent will be stored in the Sponsor’s 
clinical document repository.
c.
eCRF Documentation for Future Biomedical Research Specimens
Documentation of participant consent for future biomedical research will be captured in the 
eCRFs. Any specimens for which such an informed consent cannot be verified will be 
destroyed.
d. Future Biomedical Research Specimen(s)
Collection of specimens for future biomedical research will be performed as outlined in the 
SoA. In general, if additional blood specimens are being collected for future biomedical 
research, these will usually be obtained at a time when the participant is having blood 
drawn for other study purposes.
4.  Confidential Participant Information for Future Biomedical Research
In order to optimize the research that can be conducted with future biomedical research 
specimens, it is critical to link participant' clinical information with future test results. In fact 
little or no research can be conducted without connecting the clinical study data to the 
specimen. The clinical data allow specific analyses to be conducted. Knowing participant 
characteristics like gender, age, medical history and intervention outcomes are critical to 
understanding clinical context of analytical results.
To maintain privacy of information collected from specimens obtained for future biomedical 
research, the Sponsor has developed secure policies and procedures. All specimens will be 
single-coded per ICH E15 guidelines as described below.
At the clinical study site, unique codes will be placed on the future biomedical research 
specimens. This code is a random number which does not contain any personally identifying 
information embedded within it. The link (or key) between participant identifiers and this 
unique code will be held at the study site. No personal identifiers will appear on the specimen 
tube.
5.  Biorepository Specimen Usage
Specimens obtained for the Sponsor will be used for analyses using good scientific practices. 
Analyses utilizing the future biomedical research specimens may be performed by the 
 
 
05ND48
07YNSG


PRODUCT:  MK-7264  
104
PROTOCOL/AMENDMENT NO.:  043-03  
MK-7264-043-03 FINAL PROTOCOL
25-NOV-2020
Sponsor, or an additional third party (eg, a university investigator) designated by the 
Sponsor. The investigator conducting the analysis will follow the Sponsor’s privacy and 
confidentiality requirements. Any contracted third party analyses will conform to the specific 
scope of analysis outlined in future biomedical research protocol and consent. Future 
biomedical research specimens remaining with the third party after specific analysis is 
performed will be reported to the Sponsor.
6.  Withdrawal From Future Biomedical Research
Participants may withdraw their consent for future biomedical research and ask that their 
biospecimens not be used for future biomedical research. Participants may withdraw consent 
at any time by contacting the investigator for the main study. If medical records for the main 
study are still available, the investigator will contact the Sponsor using the designated 
mailbox (clinical.specimen.management@merck.com). Subsequently, the participant's 
specimens will be flagged in the biorepository and restricted to main study use only. If 
specimens were collected from study participants specifically for future biomedical research, 
these specimens will be removed from the biorepository and destroyed. Documentation will 
be sent to the investigator confirming withdrawal and/or destruction, if applicable. It is the 
responsibility of the investigator to inform the participant of completion of the withdrawal 
and/or destruction, if applicable. Any analyses in progress at the time of request for 
withdrawal/destruction or already performed prior to the request being received by the 
Sponsor will continue to be used as part of the overall research study data and results. No 
new analyses would be generated after the request is received.
In the event that the medical records for the main study are no longer available (eg, if the 
investigator is no longer required by regulatory authorities to retain the main study records) 
or the specimens have been completely anonymized, there will no longer be a link between 
the participant’s personal information and their specimens. In this situation, the request for 
withdrawal of consent and/or destruction cannot be processed.
7.  Retention of Specimens
Future biomedical research specimens will be stored in the biorepository for potential 
analysis for up to 20 years from the end of the main study. Specimens may be stored for 
longer if a regulatory or governmental authority has active questions that are being answered. 
In this special circumstance, specimens will be stored until these questions have been 
adequately addressed.
Specimens from the study site will be shipped to a central laboratory and then shipped to the 
Sponsor-designated biorepository. If a central laboratory is not utilized in a particular study, 
the study site will ship directly to the Sponsor-designated biorepository. The specimens will 
be stored under strict supervision in a limited access facility which operates to assure the 
integrity of the specimens. Specimens will be destroyed according to Sponsor policies and 
procedures and this destruction will be documented in the biorepository database.
 
 
05ND48
07YNSG


PRODUCT:  MK-7264  
105
PROTOCOL/AMENDMENT NO.:  043-03  
MK-7264-043-03 FINAL PROTOCOL
25-NOV-2020
8.  Data Security
Databases containing specimen information and test results are accessible only to the 
authorized Sponsor representatives and the designated study administrator research personnel 
and/or collaborators. Database user authentication is highly secure, and is accomplished 
using network security policies and practices based on international standards to protect 
against unauthorized access.
9.  Reporting of Future Biomedical Research Data to Participants
No information obtained from exploratory laboratory studies will be reported to the 
participant, family, or physicians. Principle reasons not to inform or return results to the 
participant include: Lack of relevance to participant health, limitations of predictive 
capability, and concerns regarding misinterpretation.
If important research findings are discovered, the Sponsor may publish results, present results 
in national meetings, and make results accessible on a public website in order to rapidly 
report this information to doctors and participants. Participants will not be identified by name 
in any published reports about this study or in any other scientific publication or presentation.
10. Future Biomedical Research Study Population
Every effort will be made to recruit all participants diagnosed and treated on Sponsor clinical 
studies for future biomedical research.
11. Risks Versus Benefits of Future Biomedical Research
For future biomedical research, risks to the participant have been minimized and are 
described in the future biomedical research informed consent.
The Sponsor has developed strict security, policies, and procedures to address participant 
data privacy concerns. Data privacy risks are largely limited to rare situations involving 
possible breach of confidentiality. In this highly unlikely situation, there is risk that the 
information, like all medical information, may be misused.
12. Questions
Any questions related to the future biomedical research should be emailed directly to 
clinical.specimen.management@merck.com.
 
 
05ND48
07YNSG


PRODUCT:  MK-7264  
106
PROTOCOL/AMENDMENT NO.:  043-03  
MK-7264-043-03 FINAL PROTOCOL
25-NOV-2020
13. References
1.   National Cancer Institute [Internet]: Available from 
https://www.cancer.gov/publications/dictionaries/cancer-terms?cdrid=45618
2.   International Council on Harmonisation [Internet]: E15: Definitions for Genomic 
Biomarkers, Pharmacogenomics, Pharmacogenetics, Genomic Data and Sample Coding 
Categories. Available from http://www.ich.org/products/guidelines/efficacy/efficacy-
single/article/definitions-for-genomic-biomarkers-pharmacogenomics-pharmacogenetics-
genomic-data-and-sample-cod.html 
3.   Industry Pharmacogenomics Working Group [Internet]: Understanding the Intent, Scope 
and Public Health Benefits of Exploratory Biomarker Research: A Guide for IRBs/IECs and 
Investigational Site Staff. Available at http://i-pwg.org/ 
4.   Industry Pharmacogenomics Working Group [Internet]: Pharmacogenomics 
Informational Brochure for IRBs/IECs and Investigational Site Staff. Available at http://i-
pwg.org/
 
 
05ND48
07YNSG


PRODUCT:  MK-7264  
107
PROTOCOL/AMENDMENT NO.:  043-03  
MK-7264-043-03 FINAL PROTOCOL
25-NOV-2020
10.7
Appendix 7: Country-specific Requirements
Not applicable
 
 
05ND48
07YNSG


PRODUCT:  MK-7264  
108
PROTOCOL/AMENDMENT NO.:  043-03  
MK-7264-043-03 FINAL PROTOCOL
25-NOV-2020
10.8
Appendix 8: Abbreviations
Abbreviation
Expanded Term
ACCP
American College of Chest Physicians
AE
Adverse event 
ALT
Alanine aminotransferase
ANCOVA
Analysis of covariance
APaT
All participants as treated
AST
Aspartate aminotransferase
ATP
Adenosine triphosphate
BID
Twice daily
CHS
Cough hypersensitivity syndrome
CI
Confidence interval
CONSORT
Consolidated Standards of Reporting Trials
COVID-19
Coronavirus infectious disease 2019
CP
Conditional power
CRF
Case report form 
CSD
Cough Severity Diary
CSR
Clinical study report
CT
Computed tomography
Ctrough
Concentration of study drug at the end of the dosage interval
DMC
Data Monitoring Committee
DNA
Deoxyribonucleic acid 
ECG
Electrocardiogram 
ECIs
Events of clinical interest
eCRF
Electronic case report form
EDC
Electronic data collection 
e-Diary
Electronic diary
eGFR
Estimated glomerular filtration rate
EMA
European Medicines Agency
EOC
Executive Oversight Committee
ePRO
Electronic patient-reported outcomes
FAS
Full analysis set
FDA
United States Food and Drug Administration
FDAAA
Food and Drug Administration Amendments Act
FEV1
Forced expiratory volume in 1 second
FSH
Follicle stimulating hormone 
FVC
Forced vital capacity
GCP
Good Clinical Practice 
GERD
Gastroesophageal reflux disease
HIV
Human immunodeficiency virus
HRT
Hormone replacement therapy
HRQoL
Health-related quality of life
IA
Interim analysis/analyses
IB
Investigator’s Brochure 
ICF
Informed consent form 
ICH
International Council on Harmonisation
ICMJE
International Committee of Medical Journal Editors
IEC
Independent Ethics Committee
IND
Investigational New Drug 
IRB
Institutional Review Board 
IRT
Interactive response technology
 
 
05ND48
07YNSG


PRODUCT:  MK-7264  
109
PROTOCOL/AMENDMENT NO.:  043-03  
MK-7264-043-03 FINAL PROTOCOL
25-NOV-2020
Abbreviation
Expanded Term
LCQ
Leicester Cough Questionnaire
MAR
Missing at random
PGIC
Patient Global Impression of Change
PK
Pharmacokinetic
PRO
Patient-reported outcomes
RNA
Ribonucleic acid
SAC
Scientific Advisory Committee
SAE
Serious adverse event 
SARS-CoV-2
Severe acute respiratory syndrome coronavirus 2
SD
Standard deviation
SoA
Schedule of activities
sSAP
Supplemental statistical analysis plan
SAS
Statistical analysis software
SUSAR
Suspected unexpected serious adverse reactions
UACS
Upper airway cough syndrome
VAS
Visual analog scale
WBC
White blood cell 
WOCBP
Woman/women of childbearing potential 
WPAI
Work Productivity and Activity Impairment Questionnaire
 
 
05ND48
07YNSG


PRODUCT:  MK-7264  
110
PROTOCOL/AMENDMENT NO.:  043-03  
MK-7264-043-03 FINAL PROTOCOL
25-NOV-2020
11
REFERENCES
[Barclay, J., et al 2002]
Barclay J, Patel S, Dorn G, Wotherspoon G, 
Moffatt S, Eunson L, et al. Functional 
downregulation of P2X3 receptor subunit in 
rat sensory neurons reveals a significant role 
in chronic neuropathic and inflammatory 
pain. J Neurosci. 2002 Sep 15;22(18):8139-
47.
[04JQYJ]
[Chamberlain, S. A., et al 
2015]
Chamberlain SA, Garrod R, Douiri A, 
Masefield S, Powell P, Bucher C, et al. The 
impact of chronic cough: a cross-sectional 
European survey. Lung. 2015 
Jun;193(3):401-8. Erratum in: Lung. 2015 
Aug;193(4):615.
[04MMTF]
[Chung, K. F., et al 2006]
Chung KF, McGarvey L, Widdicombe J. 
American College of Chest Physicians' 
cough guidelines. Lancet. 2006 Mar 
25;367(9515):981-2.
[04KQMY]
[Chung, K. F., et al 2006]
Chung KF, McGarvey L, Widdicombe J. 
American college of chest physicians cough 
guidelines. Lancet. 2006 Mar 
25;367(9515):981-2.
[04LRB3]
[Cockayne, D. A., et al 2000]
Cockayne DA, Hamilton SG, Zhu QM, 
Dunn PM, Zhong Y, Novakovic S, et al. 
Urinary bladder hyporeflexia and reduced 
pain-related behaviour in P2X3-deficient 
mice. Nature. 2000 Oct 26;407(6807):1011-
5.
[04K6LW]
[Dicpinigaitis, P. V., et al 
2006]
Dicpinigaitis PV, Tso R, Banauch G. 
Prevalence of depressive symptoms among 
patients with chronic cough. Chest. 2006 
Dec;130(6):1839-43.
[04MMZ4]
[Everett, C. F., et al 2007]
Everett CF, Kastelik JA, Thompson RH, 
Morice AH. Chronic persistent cough in the 
community: a questionnaire survey. Cough. 
2007 Mar 23;3:5.
[0527YB]
 
 
05ND48
07YNSG


PRODUCT:  MK-7264  
111
PROTOCOL/AMENDMENT NO.:  043-03  
MK-7264-043-03 FINAL PROTOCOL
25-NOV-2020
[French, C. L., et al 1998]
French CL, Irwin RS, Curley FJ, Krikorian 
CJ. Impact of chronic cough on quality of 
life. Arch Intern Med. 1998 Aug 10-
24;158:1657-61.
[04YYWM]
[French, C. L., et al 2017]
French CL, Crawford SL, Bova C, Irwin RS. 
Change in psychological, physiological, and 
situational factors in adults after treatment of 
chronic cough. Chest. 2017 Sep;152(3):547-
62.
[0528XQ]
[Gibson, P., et al 2016]
Gibson P, Wang G, McGarvey L, Vertigan 
AE, Altman KW, Birring SS. Treatment of 
Unexplained Chronic Cough: CHEST 
Guideline and Expert Panel Report. Chest. 
2016 Jan;149(1):27-44.
[04MMZ9]
[Irwin, R. S. 2006]
Irwin RS. Complications of cough: ACCP 
evidence-based clinical practice guidelines. 
Chest. 2006 Jan;129(1 Suppl):54S-58S.
[04N3R4]
[Irwin, R. S., et al 2014]
Irwin RS, French CT, Lewis SZ, Diekemper 
RL, Gold PM. Overview of the management 
of cough: CHEST Guideline and Expert 
Panel Report. Chest. 2014 Oct;146(4):885-9.
[052CCN]
[Irwin, R. S., et al 2018]
Irwin RS, French CL, Chang AB, Altman 
KW. Classification of cough as a symptom 
in adults and management algorithms: 
CHEST Guideline and Expert Panel Report. 
Chest. 2018 Jan;153(1):196-209.
[0528XS]
[Kardos, P., et al 2010]
Kardos P, Berck H, Fuchs KH, Gillissen A, 
Klimek L, Morr H, et al. Guidelines of the 
German Respiratory Society for diagnosis 
and treatment of adults suffering from acute 
or chronic cough. Pneumologie. 2010 
Nov;64(11):701-11.
[04KQP6]
[Khakh, B. S. 2006]
Khakh BS, North RA. P2X receptors as cell-
surface ATP sensors in health and disease. 
Nature. 2006 Aug 3;442(7102):527-32.
[04JRKF]
 
 
05ND48
07YNSG


PRODUCT:  MK-7264  
112
PROTOCOL/AMENDMENT NO.:  043-03  
MK-7264-043-03 FINAL PROTOCOL
25-NOV-2020
[Kuzniar, T. J., et al 2007]
Kuzniar TJ, Morgenthaler TI, Afessa B, Lim 
KG. Chronic cough from the patient's 
perspective. Mayo Clin Proc. 2007 
Jan;82(1):56-60.
[0528XV]
[Lan, K. K. G. and DeMets, 
D. L. 1983]
Lan KKG, DeMets DL. Discrete sequential 
boundaries for clinical trials. Biometrika 
1983;70(3):659-63.
[03P3QC]
[McCrory, D. C., et al 2013]
McCrory DC, Coeytaux RR, Yancy WS Jr, 
Schmit KM, Kemper AR, Goode A, et al. 
Comparative effectiveness review. Rockville 
(MD): Agency for Healthcare Research and 
Quality (AHRQ); 2013 Jan (errata 2014
Mar). Number 100: Assessment and 
management of chronic cough. 256 p.
[05284T]
[Miettinen, O. and Nurminen, 
M. 1985]
Miettinen O, Nurminen M. Comparative 
analysis of two rates. Stat Med 1985;4:213-
26.
[03R2SH]
[Morice, A. H., et al 2004]
Morice AH, Fontana GA, Sovijarvi AR, 
Pistolesi M, Chung KF, Widdicombe J, et al. 
The diagnosis and management of chronic 
cough. Eur Respir J. 2004 Sep;24(3):481-92.
[04KQPD]
[Morice, A. H., et al 2006]
Morice AH, McGarvey L, Pavord I, on 
behalf of the British Thoracic Society Cough 
Guideline Group. Recommendations for the 
management of cough in adults. Thorax 
2006;61(Suppl 1):i1-i24.
[03QMXM]
[North, R. A. 2004]
North RA. P2X3 receptors and peripheral 
pain mechanisms. J Physiol. 2004 Jan 
15;554(Pt 2):301-8.
[04JRR8]
[Raj, A. A., et al 2009]
Raj AA, Pavord DI, Birring SS. Clinical 
cough IV: what is the minimal important 
difference for the Leicester Cough 
Questionnaire? Handb Exp Pharmacol. 
2009;187:311-20.
[04W0Q7]
 
 
05ND48
07YNSG


PRODUCT:  MK-7264  
113
PROTOCOL/AMENDMENT NO.:  043-03  
MK-7264-043-03 FINAL PROTOCOL
25-NOV-2020
[Reilly, M. C., et al 1993]
Reilly MC, Zbrozek AS, Dukes EM. The 
validity and reproducibility of a work 
productivity and activity impairment 
instrument. Pharmacoeconomics. 1993 
Nov;4(5):353-65.
[042X3Z]
[Smith, J. A. 2016]
Smith JA, Woodcock A. Chronic cough. N 
Engl J Med. 2016 Oct 20;375(16):1544-51.
[052860]
[Song, W. J., et al 2015]
Song WJ, Chang YS, Faruqi S, Kim JY, 
Kang MG, Kim S, et al. The global 
epidemiology of chronic cough in adults: a 
systematic review and meta-analysis. Eur 
Respir J. 2015 May;45(5):1479-81.
[04MLZM]
[Souslova, V., et al 2000]
Souslova V, Cesare P, Ding Y, Akopian AN, 
Stanfa L, Suzuki R, et al. Warm-coding 
deficits and aberrant inflammatory pain in 
mice lacking P2X3 receptors. Nature. 2000 
Oct 26;407(6807):1015-7.
[04K76C]
[The committee for The 
Japanese Respiratory Society 
guidelines 2006]
The committee for The Japanese Respiratory 
Society guidelines for management of 
cough. Concept and use of guidelines. 
Respirology. 2006:11(Suppl 4);S135-S136
[04KW9M]
[Young, E. C. 2010]
Young EC, Smith JA. Quality of life in 
patients with chronic cough. Ther Adv 
Respir Dis. 2010 Feb;4(1):49-55.
[04KNZS]
 
 
05ND48
07YNSG


MK-7264
PAGE 1
PROTOCOL NO 043-03
SUPPLEMENTAL SAP
02-DECEMBER-2021 - AMENDMENT 02
TITLE PAGE
Protocol Title:  A Phase 3b Randomized, Double-blind, Placebo Controlled, Multicenter 
Study to Evaluate the Efficacy and Safety of Gefapixant in Adult Participants with 
Recent Onset Chronic Cough (P043)
07XN2S
07YNSK


MK-7264
PAGE 2
PROTOCOL NO 043-03
SUPPLEMENTAL SAP
02-DECEMBER-2021 - AMENDMENT 02
TABLE OF CONTENTS
TABLE OF CONTENTS ....................................................................................................... 2
LIST OF TABLES.................................................................................................................. 4
1.
INTRODUCTION....................................................................................................... 5
2.
SUMMARY OF CHANGES...................................................................................... 5
3.
ANALYTICAL AND METHODOLOGICAL DETAILS ...................................... 6
STATISTICAL ANALYSIS PLAN SUMMARY................................................ 6
RESPONSIBILITY FOR ANALYSES/IN-HOUSE BLINDING....................... 7
HYPOTHESES/ESTIMATION ............................................................................ 8
ANALYSIS ENDPOINTS...................................................................................... 8
Efficacy Endpoints................................................................................................ 8
Primary Efficacy Endpoint ............................................................................ 8
Safety Endpoints ................................................................................................... 9
Derivations of Efficacy Endpoints........................................................................ 9
ANALYSIS POPULATIONS .............................................................................. 10
Efficacy Analysis Populations ............................................................................ 10
Safety Analysis Population................................................................................. 10
STATISTICAL METHODS................................................................................ 11
Statistical Methods for Efficacy Analyses.......................................................... 11
Statistical Methods for Safety Analyses ............................................................. 16
Summaries of Baseline Characteristics, Demographics, and Other Analyses.... 19
Demographic and Baseline Characteristics ................................................. 19
INTERIM ANALYSES........................................................................................ 19
Interim Efficacy Analysis ................................................................................... 19
Interim Safety Analyses...................................................................................... 20
MULTIPLICITY .................................................................................................. 20
SAMPLE SIZE AND POWER CALCULATIONS........................................... 20
SUBGROUP ANALYSES.................................................................................... 21
COMPLIANCE (MEDICATION ADHERENCE)............................................ 21
EXTENT OF EXPOSURE................................................................................... 21
4.
APPENDICES........................................................................................................... 22
07XN2S
07YNSK


MK-7264
PAGE 3
PROTOCOL NO 043-03
SUPPLEMENTAL SAP
02-DECEMBER-2021 - AMENDMENT 02
Model Specification, Assumptions, and Sample SAS Implementation 
Codes for the Primary Efficacy Analysis............................................................ 22
Model Specification for the Safety Analysis....................................................... 23
5.
REFERENCES.......................................................................................................... 24
07XN2S
07YNSK


MK-7264
PAGE 4
PROTOCOL NO 043-03
SUPPLEMENTAL SAP
02-DECEMBER-2021 - AMENDMENT 02
LIST OF TABLES
Table 1
Analysis Strategy for Key Efficacy Endpoints....................................................... 12
Table 2
Analysis Strategy for Safety Parameters ................................................................ 17
Table 3
Predefined Limit of Change from Baseline ............................................................ 18
07XN2S
07YNSK


MK-7264
PAGE 5
PROTOCOL NO 043-03
SUPPLEMENTAL SAP
02-DECEMBER-2021 - AMENDMENT 02
Supplemental Statistical Analysis Plan (sSAP)
1. INTRODUCTION
This supplemental SAP (sSAP) is a companion document to the protocol. In addition to the
information presented in the protocol SAP which provides the principal features of 
confirmatory analyses for this trial, this supplemental SAP provides additional statistical 
analysis details/data derivations and documents modifications or additions to the analysis 
plan that are not “principal” in nature and result from information that was not available at 
the time of protocol finalization.
2. SUMMARY OF CHANGES
Date
Page
Changes
13JAN2021
9
Updated the week duration for calculating baseline value for mean 
weekly VAS score and CSD total score.
13JAN2021
15, 16
Added a list of terms for taste-related AEs (including dysgeusia, 
ageusia, hypogeusia, hypergeusia, and taste disorder).
13JAN2021
16
Added two Tier 3 safety endpoints in Table 2. 

Time to Onset from the First Dosing Date and Duration of 
Event for Taste-Related AEs

Frequency of taste-related AEs for time intervals
14JAN2021
19
Removed subgroup analyses for potential co-morbid conditions 
and concomitant medications.
02DEC2021
9
Fixed the typos for WPAI measured change from baseline at Week 
12 and VAS score using 100 mm visual analogue scale.
02DEC2021
10
Added important protocol violation criteria
02DEC2021
11
Added language to be aligned with phase 3 studies.
02DEC2021
11
Updated the text for the secondary efficacy endpoint.
02DEC2021
12
Updated the text of responses to the PGIC questionnaire and 
modified the analysis method using stratified M&N. 
Added description to include PGIM. 
02DEC2021
12
Updated the model structure by removing the interaction of 
treatment by visit since there is only one post-baseline time point 
for WPAI.
02DEC2021
14
Updated the tipping point analyses to be performed in two-
dimensional where missing data in both active and control arms 
are assumed to have a worse response by a constant c.
07XN2S
07YNSK


MK-7264
PAGE 6
PROTOCOL NO 043-03
SUPPLEMENTAL SAP
02-DECEMBER-2021 - AMENDMENT 02
3. ANALYTICAL AND METHODOLOGICAL DETAILS
STATISTICAL ANALYSIS PLAN SUMMARY
Key elements of the statistical analysis plan are summarized below. The comprehensive plan 
is provided in following Sections 3.2 – Responsibility for Analyses/In-House Blinding to 
3.12 – Extent of Exposure.
Study Design Overview
A Phase 3b, Randomized, Double-blind, Placebo Controlled, 
Multicenter Study to Evaluate the Efficacy and Safety of Gefapixant 
in Adult Participants with Recent Onset Chronic Cough (P043)
Treatment Assignment
Participants will be randomized in a 1:1 ratio to 1 of 2 treatment 
groups: Gefapixant 45 mg BID or Placebo.
Analysis Populations
Efficacy: Full Analysis Set (FAS) population, which consists of all 
randomized participants who have taken at least one dose of study 
intervention. For endpoints that are measures of change from baseline, 
participants need to have baseline and at least one post-baseline 
measurement for inclusion in the analysis of each specific endpoint; 
and Per-Protocol (PP) population which excludes participants due to 
important protocol violations from the FAS population.
Safety: All Participants as Treated (APaT) population, which consists 
of all randomized participants who received at least 
one dose of study intervention. In this population, participants will be 
included in the treatment group corresponding to the study 
intervention they actually received.  If a participant is found to have 
taken partial (one or more) incorrect doses of study medication from 
which he/she was randomized to, then the participant will be counted 
in the active treatment intervention group. 
Primary Endpoint
LCQ total score
Statistical Methods for 
Key Efficacy Analyses
The primary analysis will be based on the FAS population. The 
primary analysis approach will be conducted utilizing the longitudinal 
ANCOVA model. In this model, the response vector consists of LCQ 
change from baseline in total score at each post-Baseline visit. The 
model will include factors for intervention group, visit, the interaction 
between intervention group and visit, gender, and baseline LCQ total 
score. The model will use all available LCQ change from baseline in 
total score data at Weeks 6 and 12. Contrasts will be constructed to 
compare the Gefapixant group to the Placebo group at each post-
Baseline visit. The least squares mean change from baseline with the 
associated standard errors will be displayed for each intervention 
group. Estimated treatment differences (Gefapixant − Placebo) along 
with corresponding p-values and CIs will also be presented.
Statistical Methods for 
Key Safety Analyses
The analysis of safety endpoints will follow a tiered approach. The 
tiers differ with respect to the analyses that will be performed. Tier 1 
and Tier 2 safety endpoints will be evaluated via point estimates and 
95% CIs for between-group comparisons, with p-values provided for 
the Tier 1 safety endpoints. Tier 3 safety endpoints will be evaluated 
via point estimates only.
07XN2S
07YNSK


	




  
	$
!+#.!!+"38..4+#+)$)*+"!%0&&%/" %$+B*!+%0+
/%.% !"+ '+&/.%&8..4+)+-+8+"4 %0+'0+3&
&/**)<+"4+.$8'+%.&)+#)$-"+"!+%$!' E 3!%+)*
!. &+&'

*!2G$4+#+)$)*+"80+!##)$B*%+. 
K $
#)%#!%&6##)$B*%+. %0+)&%		+!)$..+"#)%#!%&7
0-++%0+)$*#.+%+"%0+&%/" $)"&$!%!/+"%0+&%/" 
!%+)-+!%$!+). '

+&%!2G@/%.% !"%)$!2+!+%6 7!. &&4&+"$!
%0+#)*) +!"#$!%$I0!2+)$*4&+.!+!%$%.&$)+
%C++>8..4+#)$-"+"'
"'$
!+%0+)+&$!. $!+0 #$%0+&&6$)%0+#)*) +!"#$!%71!$
*/.%#.% "L/&%*+!%&#.!!+"$%0+)%0!%0+3.#0"L/&%*+!%
%$%0+#)*) + +!"#$!%'
#'#)
0+#.!!+"&*#.+&<+&

#)%#!%&6#+)%)+%*+!%2)$/#7
$)$*#)!2%0+#)*) +!"#$!%$I0!2+)$*4&+.!+!
%$%.&$)+%C++>1&&/*!2#$$.+"
0&&*#.+&<+$/!%&$)5K")$#$/%)%+1
%)2+%!2$)5+-./4.+#)%#!%&%C++>'0+"+%.&)+
"+&)4+"!+%$!', E *#.+<+!"$8+)./.%$!&'
#*2#081*	2	8##;2 9*6#022
0+&%%&%.!. &&$%0+"%$4%!+")$*%0&&%/" 8..4+%0+)+&#$!&4.% $%0+
"+&2!++$%0+#$!&$)'
0&&%/" 8..4+$!"/%+"&"$/4.+4.!"&%/" /!"+)!0$/&+4.!"!2#)$+"/)+&'
0+$.1!."%4&+8..!$%4+/!4.!"+"/!%.*+".9&+!%)+-+80&4++!
#+)$)*+"1#)$%$$."+-%$!&0-+4++!"+!%+"1!""%0-+4++!"+.)+"!.!"
$*#.+%+'0+!-+&%2%$)&%+#+)&$!!+.!"%0+#)%#!%&8..4+4.!"+"%$!%+)-+!%$!
&&2!*+!%/!%.%0++!%)+&%/" &$*#.+%+"'
0+.!.$&%%&%&"+#)%*+!%8..2+!+)%+%0+)!"$*<+"..$%$!&0+"/.+6&7$)
&%/" !%+)-+!%$!&&2!*+!%')+%*+!%&&2!*+!%8..4+*#.+*+!%+"!!3& &%+*
4 &%/" -+!"$)$)"!2%$%0+"#%-+..$%$!&0+*+#)$-"+"!+%$!	'' E
3!%+)-+!%$!&&2!*+!%$%0+#)$%$$.'
	
	
.!!+"!%+)*!. &+&)+"+&)4+"!+%$!'E 3!%+)*!. &+&'%/" +!)$..*+!%
& .>+. %$4+$!2$!2%%0+%*+$! !%+)*!. &+&'.!"!2%$%)+%*+!%&&2!*+!%
8..4+*!%!+"%..!-+&%2%$!.&%+&'0+)+&/.%&$!%+)*!. &+&8..!$%4+
&0)+"8%0%0+!-+&%2%$)&#)$)%$%0+$*#.+%$!$%0+&%/" '
;16
CCI
CCI
CCI
<16.


MK-7264
PAGE 8
PROTOCOL NO 043-03
SUPPLEMENTAL SAP
02-DECEMBER-2021 - AMENDMENT 02
Treatment-level results of the interim efficacy and safety analyses will be provided by the 
external unblinded statistician to the DMC. Limited additional Sponsor personnel may be 
unblinded to the treatment-level results of the interim analyses, if required, in order to act on 
the recommendations of the DMC. The extent to which individuals are unblinded with 
respect to results of interim analyses will be documented by the external unblinded 
statistician.
The DMC will serve as the primary reviewer of the results of the interim efficacy and safety 
analyses and will make recommendations for discontinuation of the study or modification to 
an Executive Oversight Committee (EOC) of the Sponsor. If the DMC recommends 
modifications to the design of the protocol or discontinuation of the study, the EOC may be 
unblinded to the results at the treatment-level in order to act on these recommendations. 
Additional logistical details will be provided in the DMC Charter. 
Prior to final study unblinding, the external unblinded statistician will not be involved in any 
discussions regarding modifications to the protocol, statistical methods, identification of 
protocol deviations, or data validation efforts after the interim analyses.
HYPOTHESES/ESTIMATION
The primary and secondary hypotheses for this study are stated in Section 3 – Objectives/ 
Hypotheses and Endpoints of the protocol.
ANALYSIS ENDPOINTS
Efficacy and safety endpoints for evaluation are listed below.
Efficacy Endpoints
Primary Efficacy Endpoint

LCQ total score measured as change from baseline at Week 12
3.4.1.2 Secondary Efficacy Endpoint

Cough Severity VAS score measured as change from baseline at Week 12
3.4.1.3 Exploratory Efficacy Endpoints

CSD total score measured as change from baseline at Week 12

PGIC measured at Week 12

WPAI measured as change from baseline at Week 12
07XN2S
07YNSK


MK-7264
PAGE 9
PROTOCOL NO 043-03
SUPPLEMENTAL SAP
02-DECEMBER-2021 - AMENDMENT 02
Safety Endpoints

Adverse events

Study intervention discontinuations due to an adverse event
Derivations of Efficacy Endpoints
Baseline for efficacy variables is defined as the last non-missing value prior to the first study 
treatment.
Data Handling Rules for Efficacy Endpoints

LCQ Total Score
There are three domains in the LCQ instrument: Physical (items 1, 2, 3, 9, 10, 11, 14 and 15), 
Psychological (items 4, 5, 6, 12, 13, 16, and 17), and Social (items 7, 8, 18, and 19).  For 
each domain, the domain score (range 1-7) is the sum of individual item score within the 
domain divided by the number of items in the domain. The LCQ total score (range 3-21) is 
the sum of the three domain scores.
The Physical domain score will be considered as missing if more than 2 items are missing. If 
there is only 1 missing item, the Physical domain score will be based on the actual non-
missing items. Psychological domain score will be derived in a similar fashion. Social 
domain score will be considered as missing if any item is missing. The LCQ total score will 
be considered as missing if any of the 3 domain scores is missing. 

Cough Severity VAS score
Cough severity VAS is scored from 0 to 100 using a 100 mm visual analogue scale. Mean
weekly VAS score will be derived as the average of the VAS scores collected during the 
week prior to each visit. Baseline is defined as the average of VAS scores collected during 
the week prior to Day 1 (Day -7 to Day -1).
The mean weekly VAS score will be considered as missing if there are more than 3 missing 
days during the week prior to each visit. If there are less than 7 but at least 4 non-missing 
days during the week prior to a visit, the mean weekly score will be based on the actual non-
missing days of the week prior to the visit.

CSD Total Score
The daily CSD instrument has a total of 7 items, each with scores ranging from 0 (best) to 10 
(worst). The total daily CSD score is the sum of these seven item scores. Mean total daily 
score (the sum of 7 item scores divided by 7) and three subscales (cough frequency, intensity, 
and disruption) will be derived for each day. Mean weekly total score is defined as the 
average of the mean total daily scores collected during the week prior to each visit.  Mean 
weekly subscales will be derived in a similar fashion. Baseline is defined as the average CSD 
scores collected during the week prior to Day 1 (Day -7 to Day -1).
07XN2S
07YNSK


	




  
0+*+!8++>. %$%.&$)+8..4+$!&"+)+"&*&&!2%0+)+)+*$)+%0!*&&!2
" &"/)!2%0+8++>#)$)%$+0-&%'3%0+)+)+.+&&%0!4/%%.+&%
!$!*&&!2
" &"/)!2%0+8++>#)$)%$-&%1%0+*+!8++>. %$%.&$)+8..4+4&+"$!%0+%/.
!$!*&&!2" &$%0+8++>#)$)%$%0+-&%'+!8++>. &/4&.+&8..4+"+)-+"!
&*.)&0$!'
	2	8##*6	*2#
&&$	$'
0+@#$#/.%$!8..&+)-+&%0+#)*) #$#/.%$!$)%0+!. &&$+ "%!
%0&&%/" '0+@#$#/.%$!$!&&%&$..)!"$*<+"#)%#!%&80$0-+%>+!%
.+&%"$&+$&%/" !%+)-+!%$!' @$)+!"#$!%&%0%)+*+&/)+&$0!2+)$*4&+.!+1
#)%#!%&!++"%$0-+4&+.!+!"%.+&%$!+#$&%4&+.!+*+&/)+*+!%$)!./&$!!
%0+!. &&$+0&#++!"#$!%'+))$%$$.67#$#/.%$!+B./"+&#)%#!%&"/+
%$*#$)%!%-$.%$!&)$*%0+#)$%$$.%0%* &/4&%!%.. +%%0+)+&/.%&$%0+
#)*) + +!"#$!%'$%+!%.-$.%$!&%0%* )+&/.%!%0++B./&$!$
#)%#!%)$*%0+#$#/.%$!8..4+&#++"!%0&"$/*+!%##)$0!2"%4&+
.$>'0+!."+%+)*!%$!$!*#$)%!%#)$%$$.-$.%$!&1!"%0+)+4 %0+$*#$&%$!
$%0+#$#/.%$!18..4+*"+#)$)%$%0+)&%/!4.!"!2$%0+"%4&+!"8..4+
"$/*+!%+"!&+#)%+*+*$'&/##$)%-+!. &&/&!2%0+#$#/.%$!* 4+
#+)$)*+"$)%0+#)*) + +!"#$!%%0+#)$#$)%$!$%0+#)%#!%&8%0
*#$)%!%#)$%$$."+-%$!&&OK'
0+.&%4+.$8&0$8&*#$)%!%#)$%$$.-$.%$!)%+)%0%* 4+$!&"+)+"&+%!2
%0+)+&/.%& $%0++ +!"#$!%&G
)%#!%&8..4+!./"+"!%0+!%+)-+!%$!2)$/#%$800%0+ )+)!"$*<+"$)%0+
!. &&$+ "%/&!2%0+@#$#/.%$!'+%.&$!%0+##)$0%$0!".!2
*&&!2"%)+#)$-"+"!+%$!'	 E %%&%.+%0$"&'
#&$	$'
0+#$#/.%$!8..4+/&+"$)%0+!. &&$&+% "%!%0&&%/" '0+
#$#/.%$!$!&&%&$..)!"$*<+"#)%#!%&80$)++-+"%.+&%"$&+$&%/" 
!%+)-+!%$!')%#!%&8..4+!./"+"!%0+!%+)-+!%$!2)$/#$))+&#$!"!2%$%0+
&%/" !%+)-+!%$!%0+ %/.. )++-+"$)%0+!. &&$&+% "%/&!2%0+
#$#/.%$!'@$)*$&%#)%#!%&1%0&8..4+%0+!%+)-+!%$!2)$/#%$800%0+ )+
)!"$*<+"')%#!%&80$%>+!$))+%&%/" !%+)-+!%$!$)%0++!%)+!%+)-+!%$!
#+)$"8..4+!./"+"!%0+!%+)-+!%$!2)$/#$))+&#$!"!2%$%0+&%/" !%+)-+!%$!
;16
CCI
<16.


MK-7264
PAGE 11
PROTOCOL NO 043-03
SUPPLEMENTAL SAP
02-DECEMBER-2021 - AMENDMENT 02
actually received. Participants who take incorrect study intervention during only a part of the 
treatment period and took at least 1 dose of active study intervention will be included in the 
active treatment group.
At least 1 laboratory or vital sign measurement obtained subsequent to at least 1 dose of 
study intervention is required for inclusion in the analysis of each specific parameter. To 
assess change from baseline, a baseline measurement is also required.
STATISTICAL METHODS
Statistical testing and inference for efficacy and safety analyses are described in 
Sections 3.6.1 – Statistical Methods for Efficacy Analyses and 3.6.2 – Statistical Methods for 
Safety Analyses, respectively. Unless otherwise stated, all statistical tests will be conducted 
at an overall significant level of 0.05 (2-sided).
Statistical Methods for Efficacy Analyses
The analysis of efficacy endpoints will be based on the FAS population. Unless otherwise 
specified, analyses will include all follow-up efficacy data collected for those participants 
who discontinued treatment.
Primary Efficacy Analysis 
The LCQ is collected at baseline and after administration of the study intervention at Weeks 
6 and 12. The primary efficacy endpoint of this study is the LCQ change from baseline in 
total score. The primary analysis approach will be conducted utilizing the longitudinal 
ANCOVA model. In this model, the response vector consists of the LCQ change from 
baseline in total score at each post-Baseline visit. The model will include factors for 
intervention group, visit, interaction of treatment by visit, gender, and the baseline LCQ 
score. The model will use all available LCQ change from baseline in total score at Weeks 6 
and 12. Contrasts will be constructed to compare the Gefapixant intervention group to the 
Placebo group at Week 6 and Week 12. The least squares mean change from baseline with 
the associated standard errors will be displayed for each intervention group. Overall 
estimated treatment differences (Gefapixant − Placebo) along with corresponding p-values 
and 95% CIs will also be presented, with the exception of the primary efficacy endpoint, in 
which the CI width will be adjusted for an IA. 
Secondary Efficacy Analysis
The secondary efficacy endpoint will be analyzed using a similar longitudinal ANCOVA 
model as used for the primary efficacy analysis. The model will include terms for
intervention group, visit, interaction of treatment by visit, gender, and baseline score.
Table 1 summarizes the analysis strategy of the primary and secondary efficacy endpoints.
07XN2S
07YNSK


MK-7264
PAGE 12
PROTOCOL NO 043-03
SUPPLEMENTAL SAP
02-DECEMBER-2021 - AMENDMENT 02
Table 1
Analysis Strategy for Key Efficacy Endpoints
Endpoint/Variable (at Week 12)
Statistical 
Method
Missing Data Approach
Primary
Change from baseline in LCQ total 
score
Longitudinal 
ANCOVA
Model-baseda
Secondary
Change from baseline in Cough 
Severity VAS score
Longitudinal 
ANCOVA
Model-baseda
ANCOVA = analysis of covariance; LCQ = Leicester Cough Questionnaire; VAS = Visual Analogue Scale
a Includes data collected after early intervention discontinuation.
Exploratory Efficacy Analysis

CSD Total Score
Change from baseline of the weekly average total daily CSD score and three subscales will 
be analyzed using a similar longitudinal ANCOVA model as used for the primary efficacy 
analysis in the original scale.

PGIC and PGIM Questionnaire
The self-report measure PGIC reflects a participant's belief about the efficacy of treatment.
PGIC is a 7-point scale depicting a participant's rating of overall improvement. Participants 
rate their change as “much better”, “better”, “a little better”, “the same”, “a little worse”,
“worse”, or “much worse”. PGIM is a subsequent question that asks participants to indicate 
whether the level of change they report on the PGIC is a meaningful change, with yes/no 
response.
The numbers and proportions of participants with each response to the PGIC questionnaire 
will be provided at Week 12 by treatment group. Participants with improvements (“much 
better”, “better”, or “a little better” on the PGIC scale) and participants with a response of yes 
in the PGIM questionnaire to indicate important change for the improvement will be 
summarized. Proportion of participants with improvements will be analyzed by the stratified 
(region and gender) Miettinen and Nurminen (M&N) method.

WPAI Questionnaire
The WPAI questionnaire consists of 6 questions and yields four types of scores over the past 
7 days as follows: (1) absenteeism (work time missed); (2) presenteeism (impairment at work 
/ reduced on-the-job effectiveness); (3) work productivity loss (overall work 
impairment/absenteeism plus presenteeism); and (4) activity impairment. The WPAI 
outcomes are expressed as impairment percentages, with higher numbers indicating greater 
impairment and less productivity, ie, worse outcomes. The 4 scores of the questionnaire are 
07XN2S
07YNSK


MK-7264
PAGE 13
PROTOCOL NO 043-03
SUPPLEMENTAL SAP
02-DECEMBER-2021 - AMENDMENT 02
expressed as impairment percentages: the percent work time missed due to problem 
(Q2/(Q2+Q4)), the percent impairment while working due to problem (Q5/10), the percent 
activity impairment due to problem (Q6/10), and overall percent work impairment score due 
to problem Q2/(Q2+Q4)+[(1-(Q2/(Q2+Q4)))x(Q5/10)].
Change from baseline in each of the 4 scores will be analyzed using an ANCOVA model.
The response vector consists of the change from baseline in WPAI at Week 12. The model 
will include factors for intervention group, visit, gender, and the baseline WPAI score.
Handling of Missing Data and Sensitivity Analyses
A participant will be considered for inclusion in the assessment of an efficacy endpoint if the
CSD and Cough Severity VAS are completed on at least 4 days during the 7-day period prior
to a post-Baseline visit (other ePROs are completed at the clinic visit only). All efficacy
analyses will be conducted based on the observed data only. No imputation is planned for the
missing diaries or missing questionnaire items. The pattern of missing is assumed to be
missing at random (MAR). The missing pattern will be inspected to determine if the MAR 
assumption is met. Sensitivity analyses will be implemented to explore the impact of 
departures from the assumption made in missing diaries. 
The longitudinal ANCOVA model (aka. LDA method) assumes that data are missing at 
random. In this study, it is expected that missing at random and missing completely at 
random (MAR/MCAR) mechanisms will underlie most of the missingness, and the 
proportion of data missing not at random (MNAR), driven solely by unobserved values of the 
study endpoints, will be small. 
In addition to the analysis approach specified in the above mentioned primary efficacy 
endpoint analysis section, the following sensitivity analyses will be used to assess the 
robustness of the primary analysis approach.
Tipping-point Multiple-imputation Analysis
The Variant 3 of the tipping point as described in paper [Ratitch et al. 2013] will be used.  In 
that approach, missing data are first imputed for all visits under the MAR assumption, and 
then the worsening/shift is applied.  This is repeated with increasing the delta-shift 
(worsening) until the result is no longer statistically significant.  Specifically, for a given 
constant, c, the tipping point analysis is conducted in a fashion similar to that used in 
standard multiple imputation, whereby m (=100) complete datasets are randomly generated 
using the original observed dataset. These m complete datasets are subsequently analyzed 
using the primary model, and the results of those analyses are then combined. The 
construction and analysis of these m (=100) datasets requires four primary steps:
1) Using a Markov Chain Monte Carlo method, make the observed dataset monotone-
missing. This will be accomplished for each treatment group using “proc mi” within 
SAS 9.3 or higher by utilizing the options “mcmc chain=multiple 
impute=monotone;”, in conjunction with all of the covariates (excluding treatment) 
07XN2S
07YNSK


MK-7264
PAGE 14
PROTOCOL NO 043-03
SUPPLEMENTAL SAP
02-DECEMBER-2021 - AMENDMENT 02
included in the primary analysis model. The random seed will be set equal to 
72644243. This step will generate m monotone-missing datasets. 
2) Applying parametric regression to the monotone-missing datasets, impute all the 
missing values. This will be accomplished for each treatment group using “proc mi“ 
within SAS 9.3 or higher utilizing the option “monotone reg”, in conjunction with all 
of the covariates (excluding treatment) included in the primary analysis model. The 
random seed will be set equal to 72644243. This step will generate m complete 
datasets. 
3) To implement the tipping-point aspect of the procedure, subtract a constant c from 
each of the imputed values of the active arms (to the detriment of active).
4) Analyze each of the post-imputation complete datasets using the primary model, 
obtaining point estimates for the mean of interest (e.g. change-from-baseline 
treatment difference at 12 weeks) and the associated variance.
Using “proc mianalyze” within SAS 9.3 or higher, the m=100 means and variances from the 
m analyses will be combined to obtain the final test statistic and p-value (Rubin, 1987). The 
final test statistic  / (T-(1/2)) is approximately distributed as tν, where  is the sample mean 
of the m treatment difference estimates, T= + (m+1) (B/m),  is the sample mean of the m
variance estimates, and B is the sample variance of the m treatment difference estimates. The 
degrees of freedom, ν, will be computed as follows [Barnard and Rubin, 1999]: ν = [(ν1)-1 + 
(ν2)-1]-1, where  ν1 = (m-1) [ 1 + (/(1+m-1) B)]2 and ν2 = (1-γ) ν0 (ν0 +1) / (ν0 +3), with γ = 
(1+m-1) B / T and where ν0 represents the complete-data degrees of freedom .
This procedure will be repeated (using the same m imputed datasets) until the smallest c is 
found such that the significant result turns non-significant (i.e., p > 0.05). This tipping point 
value c provides a measure of robustness of the primary result. A relatively large value of c
implies better robustness of the primary analysis against the impact of missing data in the 
study.  It is noted that when c=0 the tipping point analysis described above corresponds to an 
analysis conducted under the assumption that the missing data are MAR. For values of c
larger than 0, the tipping point analyses do not assume that the missing values follow a MAR 
mechanism. In fact, the analysis is based on a special MNAR mechanism in which all 
missing data across the arms are assumed to have a worse response by a constant amount of c
than the values would have had under MAR.
Jump-to-reference (J2R) Multiple-imputation Analysis
J2R imputation falls under the category of pattern mixture models known as reference-based 
imputation (RBI). The RBI approach uses different imputation models for missing data in 
different treatment groups. In J2R, missing data in the control group are imputed under the 
MAR assumption, while missing data in the treatment groups are imputed under a MNAR 
assumption using the control group profile for time points after withdrawal.
07XN2S
07YNSK


MK-7264
PAGE 15
PROTOCOL NO 043-03
SUPPLEMENTAL SAP
02-DECEMBER-2021 - AMENDMENT 02
The following steps will be used to implement the J2R multiple-imputation analysis. 
1) A parameter-estimation model is fitted using PROC MCMC. All the covariates 
included in the primary analysis will be used for the parameter-estimation model. For 
the MCMC procedure, an initial random seed=72644243 will be used. N=500 sets of 
pseudo-independent samples of the model parameters will be drawn from the joint 
posterior distribution.
2) The imputation model is built, where, for each pattern of withdrawal, a predicted 
value model is created using the parameters estimated in Step 1. The random seed for 
the imputations is 72644243. For subjects in the control (reference) group, the 
predicted means are calculated under MAR assumption; for subjects in the other 
treatment arms, the predicted means are calculated under MNAR using the jump-to-
reference approach, that is, the mean profile is based on the same treatment arm 
before withdrawal and ‘jumps’ to the mean profile based on the reference arm after 
withdrawal. A complete dataset will be generated using the imputation model for 
each set of the N=500 parameters obtained in Step 1. 
3) For each of the imputed complete datasets, an ANCOVA model will be used for the 
change from baseline values at last time point. The model will include the same 
covariates as in the primary analysis model. The treatment difference across the 500 
datasets will then be combined using PROC MIANALYZE, i.e., using Rubin’s rule 
for multiple imputation (Rubin, 1987) to provide the final results.
The J2R sensitivity analysis was implemented using macros developed by the DIA (Drug 
Information Association) Missing Data Working Group, which were available on page of 
www.missingdata.org.uk.
To get correct variance for the jump-to-reference imputation method, a pattern mixture 
model approximation will also be used. Based on the definition, the jump-to-reference 
imputation will have 0 mean treatment difference between treatment and control for those 
who dropped out in the treatment arm. Therefore, the overall mean treatment difference for 
jump-to-reference becomes
	
 = ( 
 + (1 −)
) −
 = (
 −
)
where  is the proportion of completers in the drug group, t is the last time point, and 

and 
 are the mean effects for drug and control, respectively. It can be estimated from the 
primary analysis model as 2 = (
 −
). The variance can be approximated by, 
var"θ$%
&' = π)

var(μ+)
, −μ+)
-) + "μ+)
, −μ+)
-'

π)(1 −π))/n
where n is sample size in the drug treatment arm. The first term can be estimated from the 
primary analysis model.
07XN2S
07YNSK


MK-7264
PAGE 16
PROTOCOL NO 043-03
SUPPLEMENTAL SAP
02-DECEMBER-2021 - AMENDMENT 02
Statistical Methods for Safety Analyses
Safety and tolerability will be assessed by clinical review of all relevant parameters including 
AEs, laboratory tests, and vital signs.
The analysis of safety results will follow a tiered approach (Table 2). The tiers differ with 
respect to the analyses that will be performed. Adverse events (specific terms as well as 
system organ class terms) and events that meet predefined limits of change in laboratory and 
vital signs are either prespecified as “Tier 1” endpoints, or will be classified as belonging to 
"Tier 2" or "Tier 3" based on the observed proportions of participants with an event.
Tier 1 Events
Safety parameters or adverse events of interest that are identified a priori constitute “Tier 1” 
safety endpoints that will be subject to inferential testing for statistical significance with p-
values and 95% CIs to be provided for between-treatment differences in the proportion of 
participants with events; these analyses will be performed using the Miettinen and Nurminen 
(M&N) method (1985) [Miettinen, O. and Nurminen, M. 1985], an unconditional, asymptotic 
method. For this protocol, taste-related AEs (including dysgeusia, ageusia, hypogeusia,
hypergeusia, and taste disorder) are considered Tier 1 events. 
Tier 2 Events
Tier 2 parameters will be assessed via point estimates and 95% CIs provided for differences 
in the proportion of participants with events. 
Membership in Tier 2 requires that at least 4 participants in any treatment group exhibit the 
event. The threshold of at least 4 events was chosen because the 95% confidence interval for 
the between-group difference in percent incidence will always include zero when treatment 
groups of equal size each have less than 4 events and, thus, would add little to the 
interpretation of potentially meaningful differences. Because many 95% confidence intervals 
for Tier 2 events may be provided without adjustment for multiplicity, the confidence 
intervals should be regarded as a helpful descriptive measure to be used in review, not a 
formal method for assessing the statistical significance of the between-group differences in 
adverse events and safety parameters that meet predefined limits of change.
In addition to individual events that occur in 4 or more participants in any treatment group, 
any oral paresthesia AE, any oral hypoesthesia AE, and the broad AE categories consisting of 
the proportion of participants with any AE, a drug-related AE, a serious AE, an AE which is 
both drug-related and serious, and discontinuation due to an AE will be considered Tier 2 
events.
Tier 3 Events
Safety endpoints that are not Tier 1 or 2 events are considered Tier 3 events. Only point 
estimates by treatment group are provided for Tier 3 safety parameters.
07XN2S
07YNSK


MK-7264
PAGE 17
PROTOCOL NO 043-03
SUPPLEMENTAL SAP
02-DECEMBER-2021 - AMENDMENT 02
Continuous Safety Measures
For continuous measures such as changes from baseline in laboratory and vital signs, 
summary statistics for baseline, on-treatment, and change from baseline values will be 
provided by intervention group in table format.
The frequency of taste-related AEs across pre-defined time intervals will be provided, where 
the time intervals will be defined as: >0 to ≤1 week, >1 to ≤4 weeks, >4 to ≤8 weeks, 
and>8 to ≤12 weeks. In each time interval, the denominator for calculation of percentage 
will be the number of participants treated during the time interval and the numerator will be 
the number of participants with at least one taste-related AE occurring in this time interval.
Table 2
Analysis Strategy for Safety Parameters
Safety Tier
Safety Endpointa
p-Value
95% CI for 
Treatment 
Comparison
Descriptive 
Statistics
Tier 1
Any taste-related AE (including dysgeusia, 
ageusia, hypogeusia, hypergeusia, and 
taste disorder)
X
X
X
Tier 2
Any oral paresthesia AE
X
X
Any oral hypoesthesia AE
X
X
Any AE
X
X
Any Serious AE
X
X
Any Drug-related AE
X
X
Any Serious and Drug-related AE
X
X
Discontinuation due to AE
X
X
Specific AEs, SOCs, or PDLCsb (incidence 
≥4 participants in one of the treatment 
groups)
X
X
X
X
Tier 3
Time to Onset from the First Dosing Date 
and Duration of Event for Taste-Related 
AEs
X
Frequency of Taste-Related AEs for Time 
Intervals: >0 to ≤1 Week, >1 to ≤4 Weeks, 
>4 to ≤8 Weeks, and >8 to ≤12 Weeks
X
Specific AEs, SOCs or PDLCsb (incidence 
<4 participants in all of the treatment 
groups)
X
Change from Baseline Results (Labs, Vital 
Signs)
X
AE = adverse event; CI = confidence interval; PDLC = predefined limit of change; SOC = system organ class; X = 
results will be provided.
a Adverse experience references refer to both clinical and laboratory AEs. 
b Includes only those endpoints not prespecified as Tier 1 or not already prespecified as Tier 2 endpoints.
07XN2S
07YNSK


MK-7264
PAGE 18
PROTOCOL NO 043-03
SUPPLEMENTAL SAP
02-DECEMBER-2021 - AMENDMENT 02
Table 3
Predefined Limit of Change from Baseline
Laboratory Test
Criteria
hematocrit
≥20% and <LLN
≥20% and >ULN
WBC
≥20% and <LLN
≥20% and >ULN
Platelet
≥25% and <LLN
≥50% and >ULN
Bilirubin
≥100% and >ULN
≥50% and >1.5x ULN
≥50% and >2x ULN
>3x ULN
>5x ULN
AST
≥100% and >ULN
≥50% and >1.5x ULN
≥50% and >2x ULN
>3x ULN
>5x ULN
ALT
≥100% and >ULN
≥50% and >1.5x ULN
≥50% and >2x ULN
>3x ULN
>5x ULN
Neutrophil
≥20% and <LLN
≥20% and >ULN
BUN
≥50% 
≥20% and BLN >ULN
Serum creatinine
≥50% 
≥20% and BLN >ULN
ALT = alanine aminotransferase; AST = aspartate aminotransferase; 
BLN = baseline; BUN = blood urea nitrogen; LLN = Lower limit of normal range; ULN = 
Upper limit of normal range; WBC = white blood cell.
07XN2S
07YNSK


	
,



  
#&0!+'*	$
+'0!
0+$*#)4.% $%0+%)+%*+!%2)$/#&$)+0)+.+-!%"+*$2)#0!"4&+.!+
0)%+)&%8..4+&&+&&+"4 %0+/&+$%4.+&!"9$)2)#0&'$&%%&%.0 #$%0+&&
%+&%&8..4+#+)$)*+"$!%0+&+0)%+)&%&'0+!/*4+)!"#+)+!%2+$#)%#!%&
&)++!+"!")!"$*<+"!"%0+#)*) )+&$!&$)&)++!!2./)+!""&$!%!/%$!
8..4+"&#. +"'+*$2)#0-)4.+& 6+212+12+!"+)1)+18+20%1!"0+20%714&+.!+
0)%+)&%&1#)*) !"&+$!") "2!$&+&1!"#)$)!"$!$*%!%%0+)#+&8..4+
&/**)<+"4 %)+%*+!%+%0+)4 "+&)#%-+&%%&%&$)%+2$).%4.+&'
2"	2	8##
+&/.%&$ ..!%+)*!. &+&8..4+)+-+8+"4 !+B%+)!.18008..*>+
)+$**+!"%$!&%$%0+$%0+#$!&$)%$$!%!/+1*$" $)&%$#%0+&%/" '
&&$	$
!+#.!!+"+ 38..4+$!"/%+"80+!##)$B*%+. 
K$%)2+% #)%#!%&
6##)$B*%+. %0+)&%		+!)$..+"#)%#!%&70-++%0+)$*#.+%+"%0+&%/" 
6##)$B*%+. 
+!)$..+"#)%#!%&7$)"&$!%!/+"&%/" !%+)-+!%$!+). '..
-.4.+"%8..4+!./"+"!%0+!. &&1!./"!2$..$8/#"%!"#)%."%)$*
#)%#!%&+!)$..+"%+)%0+#)%#!%&%)22+)!2%0+3'
0+#/)#$&+$%0+3&%$..$8+). &%$#$)&%)$!24+!+%6+ 7$)$)/%.% '0+
+ 38..4+4&+"$!%0+#)*) +!"#$!%$%0+I0!2+)$*4&+.!+!%$%.
&$)+%C++>'
;16
CCI
<16.


	




  
#&$	$
3!%+)*&+% 8...&$4+&&+&&+"%%0+%*+$#)+&#++"3$)/%.% 1+180+!
##)$B*%+. 
K$%)2+%#)%#!%&6##)$B*%+. %0+)&%		+!)$..+"#)%#!%&7
0-++%0+)$*#.+%+"%0+&%/" $)"&$!%!/+"%0+&%/" !%+)-+!%$!+). '2+!+).
)+-+8$&+% )+&/.%&8..4+#+)$)*+"4&+"$!)+-+8$&1.4$)%$) &+% 
#)*+%+)&1!"$%0+)&+% +!"#$!%&'
"6!8
%0+)%0!!"L/&%*+!%%$%0+.#0.+-+.$)%0+3$)+ 1!$*/.%#.% "L/&%*+!%
&#.!!+"'
#	"#?	2*@!	!6	*2#
0+&*#.+&<+./.%$!&)+#$8+)+"%$%+&%%0+#)*) + +!"#$!%18%0%0+
$..$8!2&&/*#%$!&4&+"$!%0+)+&/.%&)$*#0&+0)$!$/20&%/" '3!	

)$%$$.1%0+0!2+)$*4&+.!+!I%$%.&$)+%C++>8&'!"'$)
*2!"5*2$*#)+"%$#.+4$'3!%0&&%/" 12-+!%0+#$#/.%$!&%)2+%+"$)
#)%#!%&8%0)++!%$!&+%0)$!$/206^ *$!%0&7800&"+)+!% )$*
#)%#!%&8%00)$!$/206\ *$!%0&7!)$%$$.1$!&+)-%-+&&/*#%$!&
8+)+/&+"$)&*#.+&<+./.%$!G

)+%*+!%"+)+!+!0!2+)$*4&+.!+!I%$%.&$)+%C++>&'
#$!%

$**$!$0!2+)$*4&+.!+!I%$%.&$)+&'5
&+"$!%0+&&/*#%$!&4$-+1%$%.$

#)%#!%&6#)%#!%&#+)!%+)-+!%$!
2)$/#78..#)$-"+%.+&%(K#$8+)'0+./.%$!&4&+"$!!$-+)..$!+&"+"
MN'5&2!!+.+-+.1"L/&%+"$)$!+3$)+ 6MN'71!"$!+!.+ 
!. &&6MN'
7'")$#$/%)%+$5K%C++>&$/!%+"$)%0+&*#.+&<+
./.%$!%$+!&/)+5+-./4.+#)%#!%&$*#.+%+%0+C++>+-./%$!'
C%0&&/*#%$!&$!%0+)%+&!%0+#.+4$2)$/#4&+"$!%0+)$%$$.)+&/.%&1%0+
*!*/*"+%+%4.+)%+"+)+!+&)+('
K1,'K1!"'K!$-+)..%&%+)+.%+"
&1$).#)+&%0+&&1!"$).0 #$+&%0+&&1)+&#+%-+. '
;16
CCI
<16.


MK-7264
PAGE 21
PROTOCOL NO 043-03
SUPPLEMENTAL SAP
02-DECEMBER-2021 - AMENDMENT 02
SUBGROUP ANALYSES
Analysis for the primary efficacy endpoint will be provided for the following subgroups of 
baseline factors:

Gender (male, female)

Region (North America, Europe, Asia-Pacific, Other)

Age group (<60 years, ≥60 years old)

Baseline Cough Severity VAS (<60 mm, ≥60 mm)
A similar longitudinal ANCOVA model as that used for the primary efficacy endpoint will 
be utilized. For each subgroup, summary statistics including means and their 95% CIs will be 
provided for each intervention group at Week 12. For the subgroups with 15% or more of the 
FAS population across both intervention groups, the mean treatment differences (gefapixant -
placebo) and their 95% CIs will also be provided at Week 12.
COMPLIANCE (MEDICATION ADHERENCE)
For each participant, percent compliance will be calculated using the following formula:
A day within the study will be considered an “on-therapy” day if the participant takes all 
required intervention as instructed in Section 8. When a participant takes less than or more 
than the required intervention on a day, that day is not considered an on-therapy day. 
For participants who are followed for the entire study period, the “Number of Days Should 
be on Therapy” is the total number of days from the first scheduled intervention day to the 
last scheduled intervention day. For participants who discontinue from the study 
permanently, the “Number of Days Should Be on Therapy” is the total number of days from 
the first scheduled intervention day to the last dose day. 
Summary statistics will be provided on percent compliance by intervention group for the 
APaT population.
EXTENT OF EXPOSURE
The duration of intervention for each participant will be evaluated by calculating the number 
of days on therapy. Exposure to study intervention will be summarized using descriptive 
statistics (mean, SD, median, minimum, and maximum) for the APaT population.
07XN2S
07YNSK


MK-7264
PAGE 22
PROTOCOL NO 043-03
SUPPLEMENTAL SAP
02-DECEMBER-2021 - AMENDMENT 02
4. APPENDICES
Model Specification, Assumptions, and Sample SAS Implementation Codes for the 
Primary Efficacy Analysis
Model
Let 012  denote the measurement for subject i, with treatment assignment j, at time t. Here 
3 = 0, 1 represent Placebo and MK-7264 45 mg BID, respectively. Also,  = 0,1, 2 represent 
Baseline, visits at Week 6 and 12, respectively. 
The longitudinal ANCOVA model, that is, a mixed linear model will treat percent change 
from baseline in measurement,  (012 −  0126)/0126, as the dependent variable, and adjust for 
the following independent variables:

baseline measurement 0126

treatment (categorical variable with 2 levels, Placebo and MK-7264 45 mg BID)

week (categorical variable with 2 levels, 6, 12)

Gender (males and females)

the interaction of treatment by week
Observations across subjects are assumed to be independent. Post-baseline measurements 
within the same subject are assumed to follow multivariate normal distribution with mean 
vector as specified above and an unstructured covariance matrix. 
This longitudinal model provides valid statistical inference in the presence of possible
missing data if the missing data mechanism is ignorable (or more specifically, MAR or
MCAR). This missing data mechanism requires that the probability of a data point being 
missing does not depend on the missing data after adjusting for the observed data.
Reasons for discontinuation from the trial may include lack of efficacy, clinical or laboratory 
adverse experiences, relocation, withdrawal of consent, protocol deviations, and/or data 
processing issues. Missing data caused by relocation and data processing issues, are likely to 
be MCAR. On the other hand, missing data caused by discontinuation due to lack of efficacy 
may belong to MAR because the discontinuation may depend on the observed efficacy 
outcomes. The MAR or MNAR mechanisms might each underlie the other reasons to some 
extent. If treatment in large part determines the loss of data for these other reasons (such as 
clinical or laboratory adverse experiences), the mechanism may be close to MAR since 
treatment assignment is an observed variable and included in the analysis model. Based on 
the prior trial results, missing data due to other reasons is relatively infrequent.
Model Convergence
If the unstructured covariance matrix fails to converge with the default algorithm, then the 
AR(1) structure can be used to provide initial values of the covariance parameters. 
07XN2S
07YNSK


MK-7264
PAGE 23
PROTOCOL NO 043-03
SUPPLEMENTAL SAP
02-DECEMBER-2021 - AMENDMENT 02
Example SAS Codes
proc mixed data=adeff;
where avisitn > 0;
class subjid trt01p avisitn sex;
model chg = base trt01p avisitn sex trt01p*avisitn/ solution notest;
repeated avisitn / subject = subjid type=un;
lsmestimate trt01p*avisitn 'MK at Week 12'   [1, 1 2];
            lsmestimate trt01p*avisitn ' Placebo at Week 12'   [1, 2 2];
lsmestimate trt01p*avisitn 'Treatment Differences at Week 12' [1, 1 2]  [-1, 2 2];
run;
Model Specification for the Safety Analysis
Miettinen and Nurminen method
Denote the sample size and response rate as 76, 6, 78, 8 for the two treatment groups. The 
100(1 −9)% confidence interval is provided by solving the equation for ;,
 (̂8
∗−̂6
∗−;)
 
∑
? @1
∑@A
A
B

CD1
E
1F8
= G8,H

Here I = 1, … , K is the index for strata and 
̂8
∗= ∑
L
MN
∑MO
O
P ̂81
E
1F8
, where ̂81is the observed response rate for group 1 in stratum I;
̂6
∗= ∑
L
MN
∑MO
O
P ̂61
E
1F8
, where ̂81is the observed response rate for group 0 in stratum I;
@1 = 
QRNQSN
QRNTQSN , which corresponds to the Cochran Mantel-Haenszel’s weights;
CD1 = U
DRN(8VDRN)
QRN
+ 
DSN(8VDSN)
QSN
W
QRNTQSN
QRNTQSNV8;
D61 is the maximum likelihood estimate for 61 under the restriction that 81 −61 = ;;
D81 = D61 +  ;.
The point estimate for the treatment difference is provided by ̂8
∗−̂6
∗with corresponding 
variance ∑
L
MN
∑MO
O
P

CD1
E
1F8
.
07XN2S
07YNSK


MK-7264
PAGE 24
PROTOCOL NO 043-03
SUPPLEMENTAL SAP
02-DECEMBER-2021 - AMENDMENT 02
5. REFERENCES
[Lan, K. K. G. and DeMets, D. L. 1983] Lan KKG, DeMets DL. Discrete sequential 
boundaries for clinical trials. Biometrika 1983;70(3):659-63.
[Miettinen, O. and Nurminen, M. 1985] Miettinen O, Nurminen M. Comparative analysis of
two rates. Stat Med 1985;4:213-26.
[Barnard and Rubin, 1999] Barnard, J., and Rubin, D. Small-Sample Degrees of Freedom 
with Multiple Imputation. Biometrika, 86(4), 948-955.
[Ratitch, B., O'Kelly, M., & Tosiello, R. 2013] Ratitch, B., O'Kelly, M., & Tosiello,
R. Missing data in clinical trials: From clinical assumptions to statistical analysis using 
pattern mixture models. Pharmaceutical Statistics, 12(6), 337–347.
07XN2S
07YNSK